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Medical interest in “blood-derived products for tissue repair/regeneration” has old roots, starting
with chronic wounds in the 1980s, and boosted by sports medicine at the beginning of the millennium,
when elite athletes treated with platelet rich plasma (PRP) resumed competition earlier than expected.
Linking blood-derived products and healing mechanisms is a past milestone that has uncovered
distinctive therapeutic approaches for disparate medical conditions. As exemplified in this issue,
the transversal nature of blood derived therapies encompasses research that falls in a variety of medical
fields: Eye surface in ophthalmology [1], regeneration of bone defects and periodontal tissues in
dentistry [2–4], osteoarticular pathology, e.g., meniscal repair [5], knee osteoarthritis [6] or radiocarpal
osteoarthritis [7]. It also reflects that research in this field encompasses in vitro [4,8–10] and in vivo [1,2]
experimentation, clinical veterinary [11] and clinical studies [3,5–7] representing all the stages of
translational research.
We fully acknowledge the explosive growth of research interest in this area, but never have the
stakes been higher. After nearly three decades of research, two key questions remain unanswered:
What can blood-derived products offer to help understand the intricacies of healing mechanisms? What
can we do to foster PRP research and take the benefits it can offer to the varied unmet medical needs?
Answering both questions means that we can identify the crucial elements that boost the healing
mechanism, and that we can refine formulations to fit with tissue needs in each clinical application.
A holistic approach to deciphering the participation of PRPs in healing mechanisms starts from
understanding that the PRP actions are more than those attributed simply to the fact that they contain
a vast array of powerful growth factors (GFs). The presence of various GFs in platelets’ alpha granules
and their involvement in boosting tissue healing grounded the hypothesis of the clinical use of PRPs, but
we should also consider that there is controversy about whether platelet number (concentration factor
relative to peripheral blood) and growth factor concentration is paramount in PRP formulations. While
traditional approaches of tissue healing research focused on separate GFs, for example recombinant
human platelet-derived growth factor (rhPDGF-BB), recombinant human fibroblastic growth factor
(rhFGF) or recombinant human epidermal growth factor (rhEGF), have shown some clinical benefits in
difficult-to-heal wounds, they provide a limited understanding of healing mechanisms. As postulated
by system biology, “networks are more than the sum of the parts”, and this premise helps understanding
the difficulties in finding quality parameters able to control efficacies of the different blood derivatives.
In this issue, two reports have focused on the molecular composition of blood-derived
products [9,10]. As proposed by Kardos et al. [9], exhaustive scrutiny of the molecular content
can provide a guide for developing better formulations tailored to specific tissue/organs’ needs.
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However, because of the intrinsic complexity of the process of healing, molecular description is not
sufficient, and functional in vitro assays can help to differentiate which formulation is more appropriate
for a given pathology and/or perhaps different formulations in the different healing stages. Therefore,
a priori, there is not a sole effective formulation and different blood derived products may be indicated
for the specific tissue needs. Grounded on this idea, Jeyakumar et al. [8] drew parallels between
PRP formulation/preparation protocols and healing mechanisms. They evidenced some advantage of
hyper-acute autologous serum in enhancing chondrocyte proliferation, while PRP was more useful
to stimulate extracellular matrix synthesis and enhance the anabolic/catabolic protein balance in the
context of engineered cartilage constructs.
Research could foster new ways of thinking, and can assist in elucidating which blood derivative
works better in specific tissues in specific conditions. The molecules released from blood derivatives
may transiently form part of the immediate cell microenvironment (local milieu), thereby activating cell
function in different tissues/organs. However, different cell phenotypes behave differently in functional
terms when exposed to blood derivatives. Moreover, Chellini et al. [12], in a narrative review about
skeletal muscle healing, reported that not a single cell phenotype but the collaborative interactions and
crosstalk between different cell phenotypes can be modified by PRP. Moreover, platelet poor plasma,
PPP, is capturing the attention of researchers in the field of muscle regeneration as it drives cells into
the myogenic differentiation pathway and lacks pro-fibrotic factors such as TGF-β1.
Blood derivatives are also interesting as adjuvants, as part of either combination therapies or
combination products. Seen in this light, Pomini et al. [2] developed a method to enhance bone
formation using platelet-rich fibrin combined with bioOss®(a popular bone filler) and associated to
photobiomodulation therapy, in dentistry. Likewise, current research [1] also evaluates the possibility
of combining PRP releasate with hyaluronan to treat corneal epithelial defects. In the clinical context,
the combination of adipose tissue (more specifically microfat) with PRP is explored as an innovative
therapy to treat wrist OA (osteoarthritis) [7].
PRP research must lift its gaze to bigger accomplishments. This will require an improved
understanding of repair, which in turn would support treatment strategies, patient selection and the
development of precise application procedures. We hope that the identification of biomarkers will
help to stratify patients, bringing about more efficient and accurate therapies, better understanding
of healing mechanisms and more rational use of PRP therapies and foster the development of new
combinational treatments.
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Abstract: The aim of this study is to assess if an adhesive biopolymer, sodium hyaluronate (NaHA),
has synergistic effects with s-PRGF (a serum derived from plasma rich in growth factors and a blood
derivative that has already shown efficacy in corneal epithelial wound healing), to reduce time of
healing or posology. In vitro proliferation and migration studies, both in human corneal epithelial
(HCE) cells and in rabbit primary corneal epithelial (RPCE) cultures, were carried out. In addition,
we performed studies of corneal wound healing in vivo in rabbits treated with s-PRGF, NaHA, or
the combination of both. We performed immunohistochemistry techniques (CK3, CK15, Ki67, ß4
integrin, ZO-1, α-SMA) in rabbit corneas 7 and 30 days after a surgically induced epithelial defect.
In vitro results show that the combination of NaHA and s-PRGF offers the worst proliferation rates in
both HCE and RPCE cells. Addition of NaHA to s-PRGF diminishes the re-epithelializing capability
of s-PRGF. In vivo, all treatments, given twice a day, showed equivalent efficacy in corneal epithelial
healing. We conclude that the combined use of s-PRGF and HaNA as an adhesive biopolymer does
not improve the efficacy of s-PRGF alone in the wound healing of corneal epithelial defects.
Keywords: corneal epithelial defect; cornea regeneration; serum eye drops; plasma rich plasma (PRP);
serum derived from plasma rich in growth factors (s-PRGF); hyaluronic acid (NaHA); wound healing
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1. Introduction
Integrity of the corneal epithelium is a critical requirement for correct vision function [1].
The maintenance of the epithelium is based on a balance among limbal stem function, tear quantity and
quality, the eyelid anatomy and function, and corneal sensitivity [2]. In cases of corneal injury, healing
mechanisms are activated involving cell proliferation, migration and reattachment of the epithelium
to its extracellular matrix, and cell differentiation. Factors needed for corneal wound healing are
provided by the tear film, aqueous humor, and limbal blood vessels. Furthermore, cornea epithelium
by itself is a rich source of cytokines that contribute to modulate the wound healing process [3].
Sometimes, corneal wounds persist over time and are resistant to conventional treatment, such as
artificial tears or topical antibiotics [4], lateral tarsorrhaphy [5], bandage contact lenses [6], punctual
plugs [7], and amniotic membrane transplantation [8]. Different topical growth factors have been
also tested in these persistent epithelial defects [9–13]. As wound healing demands a balanced
combination of different mediators, blood derivatives have been used to treat corneal epithelial
defects, including autologous serum [14] and platelet rich plasma [15]. One of these, s-PRGF (a serum
derived from plasma rich in growth factors) has already been used successfully as a treatment for
eye disorders [4,16,17] and its effectiveness has been proved in wound healing [4,18]. s-PRGF has
been proved to stimulate proliferation and migration of epithelial cells [18]. It has a moderate platelet
concentration and its leukocyte content has been removed [19,20].
On the other hand, eye barriers and the continuous turnover of tears can alter the absorption
of drugs instilled in the eye, so, although eye drops are an easy-to-use treatment, they must be
instilled frequently and/or at high concentrations to achieve therapeutic levels in the tissues. The high
frequency of instillation can induce a non-compliance of treatment by patients. The development of
vehicles capable of adhering to the conjunctival and/or corneal tissue is an interesting alternative
for increasing the bioavailability of ophthalmological medications. With this aim, hydrogels and
polymer micelles [21], biodegradable nanocapsules or HA coated nanospheres, and niosomes have
been reported as agents for the release of drugs on the ocular surface [22–24]. The role of liposomes
has also been investigated, although their potential is limited due to their short half-life on the ocular
surface and relatively low stability [23]. HA-coated liposomes have also been used to facilitate the entry
of drugs into human corneal epithelial (HCE) cells [25]. In all these cases, HA-coated nanovehicles
allow greater concentrations of the transported drug to enter into the cornea.
Other authors have tried other vehicles with well-known mucoadhesive properties, with the
intention of increasing the contact time of various drugs in the corneal tissue. Thus, the concomitant
use of 0.5% carboxymethylcellulose, 0.2% HA, or 0.3–0.5% hydroxypropylcellulose associated with
topical 0.5% timolol has been studied. In this case, combination with HA did not show improved
efficacy with respect to timolol alone [26]. However, some authors have concluded that an increase of
drug viscosity reduces its systemic absorption, so it could enhance the exposition of treatment to the
ocular surface [27].
Topical surfactant molecules (perfluorohexiloctane), as well as ophthalmic inserts of
methylpropylcellulose (Lacrisert®), have been developed with the intention of increasing the residence
time of the tear on the ocular surface and therein improving the quality [28,29]. Another strategy to
prolong the contact of drugs with the ocular surface is the use of contact lenses that slowly release the
drug over several weeks [30].
Specifically, to extend the contact time of the platelet lysates with the damaged ocular surface,
Sandri and colleagues studied their combination with molecules with mucoadhesive properties, such
as polyacrylic acid and chitosan [31]. Similarly, the combination of HA with autologous serum has also
been studied, suggesting that HA would facilitate the gradual release of growth factors and increase
its duration and effect on the ocular surface, so fewer instillations would be needed [32].
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HA is a bioadhesive molecule produced by the cells of the corneal matrix and is one of its main
components. It is a polyanionic glycosaminoglycan composed of disaccharide subunits of N-acetyl
glucosamine and D-glucuronic acid [33]. Depending on the number of disaccharides bound, hyaluronic
acids of different molecular weights will be formed. Among its characteristics, it is noteworthy that
it is biocompatible, biodegradable and non-toxic, and non-irritating [34,35]. It also possesses a high
capacity for binding to water and has a viscous and pseudoplastic fluid behavior with the ability to
act as a mucoadhesive polymer, which makes it possible to increase the residence time in the eye,
in addition to reducing friction during blinking and extraocular movements when it is being used
as a natural lubricant of the ocular surface that reduces epithelial damage [36]. A negative charge
would facilitate adhesion to the ocular surface, giving theoretically more corneal bioavailability to the
molecules associated with hyaluronic acid [37].
High molecular weight HA has immunosuppressive and anti-inflammatory properties by
reducing the migration of inflammatory cells [38] and by specifically inhibiting certain metalloproteases
that degrade the extracellular matrix [39]. It also has anti-angiogenic properties [40] and analgesic
effects [41]. However, small fragments of HA can have a proinflammatory and pro-angiogenic
effect [42]. In our work, we used intermediate molecular weight HA, as we wanted to assess its
mucoadhesive capacity for s-PRGF and not its anti-inflammatory synergy.
All commercial ophthalmic hyaluronic acids used as artificial tears contain concentrations between
0.1% and 0.4% hyaluronic acid. In order to mimic real clinical situations, the concentration used in our
work was 0.1% for in vitro assays and 0.2% for in vivo experiments.
Therefore, the beneficial effect of HA both in vitro and in vivo, as well as Platelet Rich Plasma
(PRP), seems to be evident, both in the field of traumatology [43] and in corneal epithelial wound
healing [18,44].
Given this “state of the art”, the aim of this study is to test if combining both treatments, s-PRGF
and HA, is synergistic in terms of in vitro migration and proliferation of corneal epithelial cells and
in vivo reduction of the time (or reduced posology) of corneal wound healing.
2. Results
2.1. In Vitro Proliferation Assays in Rabbit Primary Corneal Epithelial Cells and Human Corneal
Epithlial Cultures
We studied cell proliferation at 0, 24, 48, and 72 h in rabbit epithelial cells (RPCE) and HCE
cultures under the following treatments: 45% s-PRGF; 45% s-PRGF + 0.1% sodium hyaluronate
(NaHA) (combined treatment); 0.1% NaHA; 10% FBS as a positive/reference control; and 1% BSA as a
negative control.
Results showed that in RPCE cultures all treatments produced a time-dependent proliferation
pattern, with no significant differences within treatments at 72 h (Figure 1A). Viability in RPCE
cultures exposed to different treatments was very similar in all cases. We observed that viability
in the first 24–48 h (Figure 1B,C) was higher with FBS, the standard or reference culture medium.
However, differences decreased over time, especially under s-PRGF and control (BSA) treatments.
Thus, after 24 h of treatment, we observed highly significant differences between FBS and NaHA,
alone or combined with s-PRGF, and between FBS and the control treatment (Figure 1B). However,
there were not significant differences between FBS and s-PRGF at 24 h (p = 0.42). In addition, we
found significant differences in cell viability between cells cultured with s-PRGF in comparison to
those cultured with both NaHA treatments.
Thus, proliferation of RPCE cultures at 24 h was similar for FBS and s-PRGF treated cultures
and higher than cultures under the other treatments. At 48 h, we found significant differences within
treatments compared to FBS, with these being less than those at 24 h and completely disappearing at
72 h (Figure 1B–D).
In summary, NaHA, whether combined or not with s-PRGF, did not enhance either proliferation
capability or viability in RPCE cultures.
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Figure 1. Effect of serum derived from plasma rich in growth factors (s-PRGF), alone or combined with
sodium hyaluronate (NaHA), (A) on the proliferation and (B–D) viability of rabbit primary corneal
epithelial (RPCE) cultures. Cultures were exposed for 24, 48, and 72 h to 10% FBS; 45% s-PRGF;
45% s-PRGF and 0.1% NaHA (combined treatment); 0.1% NaHA; and 1% BSA as a negative control.
Proliferation results are expressed as proliferation rate ± standard deviation of viable cells with respect
to viable cells at t = 0. Viability results are expressed as percentages versus that with FBS (100% viability).
Statistically significant differences with respect to FBS (Φ) or to s-PRGF (#) (## p < 0.01; Φ p < 0.05;
ΦΦ p < 0.01; ΦΦΦ p < 0.001; n/s, not significant. Kruskal-Wallis test, Dunn test with Bonferroni
correction to Multiple Comparisons).
Results concerning HCE cultures showed a time-dependent proliferation pattern, except for the
1% BSA control treatment, while s-PRGF, with or without NaHA, produced a decrease in proliferation
at 24 h which was not statistically significant (Figure 2A). All treatments, especially 10% FBS, showed a
higher proliferation rate that the control treatment. In addition, we saw a positive tendency for higher
proliferation when cells were cultured with NaHA compared to s-PRGF or the combined treatment.
Regarding viability, we do not see significant differences between FBS and NaHA during the
first 48 h (Figure 2B,C). In addition, besides the FBS treatment, only the non-combined treatments
showed significant (s-PRGF) or very significant (NaHA) differences compared to the control treatment
at 48 and 72 h (Figure 2C,D).
In conclusion, s-PRGF and NaHA treatments showed better proliferative patterns in HCE cells,
whereas the combination of both did not improve it.
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Figure 2. Effect of s-PRGF, alone or combined with NaHA, on the (A) proliferation and (B–D) viability
of human corneal epithelial (HCE) cells. Cultures were exposed for 24, 48, and 72 h to 10% FBS;
45% s-PRGF; 45% s-PRGF and 0.1% NaHA (combined treatment); 0.1% NaHA; and 1% BSA as a
negative control. Proliferation results are expressed as proliferation rate ± standard deviation of viable
cells with respect to viable cells at t = 0. Viability results are expressed as percentages versus that with
FBS (100% viability). Statistically significant differences with respect to BSA (*) or to FBS (Φ) (* p < 0.05;
** p < 0.01; Φ p < 0.05; ΦΦ p < 0.01; ΦΦΦ p < 0.001; n/s, not significant. Kruskal–Wallis test, Dunn test
with Bonferroni correction to Multiple Comparisons).
2.2. In Vitro Scratch Wound-Healing Assays in RPCE and HCE Cultures
In order to evaluate the capability of the different treatments to promote migration and
re-epithelialization on RCPE and HCE cultures, we scraped off rounded areas on cell monolayers
and treated them with the following treatments: 45% s-PRGF; 45% s-PRGF + 0,1% NaHA (combined
treatment); 0,1% NaHA; 10% FBS as a positive/reference control; and 1% BSA as a negative control.
We measured the re-epithelialization process at 0, 12, 24, 36, 48, 60, and 72 h.
We did not find significant differences within treatments at any time when studying wound
healing evolution in RPCE cultures (Figure 3A). However, when we analyzed the percentage of wells
in which the defect in the monolayer had completely resolved, we found evident differences in cultures
treated with NaHA (alone or combined) with respect to other treatments (Figure 3B–D). Additionally,
a smaller number of completely resolved defects in cultures treated with the combined treatment was
observed, with this result being statistically significant from 48 h.
8






























































































































Figure 3. Effect of s-PRGF, alone or combined with NaHA, on the re-epithelialization of rabbit
primary corneal epithelial (RPCE) cultures. Cultures were exposed for 72 h to 10% FBS; 45% s-PRGF;
45% s-PRGF + 0.1% NaHA (combined treatment); 0.1% NaHA; and 1% BSA as a negative control.
The percentage of re-epithelialized area of RPCE cultures after 48 hr (A), and percentage of wells in
which the defect in the monolayer had completely resolved at 24 (B), 36 (C) and 48 (D) hours are
shown. Statistically significant differences with respect to the combined s-PRGF + NaHA treatment (#)
(# p < 0.05; n/s, not significant. χ2 test and Fisher’s exact test).
In HCE cultures, s-PRGF treatment (alone or combined with NaHA), as well as FBS treatment,
promoted faster re-epithelialization of the defect in the monolayer from 12 h of treatment onwards,
showing significant differences at all times (Figure 4A). Furthermore, in the HCE cultures, no
statistically significant differences were found in the mean remaining denuded area (in square
millimeters) between cells treated with NaHA and control cells.
With respect to the resolution of defects in the HCE cultures, s-PRGF treatment (alone or
combined), together with FBS, produced statistically significant differences in the number of wells
in which the denuded area had been completely covered, compared with the control and NaHA
treatments, from 24 h (Figure 4B). At 36 h, almost 100% of wounds treated with s-PRGF or
s-PRGF + NaHA were completely solved, whereas none of the denuded areas had completely closed
in the control and NaHA cultures (Figure 4C,D).
We conclude that s-PRGF promotes the highest re-epithelialization in RPCE primary cultures and
HCE cells. Furthermore, NaHA does not favor this process, and hinders the re-epithelialization effect
promoted by s-PRGF.
9































































































































Figure 4. Effect of s-PRGF, alone or combined with NaHA, on the re-epithelialization of human
corneal epithelial (HCE) cells (A). Cultures were exposed for 72 h to 10% FBS; 45% s-PRGF;
45% s-PRGF + 0.1% NaHA (combined treatment); 0.1% NaHA; and 1% BSA as a negative control.
The percentage of re-epithelialized area of HCE cultures after 36 hr (A), and percentage of wells in
which the defect in the monolayer had completely resolved at 24 (B), 36 (C) and 48 (D) hours are shown.
Statistically significant differences with respect to BSA (*) or NaHA (Φ) (*** p < 0.001; ΦΦΦ p < 0.001;
n/s, not significant. χ2 test and Fisher’s exact test).
2.3. In Vivo Corneal Re-Epithelialization Assay in a Rabbit Animal Model
To perform the assay, surgically induced epithelial defects were treated with 90% s-PRGF;
90% s-PRGF and 0.2% NaHA (combined treatment); 0.2% NaHA; and PBS as a control treatment.
We did not find any adverse effects, such as corneal inflammation or neovascularization, during
the whole experiment. In addition, all animals were healthy and gained weight progressively.
The results showed that s-PRGF promoted faster corneal wound healing after day 2 of treatment
than the other treatments. The mean time to complete the closure of the epithelial defect in the s-PRGF
group was 3.11 ± 0.22 days, whereas it was 3.31 ± 0.37 days for eyes treated with any of the other
treatments (Figure 5A and Table 1). Nevertheless, we did not find significant differences among
treatments (Kruskal–Wallis). We also performed the Kaplan–Meier test to analyze the progression of
healing of eyes at intervals of half a day. Although we again observed the marked tendency for faster
epithelial closure for the s-PRGF treatment, we could not find significant differences. This fact suggests
that increasing the number of analyzed animals would be advisable.
When we analyzed the number of corneal defects that had completely healed, we found that at
day 3 after surgery, 78% of them had re-epithelialized in the s-PRGF treatment, while only 50% of them
had healed in the eyes treated with any of the other treatments. After 3.5 days, 100% of the corneal
defects had already healed with s-PRGF, compared to only 88% of the eyes treated with any of the
other treatments. However, we did not find significant differences among treatments (Chi-Square test
and Fisher’s exact test).
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Figure 5. Re-epithelialization of corneal defects in rabbit eyes. (A) Evolution of the epithelial defect was
monitored with fluorescein staining in eyes treated with topical s-PRGF, s-PRGF and NaHA, NaHA, or
PBS as a control treatment. (B) Histological sections of rabbit central corneas after complete healing
were stained with hematoxylin and eosin. Corneas were processed seven days after surgery or at
30 days. Scale bar: 5 mm for (A), 50 μm for (B).
Table 1. In vivo experiment assessing the progression of epithelial wound healing in rabbit eyes treated
with s-PRGF, s-PRGF and NaHA, NaHA, and PBS as the control. The results are expressed as mean
wound area ± standard deviation in mm2.
Treatment
TIME (days)
Day 0 Day 1 Day 1.5 Day 2 Day 2.5 Day 3 Day 3.5
Control 72.32 ± 7.32 47.02 ± 4.84 33.28 ± 3.06 12.93 ± 3.36 6.12 ± 3.24 0.53 ± 0.99 0.06 ± 0.16
s-PRGF 71.91 ± 4.39 46.19 ± 4.06 30.22 ± 4.09 10.00 ± 3.15 3.65 ± 2.79 0.05 ± 0.10 0
NaHA 72.48 ± 5.13 45.32 ± 4.20 36.72 ± 7.74 12.46 ± 5.17 5.98 ± 3.69 0.65 ± 1.23 0.10 ± 0.27
s-PRGF + NaHA 72.57 ± 2.77 48.06 ± 8.97 37.44 ± 7.63 13.59 ± 5.26 6.14 ± 3.71 0.46 ± 0.76 0.02 ± 0.06
No significant differences between any treatments were found (Kruskal–Wallis test, p ≥ 0.05).
Analysis of hematoxylin and eosin sections of the rabbit central corneas showed complete
regeneration with normal histology of the epithelium in all corneas. However, we observed that
corneas treated with NaHA showed a less compacted epithelium in the basal layers at day 7, suggesting
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that there might be adhesion deficiencies within epithelial layers, or even between the epithelium
and stroma layers (Figure 5B). In addition, when euthanasia was performed 7 days after surgery, the
number of keratocytes in the anterior third of the stroma was influenced by the treatment, with the
s-PRGF and NaHA the only treatment that showed cells in the whole stroma. At 30 days after surgery,
treatments with NaHA (alone or combined) showed the highest cell population across the anterior
third of the stroma.
2.4. Immunohistochemical Analyses of the Epithelial Differentiation, Proliferation, Adhesion, and Fibrosis of the
Re-Epithelialized Corneas
To assess differences in the mechanisms through which the treatments performed corneal wound
healing, we used immunohistochemistry techniques to analyze cryopreserved sections of healed rabbit
corneas at 7 and 30 days after surgery. We also added a healthy control (healthy rabbit cornea, which
did not undergo surgery) and a wounded cornea (processed only 48 h after surgery, wound healing or
W-H control). Specifically, we studied the processes of differentiation, proliferation and adhesion, the
corneal barrier effect of the epithelium, and stromal fibrosis.
First, we performed a double staining for cytokeratin 3/76 (CK3), a corneal epithelium marker,
and cytokeratin 15 (CK15), a stem cell marker, in both the re-epithelialized central cornea and the
peripheral limbus. As we expected, we found CK3 positive staining and CK15 negative labeling in
the central epithelium area of all eyes (Figure 6). At the limbal area, we found positive CK15 staining
in the basal layers of all corneas (Figure 7). This staining is coherent with the presence of limbal
stem/progenitor cells, and it was especially intense in the W-H control, where these cells might be
specifically activated to regenerate the wounded epithelial area.
Figure 6. Fluorescent immunostaining for CK3 (red) and CK15 (green) on the regenerated central
cornea of rabbit corneas after healing of the epithelial defect. Corneas were treated with s-PRGF,
s-PRGF and NaHA, NaHA, or PBS (as a control) and were processed 7 and 30 days after cornea surgery.
Control corresponds to a healthy rabbit cornea with no surgery. The W-H image shows a cornea
processed 48 h after surgery without complete re-epithelialization. Magnification 200×.
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We evaluated cell proliferation by analyzing the nuclear staining of the proliferation marker
Ki76. Results showed a higher number of positive cells at 7 days after surgery than 30 days (Table 2).
Interestingly, at 7 days, the nuclear staining was not confined to the epithelium but also appeared in
the third anterior stroma. However, proliferation in the epithelium was significantly higher than in the
stroma for all treatments, both at 7 days (p < 0.001) and at 30 days (p < 0.0001) (Wilcoxon rank sum
test). Specifically, corneas treated with NaHA showed a higher number of Ki67 proliferative cells in
both areas (epithelium and stroma) than corneas under the other treatments. Differences were highly
significant for the epithelium (Table 2). This result is consistent with that of the proliferation study in
HCE cells, in which we observed that NaHA induced higher proliferation in the short-term than the
rest of the treatments under study. At 30 days after surgery, cell proliferation was lower and occurred
merely in the corneal epithelium.
Figure 7. Fluorescent immunostaining for CK3 (red) and CK15 (green) on the limbal area of rabbit
corneas after healing of the epithelial defect. Corneas were treated with s-PRGF, s-PRGF and NaHA,
NaHA, or PBS (as a control) and were processed 7 and 30 days after cornea surgery. Control corresponds
to a healthy rabbit cornea with no surgery. The W-H image shows a cornea processed 48 h after surgery
without complete re-epithelialization. The dotted line shows the limit between the epithelium and
stroma layers. Magnification 200×.
We also studied the marker of tight junctions ZO-1, in order to evaluate the recovery of the barrier
effect in the regenerated corneal epithelium. We observed apical staining of the epithelium in all
corneas, which was more intense at 30 days after surgery than at 7 days (Figure 8). Of note, W-H
corneas, which only had a cell monolayer covering the wound area, showed a positive staining as well,
meaning that the recovering of the epithelial barrier function is a priority in wound healing.
13
Int. J. Mol. Sci. 2019, 20, 1655
Figure 8. Fluorescent immunostaining for ZO-1 on rabbit central corneas after healing of the epithelial
defect. Rabbit corneas were treated with s-PRGF, s-PRGF and NaHA, NaHA, or PBS (as a control), and
were processed 7 and 30 days after cornea surgery. Control corresponds to a healthy rabbit cornea
with no surgery. The W-H image shows a cornea processed 48 h after surgery without complete
re-epithelialization. Magnification 200×.
In order to study the adhesion property between the regenerated epithelium and the underlying
stroma, we performed immunohistochemical staining for β4 integrin, a cellular component of
hemidesmosomes. Results showed that s-PRGF treatments (combined or not) had a more intense and
continuous staining at 7 days (Figure 9). At 30 days after surgery, we could observe a normal staining
underlying the epithelium all along the cornea in all the treatments. In W-H samples, although a fine
layer of regenerated epithelium appeared, we could not detect the β4 integrin staining.
Finally, by detecting the α-SMA protein, we analyzed the differentiation process from keratocytes
to myofibroblasts in the wounded area as a sign of fibrosis. We did not detect positivity in the
cytoplasm of the stromal cells of the repaired tissues in any case (data not shown).
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Figure 9. Fluorescent immunostaining for β4 integrin on rabbit central corneas after healing of the
epithelial defect. Rabbit corneas were treated with s-PRGF, s-PRGF and NaHA, NaHA, or PBS (as a
control) and were processed 7 and 30 days after cornea surgery. Control corresponds to a healthy rabbit
cornea with no surgery. The W-H image shows a cornea processed 48 h after surgery without complete
re-epithelialization. Magnification 200×.
Table 2. Number of Ki67 positive cells in rabbit corneas treated with s-PRGF, s-PRGF and NaHA,
NaHA, and PBS as the control. The results are expressed as mean number of cells ± standard deviation
in seven different areas of the central corneas at 7 and 30 days after surgery.
Treatment
7 Days PBS s-PRGF s-PRGF + NaHA NaHA
Epithelium 17 ± 10 4 ± 2 16 ± 15 43 *** ± 20
Stroma 2 ± 1 1 ± 1 2 ± 1 5 ± 4
30 days PBS s-PRGF s-PRGF + NaHA NaHA
Epithelium 12 ± 6 5 Φ ± 2 7 ± 3 4 ΦΦ ± 2
Stroma 0.3 ± 0.5 0.3 ± 0.5 0.3 ± 0.5 0.4 ± 0.8
Statistically significant differences with respect to s-PRGF (*) or PBS (Φ) (Φ p < 0.05; ΦΦ p < 0,01; *** p < 0.001,
Kruskal–Wallis test, Dunn test with Bonferroni correction to Multiple Comparisons).
3. Discussion
It has been shown that HA improves in vitro proliferation and migration of corneal and
conjunctival epithelium [44,45]. Moreover, it stabilizes the epithelial barrier of the corneal surface
by binding to its corneal and conjunctiva receptor, hialadherin CD44 [46]. It has been also proven
that HA helps migration and proliferation of fibroblasts [27]. In addition, it has no cytotoxicity to
epithelial cells of the ocular surface, has antioxidant properties, and tends to reduce the toxic effects of
preservatives [47]. However, other studies have indicated that HA specifically influences the migration
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of corneal epithelial cells, but not the proliferation, so that the benefit of HA in the healing of corneal
wounds would be related to rapid cell migration [48].
Taking into account these results and based on the premise that HA has bioadhesive properties,
we set out to assess whether the combination of the blood product s-PRGF with HA was able to
increase the exposure time of the blood product to the cornea, so that the number of instillations in the
treatment of the corneal epithelial defect could be reduced, thus facilitating therapeutic compliance in
the case of clinical treatments. To this aim, we performed in vitro proliferation and migration assays,
as well as in vivo assays in a rabbit model of an induced corneal epithelial defect.
Our proliferation results show that HA (in our case, sodium hyaluronate or NaHA) alone favors
the proliferation of the human corneal epithelial line HCE, with better results than s-PRGF and the
combination of both. However, the effect of NaHA on the capacity of induction of proliferation on the
rabbit primary cells RPCE is similar to that of the other treatments, including the reference treatment
with FBS and the negative control (BSA). On the other hand, the analysis of the Ki67 proliferation
marker confirms a greater proliferative effect of NaHA on the central corneal epithelial cells (as well as
on stromal keratocytes), with respect to the rest of treatments. This difference in proliferation rates
according to the cell type studied may be due to the fact that the HCE are more differentiated cells
and are more sensitive to certain signals in the microenvironment, while the RPCE are cells with
greater intrinsic power since they contain progenitor epithelial cells. According to certain authors, the
ability to stimulate proliferation on corneal epithelial cells depends on the concentration of EGF in the
medium they are cultured with [13]. We observed, in the primary cultures, equivalent proliferation
rates with medium containing EGF (s-PRGF treatment, combined or not combined with NaHa), or
not containing EGF (NaHA and even in the BSA control treatment). Therefore, we propose that the
proliferation of RPCE cells is independent, in the short term, from the medium to which they are
exposed, since they have an intrinsic proliferation capacity. However, HCE epithelial cells mimic cells
in the central cornea and show increased proliferation in response to HA.
On the other hand, our results suggest that a negative interaction between s-PRGF and NaHA
occurs, so that the proliferative capacity of the HCE cells decreases when both are combined with
respect to any of them alone. This result is supported by studies by other authors who have tested
other mucoadhesive polymers, such as polyacrilic acid, combined with the platelet lysate in rabbit
primary cultures, in both corneal epithelial cells and keratocytes. They show that cell proliferation is
lower than when using platelet lysate alone [31].
However, the combination of HA with PRP on chondrocytes (mesodermal cells, such as corneal
fibroblasts) improved cell proliferation, although not in a statistically significant manner [49], while
significant changes in the expression levels of certain inflammatory markers and extracellular matrix
proteins were observed. In addition, randomized controlled studies showed improvement in the
clinical outcome of osteoarthritis of the knee when treated with HA and PRP with respect to PRP at
three months, as well as with respect to HA at one year [50].
Considering this, we can conclude that the combination of s-PRGF and NaHA does not act
synergistically in the proliferation of some kinds of cells of ectodermal origin, such as the corneal
epithelium, and could even disadvantage the proliferative effect that HA has. Conversely, this
combination does favor the proliferation of some kinds of mesodermal cells [43,49]. All of this suggests
that the effect of the PRPs or the HA, or the combination of both, is dependent on the cell type and that
it can also favor different biological functions depending on the case.
To study the effect of the combination of NaHA and s-PRGF on corneal re-epithelialization, we
performed an in vitro wound healing assay in HCE cells and RPCE cells. We observed that the NaHA
alone is not as good as s-PRGF alone for re-epithelialization. In fact, s-PRGF alone is the treatment
that best stimulates corneal re-epithelialization. However, NaHA alone stimulates cell migration to a
greater extent in primary cultures (RPCE) than in the HCE cell line. On the other hand, the combination
of both did not provide any benefit in most of the assays, or was even counterproductive in the in vitro
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test with RPCE, in which the addition of NaHA to the blood product impairs the re-epithelialization
capacity of s-PRGF.
The fact that NaHA favors, in a certain way, the epithelial closure of the RPCE could be explained
by the fact that HA is an essential component of the niche matrix of limbal progenitor cells [51], so that
more undifferentiated cells, such as the RPCE (which still retain the HA receptors), when in contact
with HA, could migrate more actively than differentiated corneal epithelial cells (HCE).
We did not observe significant differences in the in vivo re-epithelialization capacity between any
of the treatments used (s-PRGF, NaHA, both combined, or PBS as the control treatment), although
s-PRGF offered a tendency to achieve better results both in the evolution of the area of the corneal
defect and in the number of defects totally closed at certain times. In other in vivo studies performed
on mesodermal tissues, different results have been found: Cartilage repair of better quality is achieved
when PRP is combined with HA, compared to HA alone [52], and excellent results with the combination
of HA and PRP in the repair of pressure ulcers and surgical wounds have also been reported [53].
However, other authors have shown equal cartilage repair capacity histologically in an in vivo model
when using PRP, with respect to the combined use of PRP and HA [54].
Our histological analysis by hematoxylin and eosin staining showed correct epithelia in all
cases, although those treated with NaHA were more disorganized than those undergoing other
treatments or healthy controls. In addition, a greater density of fibroblast cells was observed in the
anterior stroma of the corneas treated with NaHA, alone or combined with s-PRGF, at 30 days after
in vivo scraping surgery. It has been described that stromal cells, possibly myofibroblasts, migrate
to the superficial layers of the stroma to help close the exposed area [55]. By Ki67 cell proliferation
labeling, we have demonstrated that NaHA induces proliferation in both epithelial and stromal cells,
mainly in the first days after injury. The rapid initial epithelial proliferation may be the reason for
the disorganization of the epithelia in the corneas under this treatment. However, the proliferation
(Ki67 positive cells) obtained in the anterior stroma suggests that the accumulation of cells in that
area is not only due to the cell proliferation process, but is also the result of cell migration, as other
authors have described. In the case of combined treatment, s-PRGF can also contribute to this, since
the histological images show the highest cell density for this treatment. In addition, we have already
demonstrated through transwell-type migration experiments that s-PRGF exerts a chemotactic effect
on corneal keratocytes [18].
The immunohistochemical analysis revealed similar results for the CK3 and CK15 markers, as
well as for the ZO-1 protein, between the different treatments. CK15 is a marker of progenitor cells of
the corneal epithelium [56], whose positivity is restricted to the basal layers of the limbal epithelium.
Our results confirm the presence of these cells in the sclero-corneal limbus of all the corneas studied.
When these cells divide and differentiate towards corneal epithelial cells, during their displacement
of centripetal and ascending form in the cornea, they progressively express a greater labeling of the
CK3 [57,58]. Similarly, the epithelial cells located in the most anterior part of the corneal epithelium
express the protein belonging to the tight junction ZO-1 [59]. In all treatments, both at 7 days and
30 days after surgery, we observed a similar labeling of both proteins, demonstrating that all treatments
achieve re-epithelialization of damaged corneas, generating a mature and functional corneal epithelium.
It is curious to observe how the barrier function of the corneal epithelium (positivity for ZO-1) is
established from the very beginning of the repair of the lesion, being observed even in those incipient
epithelia formed by a single cell monolayer. Therefore, we could suggest that the establishment of the
corneal barrier function is a priority in corneal healing.
Regarding the adhesion property between the newly repaired epithelium and the underlying
extracellular matrix, our results show that it could be favored by treatment with s-PRGF. Thus, the
β4 integrin protein is one of the components that forms part of the hemidesmosome-type junctions
between the epithelium and the matrix [60], in order to achieve a compact and stable tissue. At short
follow up times (7 days post-surgery), corneas treated with s-PRGF, alone or in combination, show
the most intense and continuous labeling for β4 integrin, suggesting that this hemoderivative favors
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epithelial adhesion and that the combination with NaHA does not diminish this effect. This data is
very important, since it can explain the efficacy of s-PRGF in the treatment of persistent and recurrent
corneal epithelial defects [4].
4. Materials and Methods
4.1. Ethics Statements
This study was performed in accordance with the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research. The procedures and experimental designs were approved by the
Animal Experimentation Ethics Committee of the University of the Basque Country UPV/EHU (Permit
license: CEBA/49-P03-02/2010/ANDOLLO VICTORIANO, 2011/03/11) and fulfill European and
national laws.
4.2. Isolation and Expansion of Rabbit Primary Corneal Epithelial (RPCE) Cultures
To obtain RPCE cultures, 0.5 × 0.3 cm explants of corneas, including the limbal area, were seeded
in plastic culture wells, with the corneal stroma down. We used corneas from the eyes of three
2.0–2.5 kg female New Zealand rabbits. The cells that grew from the explants were maintained at 37 ◦C
under 5% CO2 in DMEM: Ham′s F12 mix with 2 mM L-glutamine (Lonza, Verviers, Belgium) and
1% penicillin–streptomycin (Lonza), together with 10% fetal bovine serum (FBS; Lonza). This culture
medium was also supplemented with 10 ng/mL EGF (Sigma, St. Louis, MO, USA), 5 μg/mL insulin
(Sigma), and 0.1 μg/mL cholera toxin (Gentaur Molecular Products, Brussels, Belgium). The positive
staining for corneal epithelial markers was confirmed by immunolabeling. Cells were positive for the
CK3 corneal epithelial, as well as for the CK15 and vimentin corneal epithelial stem/progenitor cell
markers (Data not shown or Figure S1).
4.3. Human Corneal Epithelial (HCE) Cell Line Culture
SV-40 immortalized HCE cells were kindly provided by Dr. Araki-Sasaki et al. These cells were
cultured at 37 ◦C under the same conditions as the RPCE cells, with the addition of the supplement
0.5% DMSO (Sigma) to the culture medium.
4.4. s-PRGF Preparation
For human s-PRGF preparation, blood was collected by venipuncture in tubes with 3.8% sodium
citrate as an anticoagulant (BD Biosciences, Franklin Lakes, NJ, USA). Blood was centrifuged for 8 min
at 460× g. After collection of the complete supernatant fraction above the buffy coat, in order to
induce clot formation, calcium chloride (Braun, Barcelona, Spain) was added at a final concentration of
22.8 mM. After incubation of the samples for 2 h at 36 ◦C, the fibrin clot was retracted and removed;
the remaining fraction was the s-PRGF [61].
For rabbit s-PRGF preparation, the human protocol varied as follows: Blood was centrifuged for
8 min at 650 g. Following addition of calcium chloride, samples were incubated for 1 h at 36 ◦C [18].
For in vitro assays, the complement was heat inactivated in s-PRGF, and samples from several
individuals pooled to obtain representative blood preparations that could provide reproducible results
with minimal interindividual variability. Samples were stored at −20 ◦C.
For in vivo assays, autologous s-PRGF was obtained and stored at −20 ◦C until use.
4.5. Bioadhesive (Hyaluronic Acid) Preparation
We used an ophthalmic grade sodium hyaluronate (NaHA) with a molecular weight
of 200–400 kDa (Abarán Materias Primas SL, Barcelona, Spain) in PBS (phosphate buffered
saline solution).
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4.6. In Vitro and In Vivo Treatments
RPCE and HCE cells were cultured under the following treatments for in vitro experiments: 1%
BSA (Bovine serum albumin); 10% FBS; 45% s-PRGF; 45% s-PRGF and 0.1% NaHA; and 0.1% NaHA.
The above products were diluted in supplemented culture medium (Table S1).
We used the following treatments for in vivo experiments: PBS; 90% s-PRGF; 90% s-PRGF and
0.2% NaHA; and 0.2% NaHA. The above products were diluted in PBS.
4.7. Cell Proliferation Assays
For these experiments, 3000 HCE cells (2500 in the case of RPCE cells) were seeded per well in
96-well plates. After synchronizing the cultures using DMEM:F12 with 1% BSA (Table S1) for 16 h,
culture medium was substituted by the treatments to be tested (Table S1). Cell proliferation was
analyzed at 0, 24, 48, and 72 h. Proliferation was described in terms of proliferation rate ± SD of
viable cells, with respect to viable cells just before exposure to treatment (t = 0 h). This was measured
using a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide or MTT assay (Sigma-Aldrich),
as previously described [61]. Optical densities at 540 nm were determined using a microplate
reader (ELx800 Microplate Reader, BioTek® Instruments, Winooski, VT, USA). All experiments were
performed in quadruplicate and repeated in three biological replicates.
4.8. In Vitro Wound Healing Assays
These experiments were performed as previously described [1]. Briefly, 25,000 RPCE culture cells
(20,000 in the case of HCE cells) were seeded per well in 96-well plates and left to form monolayers.
Once the cultures were synchronized by using DMEM:F12 with 1% BSA (Table S1) for 16 h, a circular
central epithelial defect was created using a tip. Wells were divided in groups depending on the
treatment (Table S1). After that, areas from which cells had been scraped away were photographed
every 12 h with a phase contrast microscope (Nikon Eclipse TS 100; Nikon, Tokyo, Japan) and the
images were acquired with the ProgRes CapturePro 2.6 software (Jenoptik, Jena, Germany). The size of
the denuded areas was quantified using ImageJ software (developed by Wayne Rasband at the Research
Services Branch, National Institute of Mental Health, Bethesda, MD). The closure rate was described
in terms of the mean remaining denuded area ± SD in square millimeters. All the experiments were
performed at least in quintuplicate (5 wells) and repeated in three biological replicates of RPCE and
HCE cultures. For wound healing experiments in HCE cells (with high proliferation capacity), cells
were previously treated with 10 μg/mL of mitomycin C for 3 h at 37 ◦C and washed three times with
PBS after that. Afterwards, HCE cells were separated from the well by using EDTA-trypsin, and then
seeded. In the case of RPCE cells, this step was not needed.
4.9. In Vivo Rabbit Corneal Re-Epithelialization Assays
Seventeen adult 2.0–2.5 kg female New Zealand white rabbits (33 eyes) were included in the
study. They were under diary observation to assess their welfare. Initially, each rabbit underwent
surgery in the right eye and the left eye was then operated on two to three weeks after the right eye
had recovered.
The corneal epithelium inside a 9-mm corneal trephine circular mark was scraped off with an
ophthalmic blade as previously described [1], without the limbal area being involved. Postoperatively,
until the epithelial closure was complete, every rabbit was treated twice a day with topical
dexamethasone and chloramphenicol (Deicol® ophthalmic ointment, Alcon laboratories, Barcelona,
Spain), diclofenac drops (Voltaren® drops, Allergan, Irvine, CA, OSA), and with one of the treatments
under study. Rabbits were randomized for each surgical intervention into one of the following four
groups: (1) PBS (control), (2) 90% s-PRGF, (3) 90% s-PRGF and 0.2% NaHA, and (4) 0.2% NaHA.
PBS was used for the dilution of treatments. In addition, the order in which the animals in the different
experimental groups were treated was randomized.
19
Int. J. Mol. Sci. 2019, 20, 1655
To assess the size of the residual epithelial defect, the eyes were photographed with and without
fluorescein once a day, with a ruler placed in the same plane as the ocular surface, and always at the
same time of day. Wounded areas were measured using ImageJ software and results were expressed
as mean wound area ± SD in mm2. Rabbit eyes were also examined for signs of corneal inflammation
and neovascularization.
4.10. Immunocytochemistry and Histochemical Analysis
The positive staining for corneal epithelial markers of primary cultures was confirmed by
immunolabeling for CK3, CK15, and vimentin markers. Single cells were spin onto microscope
slides using a cytospin (Cytofuge; Fisher Scientific, Houston, TX, USA). Cells were fixed with 2%
paraformaldehyde (Table S2) and immunostaining was performed in the same manner as with tissue
sections (see below).
After both eyes of each animal had been operated on and followed-up; that is, 7 days after
surgery for the left eyes and 30 days after surgery for the right eyes, half of the corneas from each
treatment were fixed in 2% paraformaldehyde and posteriorly included in paraffin to perform H-E
staining. Tissue sections were observed with a phase contrast microscope (Nikon Eclipse TS 100)
and images were acquired with the ProgRes CapturePro 2.6 software. We evaluated the structural
integrity and histological characteristics of the cornea, as well as the regeneration of the epithelium
and cell infiltration.
The other half of the corneas from each treatment were included in OCT (Optimal Cutting
Temperature) compound (TissueTek®, Sakura Finetek, NL) and frozen below −80 ◦C. Tissue sections
of 10 μm were made with a Leica CM 3050S cryostat (Leica Biosystems, Barcelona, Spain) and stored
below −20 ◦C until immunofluorescent staining, according to conventional protocols. Briefly, sections
were fixed using 2% paraformaldehyde or acetone (Table S2) and permeabilized in the former case with
phosphate-buffered saline (PBS) solution containing 0.5% Triton X-100 (Sigma) for 10 min. To minimize
nonspecific signals, sections were incubated for an additional hour with blocking solution, consisting of
PBS containing 0.1% Triton X-100 (PBT) with 5% BSA and 10% FBS. After that, sections were incubated
at 4 ◦C overnight with the appropriate primary antibodies at the respective dilutions in blocking
solution (Table S2). After the sections were washed with phosphate-buffered saline, the samples were
incubated with Alexa Fluor secondary antibodies (Invitrogen) (Table S2) for 1 h at room temperature
and protected from light. The DNA specific dye DAPI (1 μg/mL, Sigma) was used to detect nuclei.
Finally, the sections were mounted with Fluoromount-g (Electron Microscopy Sciences, Hatfield, PA,
USA) and photographed with a fluorescence microscope (Zeiss, Göttingen, Germany).
4.11. Statistical Analysis
R program, version 3.4.0. (R Foundation for Statistical Computing, General Public License,
University of Auckland, New Zealand) was used to calculate means and standard deviations and
to perform statistical tests. To assess the statistical significance of two mean differences we used the
Wilcoxon rank sum test. For the statistical comparison of mean differences between treatments we
used the Kruskall–Wallis test and Dunn’s test with Bonferroni correction to Multiple Comparisons.
For qualitative variables we used the Chi-squared test and Fisher’s exact test. The Kaplan–Meier
estimator was also used to study the number of days that corneal epithelial defects took to heal
completely. Differences were considered statistically significant when p-values were <0.05.
5. Conclusions
In summary, we must bear in mind that the use of biopolymers associated with medications
in the eye has its limitations, since they can produce blurred vision after instillation for longer
than usual [62,63]. In addition, we have not found additional benefit in terms of in vivo corneal
epithelial wound healing when used in combination. Therefore, it is possible that the HA used in the
concentrations employed in clinical practice (0.1–0.4%) creates a shield that restricts the contact of the
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s-PRGF components with their receptors [25], or acts by seizing growth factors, instead of as a vehicle
that facilitates long-standing contact of growth factors with the ocular surface, making their combined
use have a worse effect than their use alone.
It is critical when evaluating the results of the combination of HA and PRP to perform different
tests in which different molecular weights and concentrations of the HA are studied (our HA has
200–400 kDa) with different concentrations and formulations of the PRP it is combined with [64].
In this sense, discrepancies are again found among authors who suggest that L-PRP (leukocyte-rich
PRP) has more anti-inflammatory and anabolic effects [65] and others that affirm the opposite [66].
On the other hand, HA is a necessary component of the limbal niche. HA has a very significant
role in the maintenance of the phenotype of the limbal progenitor cells [52], so damage to the HA that
forms the limbal niche produces an alteration in epithelial corneal regeneration. Similarly, PRP also
seems to maintain the undifferentiated phenotype of mesenchymal stem cells [67,68].
In addition, the combination of PRP and HA seems to favor the viability and proliferation of
mesenchymal stem cells [69]. However, it remains to be demonstrated that the combination of PRP with
HA is superior to the use of each of the treatments separately in the maintenance of the undifferentiated
phenotype of the corneal scleral limbal cells.
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PRP Platelet Rich Plasma
s-PRGF Serum derived from Plasma Rich in Growth Factors
HCE Human Corneal Epithelial
RPCE Rabbit Primary Corneal Epithelial
PBS Phosphate Buffered Saline
FBS Fetal Bovine Serum
BSA Bovine Serum Albumin
OCT Optimal Cutting Temperature compound




CD Cluster of Differentiation
CK Cytokeratin
ZO-1 Zonula Occludens-1
α-SMA Alpha-Smooth Muscle Actin
21
Int. J. Mol. Sci. 2019, 20, 1655
References
1. Freire, V.; Andollo, N.; Etxebarria, J.; Hernáez-Moya, R.; Durán, J.A.; Morales, M.C. Corneal wound healing
promoted by 3 blood derivatives: An in vitro and in vivo comparative study. Cornea 2014, 33, 614–620.
[CrossRef] [PubMed]
2. Tseng, S.C.G.; Tsubota, K. Important concepts for treating ocular surface and tear disorders. Am. J. Ophthalmol.
1997, 124, 825–835. [CrossRef]
3. Klenkler, B.; Sheardown, H. Growth factors in the anterior segment: Role in tissue maintenance, wound
healing and ocular pathology. Exp. Eye Res. 2004, 79, 677–688. [CrossRef] [PubMed]
4. López-Plandolit, S.; Morales, M.C.; Freire, V.; Etxebarria, J.; Durán, J.A. Plasma Rich in Growth Factors as a
Therapeutic Agent for Persistent Corneal Epithelial Defects. Cornea 2010, 29, 843–848. [CrossRef] [PubMed]
5. Panda, A.; Pushker, N.; Bageshwar, L.M. Lateral tarsorrhaphy: Is it preferable to patching? Cornea 1999, 18,
299–301. [CrossRef] [PubMed]
6. Rosenthal, P.; Cotter, J.M.; Baum, J. Treatment of persistent corneal epithelial defect with extended wear of a
fluid-ventilated gas-permeable scleral contact lens. Am. J. Ophthalmol. 2000, 130, 33–41. [CrossRef]
7. Seitz, B.; Grüterich, M.; Cursiefen, C.; Kruse, F.E. Konservative und chirurgische therapie der neurotrophen
keratopathie. Ophthalmologe 2005, 102, 15–26. [CrossRef]
8. Kruse, F.E.; Rohrschneider, K.; Völcker, H.E. Multilayer amniotic membrane transplantation for
reconstruction of deep corneal ulcers. Ophthalmology 1999, 106, 1504–1511. [CrossRef]
9. Lambiase, A.; Rama, P.; Bonini, S.; Caprioglio, G.; Aloe, L. Topical Treatment with Nerve Growth Factor for
Corneal Neurotrophic Ulcers. N. Engl. J. Med. 1998, 338, 1174–1180. [CrossRef]
10. Murali, S.; Hardten, D.R.; Demartelaere, S.; Olevsky, O.M.; Mindrup, E.A.; Hecht, M.L.; Karlstad, R.;
Chan, C.C.; Holland, E.J. Effect of topically administered platelet-derived growth factor on corneal wound
strength. Curr. Eye Res. 1994, 13, 857–862. [CrossRef]
11. Pastor, J.C.; Calonge, M. Epidermal growth factor and corneal wound healing: A multicenter study. Cornea
1992, 11, 311–314. [CrossRef] [PubMed]
12. Han, K.E.; Park, M.H.; Kong, K.H.; Choi, E.; Choi, K.-R.; Jun, R.M. Therapeutic Effects of Three
Human-derived Materials in a Mouse Corneal Alkali Burn. Cutan. Ocul. Toxicol. 2019, 10, 1–24. [CrossRef]
[PubMed]
13. Yamada, N.; Matsuda, R.; Morishige, N.; Yanai, R.; Chikama, T.I.; Nishida, T.; Ishimitsu, T.; Kamiya, A.
Open clinical study of eye-drops containing tetrapeptides derived from substance P and insulin-like growth
factor-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy.
Br. J. Ophthalmol. 2008, 92, 896–900. [CrossRef] [PubMed]
14. Tsubota, K.; Goto, E.; Shimmura, S.; Shimazaki, J. Treatment of persistent corneal epithelial defect by
autologous serum application. Ophthalmology 1999, 106, 1984–1989. [CrossRef]
15. Alio, J.L.; Abad, M.; Artola, A.; Rodriguez-Prats, J.L.; Pastor, S.; Ruiz-Colecha, J. Use of autologous
Platelet-Rich Plasma in the treatment of dormant corneal ulcers. Ophthalmology 2007, 114, 1286–1293.
[CrossRef] [PubMed]
16. Geerling, G.; MacLennan, S.; Hartwig, D. Autologous serum eye drops for ocular surface disorders.
Br. J. Ophthalmol. 2004, 88, 1467–1474. [CrossRef]
17. López-Plandolit, S.; Morales, M.C.; Freire, V.; Grau, A.E.; Durán, J.A. Efficacy of Plasma Rich in Growth
Factors for the Treatment of Dry Eye. Cornea 2011, 30, 1312–1317. [CrossRef]
18. Etxebarria, J.; Sanz-Lázaro, S.; Hernáez-Moya, R.; Freire, V.; Durán, J.A.; Morales, M.C.; Andollo, N. Serum
from plasma rich in growth factors regenerates rabbit corneas by promoting cell proliferation, migration,
differentiation, adhesion and limbal stemness. Acta Ophthalmol. 2017, 95, e693–e705. [CrossRef] [PubMed]
19. Anitua, E.; de la Fuente, M.; Muruzabal, F.; Riestra, A.; Merayo-Lloves, J.; Orive, G. Plasma rich in growth
factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular
surface stromal fibroblasts. Exp. Eye Res. 2015, 135, 118–126. [CrossRef]
20. Anitua, E.; Zalduendo, M.; Troya, M.; Padilla, S.; Orive, G. Leukocyte inclusion within a platelet rich
plasma-derived fibrin scaffold stimulates a more pro-inflammatory environment and alters fibrin properties.
PLoS ONE 2015, 10, e0121713. [CrossRef]
22
Int. J. Mol. Sci. 2019, 20, 1655
21. Bongiovì, F.; Di Prima, G.; Palumbo, F.S.; Licciardi, M.; Pitarresi, G.; Giammona, G. Hyaluronic Acid-Based
Micelles as Ocular Platform to Modulate the Loading, Release, and Corneal Permeation of Corticosteroids.
Macromol. Biosci. 2017, 17, 1700261. [CrossRef]
22. De Campos, A.M.; Sánchez, A.; Alonso, M.J. Chitosan nanoparticles: A new vehicle for the improvement of
the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm. 2001, 224, 159–168.
[CrossRef]
23. Yenice, I.; Mocan, M.C.; Palaska, E.; Bochot, A.; Bilensoy, E.; Vural, I.; Irkeç, M.; Atilla Hincal, A. Hyaluronic
acid coated poly-ε-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea.
Exp. Eye Res. 2008, 87, 162–167. [CrossRef]
24. Zeng, W.; Li, Q.; Wan, T.; Liu, C.; Pan, W.; Wu, Z.; Zhang, G.; Pan, J.; Qin, M.; Lin, Y.; et al. Hyaluronic
acid-coated niosomes facilitate tacrolimus ocular delivery: Mucoadhesion, precorneal retention, aqueous
humor pharmacokinetics, and transcorneal permeability. Colloids Surf. B Biointerfaces 2016, 141, 28–35.
[CrossRef] [PubMed]
25. Lin, J.; Wu, H.; Wang, Y.; Lin, J.; Chen, Q.; Zhu, X. Preparation and ocular pharmacokinetics of hyaluronan
acid-modified mucoadhesive liposomes. Drug Deliv. 2016, 23, 1144–1151. [CrossRef] [PubMed]
26. Andrés-Guerrero, V.; Vicario-de-la-Torre, M.; Molina-Martínez, I.T.; Benítez-del-Castillo, J.M.;
García-Feijoo, J.; Herrero-Vanrell, R. Comparison of the in vitro tolerance and in vivo efficacy of traditional
timolol maleate eye drops versus new formulations with bioadhesive polymers. Investig. Ophthalmol. Vis. Sci.
2011, 52, 3548–3556. [CrossRef] [PubMed]
27. Voigt, J.; Driver, V.R. Hyaluronic acid derivatives and their healing effect on burns, epithelial surgical
wounds, and chronic wounds: A systematic review and meta-analysis of randomized controlled trials.
Wound Repair Regen. 2012, 20, 317–331. [CrossRef] [PubMed]
28. Steven, P.; Scherer, D.; Krösser, S.; Beckert, M.; Cursiefen, C.; Kaercher, T. Semifluorinated Alkane Eye Drops
for Treatment of Dry Eye Disease—A Prospective, Multicenter Noninterventional Study. J. Ocul. Pharmacol.
Ther. 2015, 31, 498–503. [CrossRef] [PubMed]
29. Prause, J.U. Treatment of keratoconjunctivitis sicca with Lacrisert. Scand. J. Rheumatol. Suppl. 1986, 61,
261–263.
30. Ciolino, J.B.; Ross, A.E.; Tulsan, R.; Watts, A.C.; Wang, R.F.; Zurakowski, D.; Serle, J.B.; Kohane, D.S.
Latanoprost-Eluting Contact Lenses in Glaucomatous Monkeys. Ophthalmology 2016, 123, 2085–2092.
[CrossRef]
31. Sandri, G.; Bonferoni, M.C.; Rossi, S.; Ferrari, F.; Mori, M.; Del Fante, C.; Perotti, C.; Scudeller, L.;
Caramella, C. Platelet lysate formulations based on mucoadhesive polymers for the treatment of corneal
lesions. J. Pharm. Pharmacol. 2011, 63, 189–198. [CrossRef] [PubMed]
32. López-García, J.S.; García-Lozano, I.; Rivas, L.; Ramírez, N.; Raposo, R.; Méndez, M.T. Autologous serum
eye drops diluted with sodium hyaluronate: Clinical and experimental comparative study. Acta Ophthalmol.
2014, 92, e22–e29. [CrossRef] [PubMed]
33. Andia, I.; Abate, M. Knee osteoarthritis: Hyaluronic acid, platelet-rich plasma or both in association?
Expert Opin. Biol. Ther. 2014, 14, 635–649. [CrossRef] [PubMed]
34. Goa, K.L.; Benfield, P. Hyaluronic Acid: A Review of its Pharmacology and Use as a Surgical Aid in
Ophthalmology, and its Therapeutic Potential in Joint Disease and Wound Healing. Drugs 1994, 47, 536–566.
[CrossRef]
35. Choi, K.Y.; Lee, S.; Park, K.; Kim, K.; Park, J.H.; Kwon, I.C.; Jeong, S.Y. Preparation and characterization of
hyaluronic acid-based hydrogel nanoparticles. J. Phys. Chem. Solids 2008, 69, 1591–1595. [CrossRef]
36. Aragona, P.; Papa, V.; Micali, A.; Santocono, M.; Milazzo, G. Long term treatment with sodium
hyaluronate-containing artificial tears reduces ocular surface damage in patients with dry eye.
Br. J. Ophthalmol. 2002, 86, 181–184. [CrossRef]
37. Müller, W. Bioquímica. Fundamentos para Medicina y Ciencias de la Vida; Ed Reverté: Barcelona, Spain, 2008;
ISBN 9788429173932.
38. Waddell, D.D. Viscosupplementation with hyaluronans for osteoarthritis of the knee: Clinical efficacy and
economic implications. Drugs Aging 2007, 24, 629–642. [CrossRef]
39. Prasadam, I.; Mao, X.; Shi, W.; Crawford, R.; Xiao, Y. Combination of MEK-ERK inhibitor and hyaluronic
acid has a synergistic effect on anti-hypertrophic and pro-chondrogenic activities in osteoarthritis treatment.
J. Mol. Med. 2013, 91, 369–380. [CrossRef] [PubMed]
23
Int. J. Mol. Sci. 2019, 20, 1655
40. Muto, J.; Yamasaki, K.; Taylor, K.R.; Gallo, R.L. Engagement of CD44 by hyaluronan suppresses TLR4
signaling and the septic response to LPS. Mol. Immunol. 2009, 47, 449–456. [CrossRef] [PubMed]
41. Zavan, B.; Ferroni, L.; Giorgi, C.; Calò, G.; Brun, P.; Cortivo, R.; Abatangelo, G.; Pinton, P. Hyaluronic acid
induces activation of the κ-opioid receptor. PLoS ONE 2013, 8, e55510. [CrossRef] [PubMed]
42. Scheibner, K.A.; Lutz, M.A.; Boodoo, S.; Fenton, M.J.; Powell, J.D.; Horton, M.R. Hyaluronan Fragments Act
as an Endogenous Danger Signal by Engaging TLR2. J. Immunol. 2006, 177, 1272–1281. [CrossRef] [PubMed]
43. Anitua, E.; Sanchez, M.; De la Fuente, M.; Zalduendo, M.M.; Orive, G. Plasma rich in growth factors
(PRGF-Endoret) stimulates tendon and synovial fibroblasts migration and improves the biological properties
of hyaluronic acid. Knee Surg. Sport Traumatol. Arthrosc. 2012, 20, 1657–1665. [CrossRef]
44. Calienno, R.; Curcio, C.; Lanzini, M.; Nubile, M.; Mastropasqua, L. In vivo and ex vivo evaluation of cell–cell
interactions, adhesion and migration in ocular surface of patients undergone excimer laser refractive surgery
after topical therapy with different lubricant eyedrops. Int. Ophthalmol. 2018, 38, 1591–1599. [CrossRef]
45. Inoue, M.; Katakami, C. The effect of hyaluronic acid on corneal epithelial cell proliferation.
Investig. Ophthalmol. Vis. Sci. 1993, 34, 2313–2315.
46. Brignole, F.; Pisella, P.J.; Dupas, B.; Baeyens, V.; Baudouin, C. Efficacy and safety of 0.18% sodium hyaluronate
in patients with moderate dry eye syndrome and superficial keratitis. Graefe’s Arch. Clin. Exp. Ophthalmol.
2005, 243, 531–538. [CrossRef]
47. Debbasch, C.; De La Salle, S.B.; Brignole, F.; Rat, P.; Warnet, J.M.; Baudouin, C. Cytoprotective effects of
hyaluronic acid and carbomer 934P in ocular surface epithelial cells. Investig. Ophthalmol. Vis. Sci. 2002, 43,
3409–3415.
48. Gomes, J.A.; Amankwah, R.; Powell-Richards, A.; Dua, H.S. Sodium hyaluronate (hyaluronic acid) promotes
migration of human corneal epithelial cells in vitro. Br. J. Ophthalmol. 2004, 88, 821–825. [CrossRef] [PubMed]
49. Chen, W.H.; Lo, W.C.; Hsu, W.C.; Wei, H.J.; Liu, H.Y.; Lee, C.H.; Tina Chen, S.Y.; Shieh, Y.H.; Williams, D.F.;
Deng, W.P. Synergistic anabolic actions of hyaluronic acid and platelet-rich plasma on cartilage regeneration
in osteoarthritis therapy. Biomaterials 2014, 35, 9599–9607. [CrossRef] [PubMed]
50. Lana, J.F.; Weglein, A.; Sampson, S.E.; Vicente, E.F.; Huber, S.C.; Souza, C.V.; Ambach, M.A.; Vincent, H.;
Urban-Paffaro, A.; Onodera, C.M.; et al. Randomized controlled trial comparing hyaluronic acid, platelet-rich
plasma and the combination of both in the treatment of mild and moderate osteoarthritis of the knee. J. Stem.
Cells Regen. Med. 2016, 12, 69–78.
51. Gesteira, T.F.; Sun, M.; Coulson-Thomas, Y.M.; Yamaguchi, Y.; Yeh, L.-K.; Hascall, V.; Coulson-Thomas, V.J.
Hyaluronan Rich Microenvironment in the Limbal Stem Cell Niche Regulates Limbal Stem Cell
Differentiation. Investig. Ophthalmol. Vis. Sci. 2017, 58, 4407–4421. [CrossRef]
52. Marmotti, A.; Bruzzone, M.; Bonasia, D.E.; Castoldi, F.; Rossi, R.; PIras, L.; Maiello, A.; Realmuto, C.;
Peretti, G.M. One-step osteochondral repair with cartilage fragments in a composite scaffold. Knee Surg.
Sport Traumatol. Arthrosc. 2012, 20, 2590–2601. [CrossRef] [PubMed]
53. Cervelli, V.; Lucarini, L.; Spallone, D.; Palla, L.; Colicchia, G.M.; Gentile, P.; De Angelis, B. Use of Platelet-Rich
Plasma and Hyaluronic Acid in the Loss of Substance with Bone Exposure. Adv. Skin Wound Care 2011, 24,
176–181. [CrossRef] [PubMed]
54. Smyth, N.A.; Ross, K.A.; Haleem, A.M.; Hannon, C.P.; Murawski, C.D.; Do, H.T.; Kennedy, J.G. Platelet-Rich
Plasma and Hyaluronic Acid Are Not Synergistic When Used as Biological Adjuncts with Autologous
Osteochondral Transplantation. Cartilage 2017, 9, 321–328. [CrossRef] [PubMed]
55. Alcalde, I.; Íñigo-Portugués, A.; Carreño, N.; Riestra, A.C.; Merayo-Lloves, J.M. Efectos de nuevos
agentes regenerativos biomiméticos sobre la cicatrización corneal en un modelo experimental de úlceras
posquirúrgicas. Arch. Soc. Esp. Oftalmol. 2015, 90, 467–474. [CrossRef]
56. Yoshida, S.; Shimmura, S.; Kawakita, T.; Miyashita, H.; Den, S.; Shimazaki, J.; Tsubota, K. Cytokeratin 15
can be used to identify the limbal phenotype in normal and diseased ocular surfaces. Investig. Ophthalmol.
Vis. Sci. 2006, 47, 4780–4786. [CrossRef] [PubMed]
57. Schlötzer-Schrehardt, U.; Kruse, F.E. Identification and characterization of limbal stem cells. Exp. Eye Res.
2005, 81, 247–264. [CrossRef] [PubMed]
58. Secker, G.A.; Daniels, J.T. Limbal Epithelial Stem Cells of the Cornea. StemBook; Harvard Stem Cell Institute:
Cambridge, MA, USA, 2008.
24
Int. J. Mol. Sci. 2019, 20, 1655
59. Wu, Z.; Zhou, Q.; Duan, H.; Wang, X.; Xiao, J.; Duan, H.; Li, N.; Li, C.; Wan, P.; Liu, Y.; et al. Reconstruction of
auto-tissue-engineered lamellar cornea by dynamic culture for transplantation: A rabbit model. PLoS ONE
2014, 9, e93012. [CrossRef] [PubMed]
60. Lauweryns, B.; Van den Oord, J.J.; Volpes, R.; Foets, B.; Missotten, L. Distribution of very late
activation integrins in the human cornea: An immunohistochemical study using monoclonal antibodies.
Investig. Ophthalmol. Vis. Sci. 1991, 32, 2079–2085.
61. Freire, V.; Andollo, N.; Etxebarria, J.; Durán, J.A.; Morales, M.C. In Vitro Effects of Three Blood Derivatives
on Human Corneal Epithelial Cells. Investig. Ophthalmol. Vis. Sci. 2012, 53, 5571–5578. [CrossRef]
62. Calonge, M. The treatment of dry eye. Surv. Ophthalmol. 2001, 45, S227–S239. [CrossRef]
63. Johnson, M.E.; Murphy, P.J.; Boulton, M. Carbomer and sodium hyaluronate eyedrops for moderate dry eye
treatment. Optom. Vis. Sci. 2008, 85, 750–757. [CrossRef] [PubMed]
64. Andia, I.; Maffulli, N. A contemporary view of platelet-rich plasma therapies: Moving toward refined clinical
protocols and precise indications. Regen. Med. 2018, 13, 717–728. [CrossRef] [PubMed]
65. Carmona, J.U.; Ríos, D.L.; López, C.; Álvarez, M.E.; Pérez, J.E.; Bohórquez, M.E. In vitro effects of platelet-rich
gel supernatants on histology and chondrocyte apoptosis scores, hyaluronan release and gene expression of
equine cartilage explants challenged with lipopolysaccharide. BMC Vet. Res. 2016, 12, 135. [CrossRef]
66. Assirelli, E.; Filardo, G.; Mariani, E.; Kon, E.; Roffi, A.; Vaccaro, F.; Marcacci, M.; Facchini, A.; Pulsatelli, L.
Effect of two different preparations of platelet-rich plasma on synoviocytes. Knee Surgery. Sport Traumatol.
Arthrosc. 2015, 23, 2690–2703. [CrossRef] [PubMed]
67. Tobita, M.; Tajima, S.; Mizuno, H. Adipose tissue-derived mesenchymal stem cells and platelet-rich plasma:
Stem cell transplantation methods that enhance stemness. Stem Cell Res. Ther. 2015, 6, 215. [CrossRef]
[PubMed]
68. Li, H.; Usas, A.; Poddar, M.; Chen, C.W.; Thompson, S.; Ahani, B.; Cummins, J.; Lavasani, M.; Huard, J.
Platelet-Rich Plasma Promotes the Proliferation of Human Muscle Derived Progenitor Cells and Maintains
Their Stemness. PLoS ONE 2013, 8, e64923. [CrossRef] [PubMed]
69. Vadalà, G.; Russo, F.; Musumeci, M.; D’Este, M.; Cattani, C.; Catanzaro, G.; Tirindelli, M.C.; Lazzari, L.;
Alini, M.; Giordano, R.; et al. Clinically relevant hydrogel-based on hyaluronic acid and platelet rich plasma
as a carrier for mesenchymal stem cells: Rheological and biological characterization. J. Orthop. Res. 2017, 35,
2109–2116. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
25
 International Journal of 
Molecular Sciences
Article
Fibrin Sealant Derived from Human Plasma as
a Scaffold for Bone Grafts Associated with
Photobiomodulation Therapy
Karina Torres Pomini 1 , Daniela Vieira Buchaim 1,2,3, Jesus Carlos Andreo 1,
Marcelie Priscila de Oliveira Rosso 1, Bruna Botteon Della Coletta 1, Íris Jasmin Santos German 4,
Ana Carolina Cestari Biguetti 1, André Luis Shinohara 1, Geraldo Marco Rosa Júnior 5,6,
João Vitor Tadashi Cosin Shindo 1, Murilo Priori Alcalde 5,7, Marco Antônio Hungaro Duarte 7,
Daniel de Bortoli Teixeira 2 and Rogério Leone Buchaim 1,2,*
1 Department of Biological Sciences (Anatomy), Bauru School of Dentistry, University of São Paulo (USP),
Bauru 17012-901, Brazil; karinatorrespomini@gmail.com (K.T.P.); danibuchaim@usp.br (D.V.B.);
jcandreo@usp.br (J.C.A.); marcelierosso@usp.br (M.P.d.O.R.); brucoletta@hotmail.com (B.B.D.C.);
anacarolinacb25@gmail.com (A.C.C.B.); andreshinohara@yahoo.com.br (A.L.S.);
jvshindo@gmail.com (J.V.T.C.S.)
2 Department of Human Morphophysiology, Medical and Dentistry School, University of Marilia (UNIMAR),
Marília 17525-902, Brazil; daniel.dbt@hotmail.com
3 Department of Human Anatomy and Neuroanatomy, Medical School, University Center of
Adamantina (UniFAI), Adamantina 17800-000, Brazil
4 Department of Dentistry, Faculty of Health Science, Universidad Iberoamericana (UNIBE),
Santo Domingo 10203, Dominic Republic; irish_knaan@hotmail.com
5 Department of Health Science, University of the Sacred Heart (USC), Bauru 17011-160, Brazil;
geraldomrjr@yahoo.com.br (G.M.R.J.); murilo_alcalde@hotmail.com (M.P.A.)
6 Department of Anatomy, University of the Ninth of July (UNINOVE), Bauru 17011-102, Brazil
7 Department of Dentistry, Endodontics and Dental Materials, Bauru School of Dentistry, University of
São Paulo (USP), Bauru 17012-901, Brazil; mhungaro@fob.usp.br
* Correspondence: rogerio@fob.usp.br
Received: 14 March 2019; Accepted: 7 April 2019; Published: 10 April 2019
	

Abstract: Fibrin sealants derived from human blood can be used in tissue engineering to assist in the
repair of bone defects. The objective of this study was to evaluate the support system formed by a
xenograft fibrin sealant associated with photobiomodulation therapy of critical defects in rat calvaria.
Thirty-six rats were divided into four groups: BC (n = 8), defect filled with blood clot; FSB (n = 10),
filled with fibrin sealant and xenograft; BCPBMT (n = 8), blood clot and photobiomodulation; FSBPBMT
(n = 10), fibrin sealant, xenograft, and photobiomodulation. The animals were killed after 14 and 42
days. In the histological and microtomographic analysis, new bone formation was observed in all
groups, limited to the defect margins, and without complete wound closure. In the FSB group, bone
formation increased between periods (4.3 ± 0.46 to 6.01 ± 0.32), yet with lower volume density when
compared to the FSBPBMT (5.6 ± 0.45 to 10.64 ± 0.97) group. It was concluded that the support system
formed by the xenograft fibrin sealant associated with the photobiomodulation therapy protocol had
a positive effect on the bone repair process.
Keywords: bone regeneration; bone repair; fibrin sealant; biomaterial; photobiomodulation therapy;
low-level laser therapy
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1. Introduction
There are currently available treatment options for the repair of bone defects, but their effectiveness
is limited in large defects, and the influence of extrinsic factors such as smoking and alcohol
exposure are unfavourable in this process [1–3]. Annually more than two million bone grafts are
performed worldwide, the second most frequent tissue transplantation, being surpassed only by blood
transfusion [4,5].
Among all available types, the autologous graft is still considered the gold standard, since
all the necessary properties in bone regeneration in terms of osteoconduction, osteoinduction, and
osteogenesis are combined [6,7]. However, its availability is limited, and morbidity at the donor site
has led to the development of new bone substitutes that restore, ameliorate, or prevent aggravation of
compromised tissue function [8,9].
In order to solve this problem, tissue engineering has developed xenografts that are skeletal
derivatives of other species, mainly bovine, with satisfactory osteoconductive properties and widely
used in reconstructive procedures with greater scientific evidence among biomaterials [4,10].
To form a graft material mouldable to the surgical bed, facilitate its insertion and agglutination,
and prevent its dispersion and collapse of soft tissue into the defect, biodegradable polymers known
as scaffolds are used as three-dimensional supports for the lodging of cells and biologically active
molecules, providing a favourable environment for tissue regeneration [10].
Among the scaffolds, fibrin sealants derived from human blood may have the potential to guide
this process of bone remodelling, because it has compatible physiological characteristics to human
tissue and thus is readily colonised by the surrounding cells. Thus, they allow surgeons to influence
and improve the cellular microenvironment in vitro or in vivo, increasing the success rate of the bone
graft [11].
Other attempts have been studied to minimise the time of bone healing and to reduce the
chance of possible complications arising from the abnormal regeneration process. Among them,
low-intensity pulsed ultrasound [12] and laser photobiomodulation therapy have been highlighted by
their satisfactory effects on bone metabolism and repair, due to their possible osteogenic effect [13,14].
Laser photobiomodulation therapy is a non-invasive treatment method with relatively low
cost [15]. However, there are controversies regarding the best parameters to be used to obtain an
effective result in the process of bone repair of critical size defects filled with biomaterials [5].
Despite the growing interest in blood-derived biomaterials in the reconstruction of bone defects,
in the literature reviewed, no studies were found on the effects of the combination of sealant with bone
grafts and alternative methods such as photobiomodulation. Thus, this study evaluated the support
system formed by a xenograft fibrin sealant associated with the protocol of photobiomodulation
therapy in critical size defects in rats.
2. Results
2.1. Microtomographic Analysis
In microtomographic images, at 14 days, it was observed that in all the defects, the new bone
formation occurred centripetally from the critical defect margins towards the centre. All groups
exhibited a continuous increase of new bone formation during the analysed periods; however, in no
specimen was there a complete closure of the defect, and the formed bone was restricted to the defect
borders (blue arrow—Figure 1A).
In the groups where the defects were filled with fibrin sealant associated with the xenogeneic
graft (FSB—Fibrin sealant with xenograft, and FSBPBMT—Fibrin sealant with xenograft and
photobiomodulation therapy), the images showed the surgical cavity filled with the materials
implanted and fine bone trabeculae adjacent to the border of the defect and under the dura mater. In
animals that were biostimulated with a low-level laser, a more evident formation of the bone tissue
was observed in FSBPBMT compared to the FSB group (Figure 1A).
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Figure 1. Microtomographic images showing the evolution of the repair of defects filled with clot
and fibrin sealant plus xenograft (biomaterial) with or without low-level laser biostimulation therapy.
Biomaterial particles (red arrow) and newly formed bone tissue (blue arrow). Two-dimensional
trans-axial cuts at (A) 14 days; and (B) 42 days, respectively.
In the subsequent period, at 42 days, an increase in the amount of bone tissue, interweaving the
biomaterial, in a more organised configuration, especially in the FSBPBMT group was observed. The
xenograft particles were still evident (red arrow), with some areas of remodelled tissue at the defect
margins (Figure 1B).
2.2. Histological Evaluation
In all groups, the repair of bone defects occurred centripetally, with the absence of necrotic tissue,
the presence of bone cells, osteoid matrix, and budding of new blood vessels at the site.
At 14 days, all BC (defect filled with Blood Clot without photobiomodulation therapy) and BCPBMT
(defect filled with Blood Clot with photobiomodulation therapy) animals presented incomplete bone
repair both in the height and in the conformation of the newly formed bone, which was irregular along
the dura mater (Figures 2A(i)–A(ii) and 3A). In the animals in the BC group, the central area of the
defect was predominantly filled by loose connective tissue with small loci of new bone formation at the
defect border, but in the BCPBMT animals, the defects were filled by immature bone and more obvious
blood vessels (Figures 2A(i)–A(ii) and 3A).
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Figure 2. Panoramic histological views at (A) 14 days; and (B) 42 days, respectively; (C) graphs of
volume density of newly formed bone in skull defects filled with a blood clot or fibrin sealant plus
xenograft and with or without laser photobiomodulation therapy. (A) A(i)–A(ii) bone formation (blue
arrows) occurring at the defect border and under the dura mater surface. A(iii)–A(iv): the defect
showed trabecular bone formation (blue arrows) adjacent to the defect border, in a more advanced
stage of bone maturation. (B) B(i)–B(ii) both groups showed similar bone formation limited to the
defect border and a large region filled with fibrous connective tissue (red arrows); B(iii)–B(iv) a large
part of the defect was filled by connective tissue and biomaterials (red arrows), but in the FSBPBMT
group, greater bone formation defect could be observed compared to the FSB group; (C) Graphs of
newly formed bone showed smaller bone formation in the non-biostimulated group (BC and FSB)
than the biostimulated group (BCPBMT and FSBPBMT). (BC and BCPBMT: N = 4/group and periods),
(FSB and FSBPBMT: N = 5/group and periods). C(i) and C(ii) where different letters (A =B) indicate
a statistically significant difference between groups in the same period and C(iii) where the different
letters (A =B) indicate a statistically significant difference in the same group in the two periods analysed
(p < 0.05). (HE; original magnification × 4; bar = 2 mm).
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Figure 3. Details of the evolution of the bone healing of the skull defects filled with a blood clot
or fibrin sealant plus xenograft (biomaterial) with or without low-level laser biostimulation therapy.
(A) At 14 days, BC and BCPBMT: the defect shows the trabecular bone formation (asterisks) adjacent to
the defect border and spaces between the trabeculae filled by connective tissue. FSB: the defect was
filled by particles of the biomaterial (P) surrounded by connective tissue with some inflammatory cells
(RT—reactional tissue). Collagen fibres surrounding the xenograft particles (red arrow). FSBPBMT:
the defect was filled by particles of the biomaterial (P) surrounded by connective tissue with some
inflammatory cells (RT—reactional tissue). Presence of many red blood cells (inside the blue lined area)
and blood vessels (V) permeating connective tissue; (B) At 42 days, BC and BCPBMT: the new bone
shows a gradual increase in thickness of the trabeculae leading to a compact structure. FSB: the new
bone formation increases, becoming compact, there is a presence of xenograft particles and a decrease
in inflammatory response. In FSBPBMT, the collagen fibres are arranged in more layers surrounding the
particles. (HE; original magnification × 40; bar = 200 μm; and Insets, magnified images × 100; bar =
50 μm).
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In all animals of the FSB and FSBPBMT groups, in the same experimental period, the defects
presented with large amounts of the biomaterial. The new bone formation also occurred from the defect
border, with trabecular conformation, being more pronounced in the FSBPBMT group. The presence
of inflammatory infiltrate was identified in both groups, diffusely distributed in the interstitial space
(Figures 2A(iii)–A(iv) and 3A).
At 42 days, in the BC group, the formed connective tissue filled the entire extent of the defect,
maintaining a seemingly smaller thickness in relation to the remaining (original) bone, and the
new bone formed was limited to the proximities of the injured borders. In the BCPBMT animals,
biostimulated with low power laser, the defect was still filled by a large amount of connective tissue,
exhibiting a thin layer of bone tissue (asterisk) with diploe characteristics, and in some cases partial
closure of the defect, but without recovery of its height (Figures 2B(i)–B(ii) and 3B).
In the same period, in all FSB and FSBPBMT animals, the surgical area was almost completely
filled by biomaterial particles, without any significant changes in relation to the previous period. The
bone formation remained limited to the edges, but with a denser and lamellar arrangement. The
tissue reaction appeared to be in the resolution phase, with the most fibrotic interstitial space. In the
FSBPBMT group, the reduction of oedema was more evident resulting in the formation of a denser
stroma with more cells and with concentric collagen fibres forming a capsule around the biomaterial
(Figures 2B(iii)–(iv) and 3B).
2.3. Histomorphometric Evaluation
At 14 days of the repair process and after a quantitative evaluation of the volume density of
the newly formed bone, it was observed that animals of the BCPBMT group presented the highest
means (8.9 ± 0.64) with significant difference in relation to the other experimental groups BC, FSB,
and FSBPBMT (5.9 ± 0.38; 4.3 ± 0.46; 5.6 ± 0.45, respectively), that were not significantly different to
each other (Figure 2C(i)).
In the 42-day period, the groups biostimulated with a low-power laser (BCPBMT and FSBPBMT)
presented the highest means, but without significant difference between them (11.22 ± 0.94; 10.64 ±
0.97, respectively). However, the animals in the aforementioned groups showed a significant difference
when compared to the non-biostimulated animals BC and FSB (7.06 ± 0.49; 6.02 ± 0.32, respectively),
but did not show any significant difference when compared to each other (Figure 2C(ii)).
The evaluation of the volume density of the newly formed bone within the same group in the two
experimental periods (14 and 42 days) revealed that bone formation was higher in all groups in the
42-day period, with a significant difference between periods except for the BC group (Figure 2C(iii)).
3. Discussion
The existing scientific evidence in the field of tissue engineering indicates promising results in the
treatment of bone defects with the use of fibrin sealants derived from human plasma as scaffolds for
cellular development [11,16–19]. However, there is no data in the literature which reports its effect on
the bone repair process when associated with xenograft and alternative therapeutic methods. Thus,
the results in this study show that the association of these treatments favoured the repair process of
critical bone defects in the calvaria of rats.
The bone calvarium defect rat model is the most used among others in the scientific literature
since it provides a clinically relevant evaluation of regenerative therapies and bone substitute materials,
allowing for more effective clinical interventions. The defect produced is perfectly reproducible, fast,
and does not require fixation for stabilisation, as compared to long bones [20].
The search for noninvasive methods, such as low intensity ultrasound (LIPUS), electromagnetic
fields, and laser photobiomodulation therapy, has been increasing exponentially in recent years to
improve the bone healing process [12]. As a consequence, there are numerous clinical and experimental
studies with low-level laser photobiomodulation therapies, but so far without consensus on the optimal
parameters for the bone repair process [5].
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This study used a wavelength of 830 nm, a power density of 258.6 mW/cm2, and mode of
continuous operation, corroborating previous studies that presented satisfactory results in the process
of bone repair [21].
Therefore, with the knowledge that the biomodulation effects of the laser are intrinsically related
to the wavelength and that the loss of intensity may compromise its function, the right choice of the
spectral band has become of extreme importance in the treatment. Thus, the wavelength in the infrared
spectrum became widely used due to its lower loss, which can reach up to 37% of its intensity after a
depth of 2 mm [22]. Knowing previously that the pre-calvarial tissue thickness in the rat has small
dimensions, it is assumed that the loss is minimal. In situations exceeding 2 mm, there may be a
maximum loss of 162.92 mW for each cm2 of tissue, with the same protocol used in this study.
In addition, the infrared spectrum, between 780 and 1100 nm, is based on non-thermal
mechanisms, which do not generate a significant increase in tissue temperature (up to 37.5 ◦C). In
excitation states, a fraction of energy is converted into heat, which causes local and transient increases
in the temperature of absorbent chromophores, without heating the total cell [23].
To evaluate the potential of fibrin sealants derived from human blood, this study comprised
microtomographic, histological, and histomorphometric analyses. In the microtomographic analysis,
at 14 days it was possible to observe the formation of new bone at the margins of the surgical wound
in all groups, probably via the stimulation of growth factors released after craniotomy. The growth
remained limited to this region until the end of the experiment, as reported in other experimental
studies [24,25].
In the groups where the defects were filled with the fibrin sealant associated with the xenogeneic
graft (FSB and FSBPBMT), the particles remained at the site of implantation without dispersion,
corroborating with studies that report on the mechanical stability and the binding effects provided by
the fibrin sealant to bone grafts [26,27].
Histologically, at 14 days, the BC and BCPBMT groups exhibited new bone formed in the defect
margins, overlapping the dura, with a trabecular and immature arrangement. This can be attributed to
the action of growth factors in this region after vascular rupture due to craniotomy and the presence
of the underlying periosteum, which is the main source of osteoprogenitor cells and osteoinductive
factors [28]. At 42 days, the newly formed bone became lamellar and compact. These findings are
generally observed in repair procedures in lesions similar to those performed in this study [3,29,30].
However, none of the defects presented complete closure, with a large part being filled by fibrous
connective tissue, in agreement with studies that reported that this is a critical defect according to
Gosain et al. [31], An et al. [32], and Maciel et al. [30].
In the two analysed periods, the animals biostimulated with the laser presented greater evidence
of new bone formation and greater tissue organisation at the end of the experiment [33]. These results
are consistent with the literature that indicates the positive photobiomodulatory effects of the laser in
the initial phases of bone repair, when, among several events, there is a proliferation of osteoblasts and
differentiation of mesenchymal cells [34,35].
The defects filled with fibrin and xenograft (FSB and FSBPBMT) sealers showed intense
angiogenesis as early as 14 days, as well as the presence of reactional tissue at 42 days of resolution [36].
The tissue reaction observed in these groups did not trigger a foreign body type granulomatous
reaction, which suggests that the grafts used were biocompatible [26,37,38] and the biological response
was consistent with the inflammatory process after implantation of the biomaterial [14,35,39–43].
Histomorphometric analysis of the clot-treated and biostimulated laser defects, BCPBMT, revealed
a gradual and significant increase in bone volume during the experimental periods (8.9 ± 0.64 to
11.22 ± 0.94) in relation to the animals of group BC (5.9 ± 0.38 to 7.06 ± 0.49) in periods of 14 to 42
days, respectively [44]. The biological mechanisms involved in improving the growth of bone tissue
irradiated by a low-power laser are still not clearly understood. Studies suggest that laser energy can
excite intracellular chromophores, especially the cytochromes of mitochondria, stimulating the cellular
32
Int. J. Mol. Sci. 2019, 20, 1761
activity and consequently increasing ATP concentration, calcium, protein synthesis, and signalling
pathways actively interconnected with the differentiation of stem cells into osteoblasts [45,46].
In the group with defects treated with sealant and xenograft, FSB, the bone formation was
increasing between the periods (4.3 ± 0.46 to 6.01 ± 0.32), but in lower volume density compared to
the animals of the FSBPBMT group (5.6 ± 0.45 to 10.64 ± 0.97), supporting the positive influence of
laser photobiomodulation in the repair process. Similar results were reported by De Oliveira et al. [21]
in calvarial defects of autogenous graft-filled rats treated with low-power laser, in which a higher bone
formation was also observed in all analysed periods.
The results obtained in this experiment provide evidence that defects filled with fibrin sealant and
xenograft, and treated with low-power laser presented an evolution in the tissue repair process,
with a better response compared to the other groups investigated, suggesting that there was a
photobiomodulatory action in the inflammatory process, with a more organised deposition of collagen
fibres in the defect area and consequently with a more homogenous bone conformation.
3.1. Strengths
The present research is a pioneer experimental study on the use of a fibrin sealant derived from
human blood and xenograft associated with the protocol of photobiomodulation therapy with the
use of low-power laser demonstrating effective repair of nerve and bone lesions. In addition, the
association provided ease of insertion, local haemostasis, and maintenance of the implanted materials
in the surgical bed, allowing the accomplishment of procedures in a shorter operative time.
3.2. Limitations
One limitation of this study is the absence of a quantitative evaluation of the microtomographic
images due to the similar radiopacity between the newly formed bone and the xenograft, which makes
it difficult to quantify [47].
For prospective studies requiring repair of bone defects, analysis of other fibrin sealants may
be proposed, such as a promising fibrin biopolymer free of human blood components [16], and
associations with complementary therapies that present osteogenic potential as pulsed ultrasound
(LUPUS) and ultralaser [12].
4. Materials and Methods
4.1. Blood-Derived Biomaterials—Fibrin Sealant
Tisseel Lyo™ (Baxter Healthcare Ltd., Norfolk, United Kingdom; Ministry of Health Registration
no: 1.0683.0182) is a two-component fibrin sealant that contains two of the proteins that make the
blood clot, fibrinogen and thrombin. Tisseel Lyo is prepared as two solutions which mix when applied.
When prepared, 1 mL of each solution contains human fibrinogen (as a clotting protein), 91 mg/mL
in 3000 UIC/mL protein; aprotinin (synthetic) and human thrombin, 500 UI/mL, in 40 μmol/mL
calcium chloride.
Initially, the vials containing lyophilised sealer protein concentrate and aprotinin solution,
lyophilised human thrombin, and calcium chloride solution were preheated for approximately three
minutes in a water bath at a temperature of 33–37 ◦C, with the aid of a mercury thermometer
(Termometros Labor™, São Paulo, Brazil). Thereafter, the sealant protein concentrate was dissolved
with the aprotinin solution to form the sealant solution. Simultaneously, the lyophilised human
thrombin was dissolved with the calcium chloride solution to form the thrombin solution. The two
solutions were kept in the water bath until use.
4.2. Biomaterial—Xenograft
The commercial demineralised bovine bone matrix (Bio-Oss™; Geistlich Pharma AG, Wolhusen,
Switzerland; Ministry of Health Registration no: 806.969.30002) is a natural biomaterial available as
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granules of cancellous bone (0.25–1 mm granule size; 2.0 g vial). The highly purified osteoconductive
mineral structure is produced from natural bone in a multi-stage purification process and sterilisation is
carried out by γ-irradiation. Thus, it is chemically as well as structurally comparable to the mineralized
human bone. Bio-Oss™ contains pores of different sizes: macropores (300–1500 μm), micropores
(size of Haversian and vascular marrow canals), and intracrystalline spaces (3–26 nm), resulting in an
overall porosity of 70–75% and a wide internal surface area of almost 100 m2/g [48].
4.3. Experimental Design
Thirty-six adult male Wistar rats (Rattus norvegicus), 90 days old, weighing around 400 g, were
obtained from the animal laboratory of the Ribeirão Preto campus of the University of São Paulo.
The animals were housed in conventional cages initially containing four animals each (alteration
according to the animal weight recommended by the Animal Laboratory of Bauru School of
Dentistry—University of São Paulo), with feeders and drinkers “ad libitum” (irradiated feed—Nuvilab
rodents and filtered water), in an air-conditioned environment, air exhaustion, light-dark period
12L/12D, temperature 22 ◦C ± 2 ◦C, humidity 60% ± 10, lighting 150lux/1 m floor, maximum
noise 70 dB (decibel—SPL, Sound Pressure Level). All experimental procedures in the animals were
conducted with the approval of the Institutional Review Board in Animal Studies of the Bauru School
of Dentistry, University of São Paulo (Protocol: CEEPA-019/2016).
Initially, the animals were randomly divided into two groups: BC, n = 16 (Blood Clot, the defect
was filled with a blood clot) and FSB, n = 20 (the defect was filled with a mixture of xenograft and fibrin
sealant). After the surgical procedures, four subgroups were preformatted according to the treatment:
BC, n = 8 (the defect was filled with blood clot without photobiomodulation), BCPBMT, n = 8 (the defect
was filled with blood clot and photobiomodulation), FSB, n = 10 (the defect was filled with a mixture
of fibrin sealant and biomaterial without photobiomodulation) and FSBPBMT, n = 10 (the defect was
filled with a mixture of fibrin sealant and biomaterial and photobiomodulation) (Figure 4A).
4.4. Surgical Procedures
All surgical procedures were performed at the Mesoscopic Laboratory—discipline of Anatomy
(Bauru School of Dentistry, University of São Paulo, Brazil) by the same team of professionals.
The animal surgeries were performed under general anaesthesia with an intramuscular injection
of Ketamine (50 mg/kg i.m. (Dopalen ™, Ceva, Paulínia, SP, Brazil) and Xylazine (10 mg/kg i.m.
(Anasedan ™, Ceva, Paulínia, SP, Brazil) followed by fronto-parietal trichotomy and disinfection with
10% povidone-iodine (PI). With a scalpel blade n. 10, a half-moon incision was made in the cranial
tegument and folded to expose the calvarium. Then, a defect was created in the centre of the parietal
bone using an 8 mm diameter trephine bur, under continuous irrigation with saline, exposing the dura
mater [20,49] (Figure 4B1). The defects in the BC group were filled with 0.25 mm3 of cardiac puncture
blood [50] (Figure 4B2).
In the FSB group, the defects were filled with 0.1 mm3 of xenograft incorporated into 40 μL of the
reconstituted fibrinogen solution in aprotinin and 40 μL of reconstituted human thrombin solution in
sodium chloride (proportion 1:1, according to the manufacturer’s recommendations) (Figure 4B3–B4).
The amounts of xenograft and fibrin sealant used were previously established in a pilot study.
The periosteum and tegument were repositioned and sutured with nylon 5-0 (MononylonTM,
Somerville S.A, NJ, USA) and silk 4-0 (EthiconTM Johnson & Johnson Company, New Orleans, LA,
USA), respectively, to provide stability to the graft, decreasing the risk of soft tissue collapse [20,51].
The postoperative care consisted of a single oral administration of acetaminophen at a dose of 200
mg/kg (Paracetamol, Medley, São Paulo, Brazil) dissolved in water, available in the cages.
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Figure 4. (A) Experimental design (A1) Random allocation: Thirty-six rats were divided into two
groups; (A2) BC (n = 16)—Blood Clot and FSB (n = 20)—Fibrin Sealant + Biomaterial; (A3) After surgical
procedures, two subgroups were preformatted according to treatment: BC, n = 8 (Blood Clot, the defect
was filled with blood clot and without photobiomodulation), BCPBMT, n = 8 (Blood Clot, the defect was
filled with blood clot and photobiomodulation), FSB, n = 10 (the defect was filled with a mixture of
biomaterial and fibrin sealant and without photobiomodulation), and FSBPBMT, n = 10 (the defect was
filled with a mixture of biomaterial and fibrin sealant and photobiomodulation); (A4) illustration of the
four points of cross-application of the low-level laser on rat calvarium; (B) Surgical procedures—bone
defect model; (B1) Osteotomy using an 8 mm trephine bur with exposure of the fragment removed
from the parietal bones; (B2) defect filled with blood clot; (B3) deposition of the mixture fibrin
sealant + biomaterial in the defect; (B4) defect filled with mixture; (B5) low-level laser therapy
(photobiostimulation).
4.5. Photobiomodulation Therapy Protocol
The animals of Groups BCPBMT and FSBPBMT underwent laser irradiation (Laserpulse IBRAMED,
Amparo, SP, Brazil) with continuous pulse GaAlAs (gallium–aluminium–arsenide). The following
parameters were used for photobiomodulation therapy [21]—Table 1 below (Figure 4A4,B5):
Table 1. Therapeutic parameters of the photobiomodulation therapy used in this study.
Parameter Unit/Explanation
Optical Power 30 mW
Wavelength 830 nm
Density of Power or Irradiance 258.6 mW/cm2
Fluency or Density of Energy or Dosimetry 6 J/cm2
Beam Area 0.116 cm2
Total Power 2.9 J
Type of Beam Positioned for laser irradiation at perpendicular incidence to the skull
Emission Mode Continuous (laser power remains constant at all times)
Form of Application Four points surrounding the surgical area, north, south, east, and west
Duration of Irradiation 24 s/point
Total Time of each Application 96 s
Treatment Time Immediately after surgery and three times a week until euthanasia
Laser beam emissions were self-calibrated by the device during all applications.
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4.6. Collection of Samples and Histological Procedures
All animals were killed with an overdose of a Ketamine/Xylazine mixture following the guidelines
of the Brazilian College of Animal Experimentation after 14 and 42 days, BC and BCPBMT groups—4
animals/period and FSB and FSBPBMT—5 animals/period. The cranial vaults with the lining skin
were collected and fixed in 10% phosphate-buffered formalin for 48 h, and later, for examination in
the microtomography.
4.7. MicroCT Scan (μ-CT)
The specimens were subjected to an X-ray beam scan in the computed microtomograph machine
SkyScan 1174v2 (μ-CT—Bruker microCT, Kontich, Belgium). Initially they were packaged in an acrylic,
cylindrical sample holder, (diameter 18.3 mm; height 10.9 mm), with exo- and endocranial aspects of
the parietal bones in the vertical position. The images were captured with 13.76 μm voxel, 0.73◦ at
each pace, and further reconstructed using the NRecon® v.1.6.8.0, SkyScan, 2011, Bruker microCT, with
the same reconstruction parameters for all specimens. Then, the reconstructed images were realigned
using the DataViewer® 1.4.4.0 software.
4.8. Histotechnical Processing
The specimens were washed in tap water for 24 h and immersed in 10% ethylenediaminetetraacetic
acid (EDTA—a solution containing 4.13% Titriplex™ III Merck KGaA, Darmstadt, Germany and 0.44%
sodium hydroxide Labsynth, São Paulo, Brazil), for a period of approximately 60 days [52]. Then, the
collected bone fragments underwent successive standard histological staging and were finally included
in HistosecTM (Merck KGaA, Darmstadt, Germany). Semi-serial coronal cuts of 5 μm thickness were
performed, prioritising the centre of the circular defect and stained with haematoxylin-eosin.
4.9. Histological and Histomorphometric Evaluation of Defects Bone Healing
The histological sections were analysed by light microscopy (Olympus model BX50) at
approximate magnifications of × 4, 10, and × 40 in the Histology Laboratory of the Bauru School of
Dentistry, the University of São Paulo (São Paulo, Brazil). To standardise and avoid bias, a training
session was performed with an experienced pathologist.
Histological analysis of sections stained with HE consisted of an evaluative description of the
healing events such as inflammation, granulation tissue, new bone formation, and remodelling, and
the interaction among the biomaterial bone graft and the newly formed bone.
For morphometric evaluation, two central sections stained with HE were used for quantification
of newly formed bone areas using an image capture system (DP Controller 3.2.1.276—2001–2006,
Olympus Corporation, Tokyo, Japan). Initially, the total area to be analysed was established as every
area of the surgical defect. The limits of this area were determined from the external and internal
surfaces of the original calvarium on the right and left margins of the surgical defect. Then, the drawn
lines were connected following their respective curvatures. Considering the total length of the defect,
its centre point, measuring from this point, was 4 mm to the right and left to the edges of the surgical
wound to determine the limits of the original surgical defect.
Morphometric analysis under light microscopy allowed the determination of the volumetric
density (%), defined as the volume fraction of the entire graft filled by a given component/structure
(newly formed bone). The volume density (Vvi) that is equal to the area density (AAi) was determined
by AxioVision Rel. 4.8 Ink (Carl Zeiss MicroImaging GmbH, Jena, Deutschland), Vvi = AAi [53]. The
area of graft filled by each structure (Ai) and the total area examined (A) were determined in pixels,
and the volume density (Vvi) of each type of structure was calculated according to the relation Vvi =
AAi = Ai/A × 100.
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4.10. Statistical Analysis
An analysis of variance (ANOVA) was applied to the data obtained for the percentage of
newly formed bone to verify the effect of the different groups tested in each evaluated period. The
homogeneity of variances and normality of residues and the necessary assumptions for the conduction
of ANOVA, were tested, respectively, by the Shapiro–Wilk and Bartlett tests, both at 5% probability.
Subsequently, the means were compared by the Tukey test at 5% probability. The effect of the period
evaluated in each group was compared by Student’s t-test at 5%. All analyses were conducted with R
(R Core Team, 2017).
5. Conclusions
It was concluded that the support system formed by the xenograft fibrin sealant associated with
the photobiomodulation therapy protocol had a positive effect on the bone repair process in critical
size defects in rat calvaria.
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Abstract: Background: The aim of this review was to evaluate the adjunctive effect of autologous
platelet concentrates (APCs) for the treatment of furcation defects, in terms of scientific quality
of the clinical trials and regeneration parameters assessment. Methods: A systematic search was
carried out in the electronic databases MEDLINE, SCOPUS, CENTRAL (Cochrane Central Register of
Controlled Trials), and EMBASE, together with hand searching of relevant journals. Two independent
reviewers screened the articles yielded in the initial search and retrieved the full-text version of
potentially eligible studies. Relevant data and outcomes were extracted from the included studies.
Risk of bias assessment was also carried out. The outcome variables, relative to baseline and
post-operative defect characteristics (probing pocket depth (PPD), horizontal and vertical clinical
attachment loss (HCAL, VCAL), horizontal and vertical furcation depth (HFD, VFD) were considered
for meta-analysis. Results: Ten randomized trials were included in this review. Only one study
was judged at high risk of bias, while seven had a low risk, testifying to the good level of the
evidence of this review. The meta-analysis showed a favorable effect regarding all outcome variables,
for APCs used in adjunct to open flap debridement (p < 0.001). Regarding APCs in adjunct to bone
grafting, a significant advantage was found only for HCAL (p < 0.001, mean difference 0.74, 95% CI
0.54, 0.94). The sub-group analysis showed that both platelet-rich fibrin and platelet-rich plasma in
adjunct with open flap debridement, yielded significantly favorable results. No meta-analysis was
performed for APCs in combination with guided tissue regeneration (GTR) as only one study was
found. Conclusion: For the treatment of furcation defects APCs may be beneficial as an adjunct to
open flap debridement alone and bone grafting, while limited evidence of an effect of APCs when
used in combination with GTR was found.
Keywords: autologous platelet concentrates; bone defects; bone grafting; bone regeneration; furcation
defects; periodontal defects; periodontal regeneration; periodontal surgery; platelet-rich plasma;
platelet-rich fibrin; plasma rich in growth factors; tissue healing
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1. Introduction
Furcation involvement is defined as bone resorption and attachment loss in the inter-radicular
space that results from plaque associated periodontal disease [1]. The treatment of periodontal disease
associated with furcation represents a challenge for the clinician, due to the complexity in anatomy
and morphology of such area. The unfavorable anatomic feature of the furcation restricts adequate
instrumentation for proper debridement, thereby limiting the prognosis of the involved teeth [2].
Various treatment modalities, including surgical and non-surgical therapy, have been proposed to
improve the prognosis based on the degree of furcation involvement. Several classifications have been
proposed over the years (Table 1), based either on the severity of horizontal probing depth into the
furcation defect or on the vertical amount of alveolar bone loss within the defect [3]. The most popular
one was developed by Glickman, which divides furcation defects into four grades [4]. Non-surgical
strategies such as scaling and root planing, furcation-plasty, etc. are employed to treat the furcations
with Grade I initial involvement which restores the gingival health. Conversely, surgical procedures
including regenerative and resective approaches, are performed for the treatment of more advanced
lesions, to allow access to the internal complex areas of furcations. The traditional resective approach
may negatively affect the long term prognosis of the treated teeth, however, it is considered as the
treatment of choice for grade III and IV furcation lesions, aiming at facilitating maintenance of the
furcation area.
Regenerative approaches are aimed at furcation closure by the formation of new bone, cementum
and periodontal ligament in the involved inter-radicular space. Thorough debridement with adequate
instrumentation following surgical exposure of furcation involved area, is one of the earliest and
most well-documented treatment protocols to achieve regeneration in grade II furcation lesions [5].
In addition, various studies were carried out in the recent past, using bone substitutes, barrier
membrane, autologous, and recombinant growth factors in order to provide evidence of improved
bone fill and attachment gain in treating grade II furcation lesions [6,7].
The use of biologic agents consisting of growth and differentiation factors like rhBMP2
(recombinant human bone morphogenetic protein-2), rhPDGF (recombinant human platelet-derived
growth factor), and TGF-β (transforming growth factor beta), had proven to promote osteogenic
induction in cases of furcation treatment, in animal studies [8–10]. Additionally, the use of autologous
platelet concentrates (APCs) is gaining popularity as a source of multiple growth factors in high
concentrations, for regenerative treatments in many clinical applications. The contribution of
blood-derived platelets to the bone healing process is mainly based on the growth factors stored
in their granules and released upon activation. Autologous platelet concentrates are advantageously
used as a cost-effective adjunct to surgical regenerative therapy, even in combination with bone grafts
and barrier membranes. Several randomized controlled trials have reported on the efficacy of the use of
these APCs when used alone or in combination with various regenerative strategies and other biologic
agents, suggesting improvement of post-operative soft and hard tissue healing, and improved bone fill
and attachment gain [6,11–17]. Different types of APCs are available, each with peculiar features, the
most popular being platelet-rich plasma (PRP), along with platelet-rich fibrin (PRF), plasma rich in
growth factors (PRGF) and concentrated growth factors (CGF).
A recent systematic review and meta-analysis [18], evaluating the effect of use of platelet-rich
fibrin (PRF) in adjunct to open flap debridement, included two clinical trials in treatment of grade II
furcation with nine month follow-up and concluded favorable results with the use of PRF in terms of
clinical attachment level gain (mean difference 1.25 CI 95% [0.82, 1.65], p = 0.07) and bone fill (mean
difference 1.52 CI 95% [1.18, 1.87], p = 0.05). Another systematic review [19] included two split-mouth
clinical trials evaluating the effect of platelet-rich plasma and reported no consistent evidence regarding
the effect of PRP in treatment of furcation defects.
The aim of this systematic review is to evaluate the adjunctive effect of APCs in treatment of
furcation defects both qualitatively and quantitatively, in terms of scientific quality of the clinical trials
and regeneration parameters assessment.
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Table 1. Various proposed classification systems of furcation involvement.
Sl Author Year Classification System
Horizontal Component
1 Goldman, H.M [20] 1958
Grade I: Incipient lesion;
Grade II: Cul-de-sac lesion;
Grade III: Through-and-through lesion
2 Staffileno, H.J. [21] 1969
Class I: Furcations with a soft tissue lesion extending to furcal level but with a
minor degree of osseous destruction;
Class II: Furcations with a soft tissue lesion and a variable degree of osseous
destruction but not a through-and-through communication through the furca;
Class III: Furcations with osseous destruction with through-and-through
communication
3 Glickman, I. [4] 1972
Grade I: Incipient lesion. Suprabony pocket and slight bone loss in the
furcation area.
Grade II: Loss of interradicular bone and pocket formation but a portion of the
alveolar bone and periodontal ligament remain intact.
Grade III: Through-and-through lesion.
Grade IV: Through-and-through lesion with gingival recession, leading to a
clearly visible furcation area.
4 Hamp, S.E. et al. [22] 1975
Degree I: Horizontal attachment loss < 3 mm;
Degree II: Horizontal attachment loss > 3 mm not encompassing the width of
the furcation area;
Degree III: Horizontal through-and-through destruction of the periodontal
tissue in the furcation area.
5 Ramjford, S.P. et al. [23] 1979
Class I: Tissue destruction < 2 mm (1/3 of tooth width) into the furcation;
Class II: Tissue destruction > 2 mm (>1/3 of tooth width);
Class III: Through-and-through involvement.
6 Richietti, P.A. [24] 1982
Class I: 1 mm of horizontal invasion;
Class Ia. 1–2 mm of horizontal invasion;
Class II: 2–4 mm of horizontal invasion;
Class IIa. 4–6 mm of horizontal invasion;
Class III: >6 mm of horizontal invasion.
7 Grant, D.A. et al. [25] 1988
Class I: Involvement of the flute only;
Class II: Involvement partially under the roof;
Class III: Through-and-through loss.
8 Goldman, H.M. et al.[26] 1988
Degree I: Involves furcation entrance;
Degree II: Involvement extends under the roof of furcation;
Degree III: Through-and-through involvement.
9 Basaraba, N. [27] 1990
Class I: Initial furcation involvement;
Class II: Partial furcation involvement;
Class III: Communicating furcation involvement.
10 Nevins, M. et al. [28] 1998
Class I: Incipient or early loss of attachment;
Class II: A deeper invasion and loss of attachment that does not extend to a
complete invasion;
Class III: Complete loss of periodontium extending from buccal to lingual
surface. Diagnosed radiographically and clinically
11 Walter, C.et al [29] 2009
Modification of the Hamp et al. classification.
Degree I: Horizontal attachment loss < 1/3 of the width of the tooth;
Degree II: Horizontal loss of support > 3 mm, < 6 mm;
Degree II–III: Horizontal loss of support > 6 mm, but not extending completely.
Degree III: Horizontal through-and-through destruction.
12 Carnevale, G. et al. [30] 2012
Degree I: Horizontal attachment loss < 1/3;
Degree II: Horizontal attachment loss > 1/3;
Degree III: Horizontal through-and-through destruction.
Vertical Component
1 Tal, H. et al. [31] 1982
Furcal rating 1: Depth of the furcation is 0 mm;
Furcal rating 2: Depth of the furcation is 1–2 mm;
Furcal rating 3: Depth of the furcation is 3 mm;
Furcal rating 4: Depth of the furcation is 4 mm or more.
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Table 1. Cont.
Sl Author Year Classification System
2 Eskow, R.N. et al. [32] 1984
Furcation involvement grade 1 is classified as:
Subclass A: Vertical destruction > 1/3;
Subclass B: Vertical destruction of 2/3;
Subclass C: Vertical destruction beyond the apical third of interradicular
height.
3 Tarnow, D. et al. [33] 1985
For each class of horizontal classification (I–III), a subclass based on the vertical
bone resorption was added: Subclass A: 0–3 mm; Subclass B: 4–6 mm; Subclass
C: >7 mm.
Horizontal & Vertical Component (Combined)
1 Easley, J.R. et al. [34] 1969
Class I: Incipient involvement, but there is no horizontal component to the
furca;
Class II: Type 1. Horizontal attachment loss into the furcation;
Type 2. Vertical attachment loss into the furcation;
Class III: Through-and-through attachment loss into the furcation;
Type 1. Horizontal attachment loss into the furcation;
Type 2. Vertical attachment loss into the furcation.
2 Fedi, P.F. [35] 1985
Glickman + Hamp classifications: Grades are the same as Glickman’s
classification (I–IV);
Grade II is subdivided into degrees I and II;
Degree I. Vertical bone loss 1–3 mm;
Degree II. Vertical bone loss > 3 mm, but not communicate
through-and-through.
3 Rosemberg, M.M. [36] 1986
Horizontal: Degree I: Probing < 4 mm; Degree II: Probing > 4 mm; Degree III:
Two or three furcations classified as degree II are found.
Vertical: Shallow: Slight lateral extension of an interradicular defect, from the
center of the trifurcation in a horizontal direction; Deep: Internal furcation
involvement but not penetrating the adjacent furcation.
4 Hou, G.L. et al. [37] 1998
Classification based on root trunk length and horizontal and vertical bone loss.
Types of root trunk:
• Type A: Furcation involving a cervical third of root length;
• Type B: Furcation involving a cervical third and two thirds of root length;
• Type C: Furcation involving a cervical two thirds of root length.
Classes of furcation:
• Class I: Horizontal loss of 3 mm;
• Class II: Horizontal loss > 3 mm;
• Class III: Horizontal “through-and-through” loss.
Subclasses by radiographic assessment of the periapical view:
• Sub-class ‘a’. Suprabony defect;
• Sub-class ‘b’. Infrabony defect.
2. Results
2.1. Study Characteristics
A total of ten studies were included in this systematic review after independent screening of titles
and abstracts from a pool of 153 articles retrieved from the search platforms. The systematic flow
chart of the study selection process is provided in Figure 1. Out of 21 eligible studies, 11 studies were
excluded with reasons provided in Table 2. The general information and the study characteristics of
the included studies are detailed in Table 3.
The general comparison was between a group that received APC as an adjunct to surgical
treatment (experimental group), and a group that received surgical treatment alone (control group).
Three different types of comparisons were assessed, based on the treatment type. Five studies reported
the comparison of open flap debridement (OFD) + APC versus OFD alone (Bajaj 2009 study evaluated
the adjunctive effects of two different types of APCs in the same study, compared to OFD alone as the
control group). Four studies reported the comparison of bone graft (BG) + APC versus BG alone, and
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only one study reported the comparison of guided tissue regeneration (GTR) + APC versus GTR alone.
The results of these studies were separated for types of platelet concentrate data to facilitate subgroup
meta-analysis for OFD + APC versus OFD comparison. However, it was impossible to undertake the
subgroup analysis for the other two comparisons due to the lack of enough studies for sub-grouping.
The risk of bias of all included studies is synthesized in Figure 2.
 
Figure 1. Flow chart depicting study selection process.
Table 2. List of excluded studies.
Study & Year Reason for Exclusion
Mehta et al. 2018 [38] Use of Collagen Membrane along with DFDBA in control group
Wanikar et al. 2018 [39] Both Control and Experimental group use PRF
Kaur et al. 2018 [40] Both Control and Experimental group use PRF
Sharma et al. 2017 [41] Both Control and Experimental group use PRF
Asimuddin et al. 2017 [42] Comparison between use of PRF and Allograft + GTR
Salaria et al. 2016 [43] Case Report
Biswas et al. 2016 [44] Comparison between PRF and Bioactive Glass.
Pradeep et al. 2016 [45] Both Control and Experimental group uses PRF
Sandhu et al. 2015 [46] Case Report
Mellonig et al. 2009 [47] Histological assessment
Lekovic et al. 2003 [48] Comparison of PRP/BPBM/GTR versus OFD alone
PRF—platelet-rich fibrin, PRP—platelet-rich plasma, DFDBA—de-mineralized freeze-dried allograft,
BPBM—bovine porous bone mineral, GTR—guided tissue regeneration.















2017 [13] RCT Parallel OFD vs. OFD + PRF 26/26 30–50 (38) 36/36 9 m
Siddiqui et al.
2016 [49] RCT Parallel OFD vs. OFD + PRF 17/17 30–50 24/7 6 m
Bajaj et al.
2013 [11] RCT Parallel
OFD vs. OFD + PRP
OFD vs. OFD + PRF
27/27




Mouth OFD vs. OFD + PRF 18/18 34.2 10/8 9 m
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Mouth OFD vs. OFD + PRP 20/20 42.8 10/10 6 m
Lohi et al.
2017 [14] RCT Parallel
BCCG + PRF vs.
BCCG alone 10/10
25–65
(43.05 + 10.73) 12/4 6 m
Lafzi et al.
2013 [15] RCT Parallel
ABG + PRGF vs.





BPBM + PRGF vs.
BPBM alone 7/7 44.7 + 11.2 4/3 6 m
Qiao et al.
2017 [16] RCT Parallel
BG + CGF vs. CGF





GTR + PRGF vs.
GTR alone 8/8 NR NR 6 m
RCT—randomized clinical trial, OFD—open flap debridement, PRF—platelet-rich fibrin, PRP—platelet-rich plasma,
BCCG—bioactive ceramic composite granules, ABG—autogenous bone graft, BG—bone graft, GTR—guided
tissue regeneration.
Figure 2. Risk of bias (RoB) assessment.
46
Int. J. Mol. Sci. 2019, 20, 1347
2.2. Meta-Analysis of Primary Outcomes
2.2.1. Probing Pocket Depth (PPD)
APC + OFD vs. OFD Alone (Figure 3)
The forest plot of the included studies evaluating the change in PPD shows evidence of an
advantage of using APC in adjunct to OFD (p < 0.001, mean difference 1.59, 95% CI 1.38, 1.80).
The subgroup analysis is also favorable for both PRF (p < 0.001, mean difference 1.46, 95% CI 1.22, 1.70)
and PRP (p < 0.001, mean difference 2.09, 95% CI 1.62, 2.55).
 
Study or Subgroup






Heterogeneity: Chi² = 20.83, df = 3 (P = 0.0001); I² = 86%
Test for overall effect: Z = 12.08 (P < 0.00001)
1.1.2 Platelet RIch Plasma
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Bajaj  2013 b
Subtotal (95% CI)
Heterogeneity: Chi² = 2.66, df = 1 (P = 0.10); I² = 62%
Test for overall effect: Z = 8.84 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 29.10, df = 5 (P < 0.0001); I² = 83%
Test for overall effect: Z = 14.78 (P < 0.00001)





































































APC + OFD OFD alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours OFD Favours APC + OFD
Figure 3. Forest plot showing the effect on probing pocket depth for comparison of APC + OFD versus
OFD alone at end of all-follow-up (6–12 m).
APC + BG vs. BG Alone (Figure 4)
The forest plot of the included studies evaluating the change in PPD in using APC in adjunct
with BG favors the use of BG alone; however, the result is not statistically significant (p = 0.26, mean







Heterogeneity: Chi² = 9.22, df = 3 (P = 0.03); I² = 67%













































APC + BG BG alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
BG alone APC + BG
Figure 4. Forest plot showing the effect on probing pocket depth for comparison of APC + BG versus
BG alone at end of all-follow-up (6–12 m).
2.2.2. Vertical Clinical Attachment Level (VCAL)
APC + OFD vs. OFD Alone (Figure 5)
The forest plot of the included studies evaluating the change in VCAL shows evidence of an
advantage of using APC in adjunct to OFD (p < 0.001, mean difference 1.24, 95% CI 1.08, 1.40).
The subgroup analysis is also favorable for both PRF (p < 0.001, mean difference 1.18, 95% CI 1.01, 1.36)
and PRP (p < 0.001, mean difference 1.58, 95% CI 1.17, 2.00).
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Heterogeneity: Chi² = 4.84, df = 3 (P = 0.18); I² = 38%
Test for overall effect: Z = 13.30 (P < 0.00001)
1.2.2 Platelet Rich Plasma
Bajaj  2013 b
Pradeep 2009
Subtotal (95% CI)
Heterogeneity: Chi² = 4.44, df = 1 (P = 0.04); I² = 77%
Test for overall effect: Z = 7.49 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 12.32, df = 5 (P = 0.03); I² = 59%
Test for overall effect: Z = 15.17 (P < 0.00001)





































































APC + OFD OFD alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours OFD Favours APC + OFD
Figure 5. Forest plot showing the effect on vertical clinical attachment level for comparison of APC +
OFD versus OFD alone at end of all-follow-up (6–12 m).
APC + BG vs. BG Alone (Figure 6)
The forest plot of the included studies evaluating the change in VCAL in using APC in adjunct
with BG is favorable; however, the result is not statistically significant (p = 0.62, mean difference 0.06,







Heterogeneity: Chi² = 12.16, df = 3 (P = 0.007); I² = 75%













































APC + BG BG alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
BG alone APC + BG
Figure 6. Forest plot showing the effect on vertical clinical attachment level for comparison of APC +
BG versus BG alone at end of all-follow-up (6–12 m).
2.2.3. Horizontal Clinical Attachment Level (HCAL)
APC + OFD vs. OFD Alone (Figure 7)
The forest plot of the included studies evaluating the change in HCAL shows evidence of an
advantage of using APC in adjunct to OFD (p < 0.001, mean difference 1.01, 95% CI 0.89, 1.12).
The subgroup analysis is also favorable for both PRF (p < 0.001, mean difference 0.93, 95% CI 0.80, 1.06)
and PRP (p < 0.001, mean difference 1.50, 95% CI 1.18, 1.83).
 
Study or Subgroup






Heterogeneity: Chi² = 20.38, df = 3 (P = 0.0001); I² = 85%
Test for overall effect: Z = 14.45 (P < 0.00001)
1.3.2 Platelet Rich Plasma
Bajaj  2013 b
Pradeep 2009
Subtotal (95% CI)
Heterogeneity: Chi² = 0.62, df = 1 (P = 0.43); I² = 0%
Test for overall effect: Z = 9.20 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 31.69, df = 5 (P < 0.00001); I² = 84%
Test for overall effect: Z = 16.81 (P < 0.00001)





































































APC + OFD OFD alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
OFD alone APC + OFD
Figure 7. Forest plot showing the effect on horizontal clinical attachment level for comparison of APC
+ OFD versus OFD alone at end of all-follow-up (6–12 m).
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APC + BG vs. BG Alone (Figure 8)
The forest plot of the included studies evaluating the change in HCAL shows evidence of an
advantage of using APC in adjunct with BG (p < 0.001, mean difference 0.74, 95% CI 0.54, 0.94).
Figure 8. Forest plot showing the effect on horizontal clinical attachment level for comparison of APC
+ BG versus BG alone at end of all-follow-up (6–12 m).
2.2.4. Vertical Furcation Depth (VFD)
APC + OFD vs. OFD Alone (Figure 9)
The forest plot of the included studies evaluating the change in VFD shows evidence of an
advantage of using APC in adjunct to OFD (p < 0.001, mean difference 1.60, 95% CI 1.53, 1.68).
The subgroup analysis is also favorable for both PRF (p < 0.001, mean difference 1.65, 95% CI 1.57, 1.74)
and PRP (p < 0.001, mean difference 1.38, 95% CI 1.21, 1.56).
 
Study or Subgroup






Heterogeneity: Chi² = 53.23, df = 3 (P < 0.00001); I² = 94%
Test for overall effect: Z = 38.43 (P < 0.00001)
1.4.2 Platelet Rich Plasma
Bajaj  2013 b
Pradeep 2009
Subtotal (95% CI)
Heterogeneity: Chi² = 27.34, df = 1 (P < 0.00001); I² = 96%
Test for overall effect: Z = 15.42 (P < 0.00001)
Total (95% CI)
Heterogeneity: Chi² = 88.00, df = 5 (P < 0.00001); I² = 94%
Test for overall effect: Z = 41.32 (P < 0.00001)





































































APC + OFD OFD alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
OFD alone APC + OFD
Figure 9. Forest plot showing the effect on vertical furcation depth for comparison of APC + OFD
versus OFD alone at end of all-follow-up (6–12 m).
APC + BG vs. BG Alone (Figure 10)
The forest plot of the included studies evaluating the change in VFD in using APC in adjunct
with BG favors the use of BG alone; however, the result is not statistically significant (p = 0.90, mean
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APC + BG BG alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
BG alone APC + BG
Figure 10. Forest plot showing the effect on vertical furcation depth for comparison of APC + BG
versus BG alone at end of all-follow-up (6–12 m).
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2.2.5. Horizontal Furcation Depth (HFD)
APC + OFD vs. OFD Alone (Figure 11)
The forest plot of the included studies evaluating the change in HFD shows evidence of
an advantage of using APC in adjunct to OFD (p < 0.001, mean difference 1.13, 95% CI 0.85,1.41).
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APC + OFD OFD alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
OFD alone APC + OFD
Figure 11. Forest plot showing the effect on horizontal furcation length for comparison of APC + OFD
versus OFD alone at end of all-follow-up (6–12 m).
APC + BG vs. BG Alone (Figure 12)
The forest plot of the included studies evaluating the change in VFD shows evidence of
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APC + BG BG alone Mean Difference Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
BG alone APC + BG
Figure 12. Forest plot showing the effect on horizontal furcation length for comparison of APC + BG
versus BG alone at end of all-follow-up (6–12 m).
3. Discussion
The use of platelet concentrates to promote periodontal regeneration has gained popularity in
the last 10 years, as demonstrated by the increasing number of evidence-based randomized studies
and systematic reviews [19,51,52]. A recent Cochrane systematic review [53] investigated the effect
of APC for the surgical treatment of infrabony defects, reporting positive effects when APC is used
in combination with OFD, OFD + BG, but not with GTR and enamel matrix derivative. The latter
two treatments have a predictable and well-documented efficacy, and they are since long considered
the gold standard for periodontal defects, so it can be difficult for any adjunctive therapy to further
enhance the clinical outcomes. Evidence-based studies on the efficacy of APC for the regeneration
therapy of furcation defects are relatively scarce as compared to infrabony defects. Our systematic
review published in 2011 investigated the effects of APC on infrabony defects, gingival recessions and
furcation defects but found only two studies on the latter topic, both using platelet-rich plasma [19].
The present study is the first comprehensive systematic review that was aimed at exploring and
comparing the effect of various APCs for enhancing furcation treatment. It was designed according
to a standard protocol, aimed at selecting only the best evidence studies, so as to provide the most
reliable results. Only one of the ten included studies was judged at high risk of bias [50], while seven
had a low risk, testifying to the good level of the evidence of this review. The results, derived from the
analysis of different clinical outcome variables, suggested that the use of APC may be beneficial for
improving the regeneration of furcation defects, when associated with OFD, in line with the above
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findings regarding infrabony defects. Further, it may be noted that APC in adjunct to OFD + BG also
showed significant improvement in HCAL and HFL. Since only one RCT evaluated the adjunctive
effect of APC when using GTR for grade II furcation defects, no meta-analysis was feasible. The results
of this study, suggested that the adjunct of APC produced no significant advantage as compared to
GTR alone, in line with previous findings for infrabony defects.
This review has some strengths and limitations. In recent years, there has been fierce competition
among companies producing different types of platelet concentrates, all claiming that their product
was superior to the others. This also introduced a number of different protocols for the preparation
of APC. Indeed, very few studies comparing different types of APC have been performed in the
periodontal field (as well as in other fields), so that it seems difficult to indicate if there is really
a superiority of some APCs over the others for specific conditions. In the present review, we were
able to perform a meta-analysis with subgroups, keeping separate different APC (PRP and PRF), only
in the group considering OFD alone. The outcomes using different APC was very similar as can be
seen in Figures 3–6 This can be considered a strong point of the present review. However, the precise
difference in effects between different APC cannot be estimated, due to a lack of direct comparisons.
The same subgroup analysis could not be performed in the OFD + BG group, due to heterogeneity
among studies in the type of APC used, and the insufficient number of studies using the same type
of APC. Indeed, also when different studies use the same type of APC, this does not necessarily
represent a warranty of homogeneity in the protocols. For example, over 20 different types of devices
producing PRP are currently available on the market, and at least five different companies produce
centrifuges for PRF [54]. A recent in vitro study compared the characteristics of PRF obtained using
four different centrifuge systems [55]. This study found that, even though in all cases a leukocyte- and
platelet-rich fibrin is obtained after centrifugation, the centrifuge characteristics and centrifugation
protocols significantly impact the cell composition and distribution, the growth factors release pattern
and the fibrin architecture of the final products. So, when PRF is used in different studies, one cannot
be sure to refer to a product with the same features, unless the same centrifuge system is used. In spite
of the above limitations, caused by lack of homogeneity in study protocols, it can be noted that all
studies investigating the effect of APC as an adjunct to OFD alone, consistently reported a beneficial
effect. The latter can be considered a strength point evidenced by this review.
In addition to the regenerative properties, platelet concentrates have also been demonstrated to
carry further advantages in the postsurgical healing period. Evidence-based studies in different oral
surgery procedures have reported that the adjunctive use of APC is associated with an improvement
of patients’ quality of life and pain reduction in the post-surgical period [56,57] Unfortunately, such
effects were not consistently addressed in the studies included in the present review.
Finally, though specific clinical studies have not been performed so far, there is consistent
preclinical evidence that APCs have an antimicrobial effect against a number of species commonly
found in the oral cavity, which suggest they may potentially represent a beneficial tool for the control of
postsurgical infection [58,59]. Indications for future research: There is a huge demand for conducting
more evidence-based comparative studies with wide sample size (among different APC and grafting
materials and versus other biological agents), to investigate patients’ quality of life, to treat various
grades of furcation, in order to verify the actual beneficial effects of use of APC as adjunct with wide
variety of regenerative strategies.
4. Material and Methods
This systematic review and meta-analysis were carried out based on preferred reporting items for
systematic reviews and meta-analysis (PRISMA) guidelines. The protocol of this systematic review
was registered on the international prospective register of systematic reviews (PROSPERO) with
registration number CRD42019100015.
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4.1. Research Question
What is the effectiveness of autologous platelet concentrates used as an adjunct to different
types of surgical techniques for the treatment of furcation defects, compared to the same surgical
techniques alone?
4.2. Search Strategy
A systematic digitalized search was carried out in the following electronic databases: MEDLINE,
SCOPUS, CENTRAL (Cochrane Central Register of Controlled Trials), and EMBASE, using a series of
search terms combined with the Boolean Operators “AND”, “OR”, and “NOT”. The following search
string was developed with the combination of relevant keywords: “(((Furcation Defects) OR Furcation
Involvement)) AND (((((((Platelet Concentrates) OR Platelet-rich plasma) OR Platelet-rich fibrin) OR
Growth factors) OR PRP) OR L-PRF) OR CGF)”. The last electronic search was carried out in October
2018. In addition, a hand search was performed in the following dental journals: British Dental Journal,
British Journal of Oral and Maxillofacial Surgery, Clinical Implant Dentistry and Related Research,
Clinical Oral Implants Research, Clinical Oral Investigations, European Journal of Oral Implantology,
European Journal of Oral Sciences, Implant Dentistry, International Journal of Oral and Maxillofacial
Implants, International Journal of Oral and Maxillofacial Surgery, International Journal of Periodontics
and Restorative Dentistry, Journal of Clinical Periodontology, Journal of Dental Research, Journal of
Dentistry, Journal of Implantology, Journal of Maxillofacial and Oral Surgery, Journal of Oral and
Maxillofacial Surgery, Journal of Periodontal Research, Journal of Periodontology, and Oral Surgery,
Oral Medicine, Oral Pathology, Oral Radiology. The reference citations of the eligible studies and other
systematic reviews were also searched for possible additional eligible studies. Finally, the online trial
registries were also searched for any ongoing studies: US National Institutes of Health Ongoing Trials
Register ClinicalTrials.gov (clinicaltrials.gov; searched 20 October 2018); World Health Organization
International Clinical Trials Registry Platform (apps.who.int/trialsearch; searched 20 October 2018).
No language restrictions were applied.
4.3. Inclusion Criteria
The criteria for the articles to be included in this present systematic review were as follows:
• Randomized clinical trials (RCT), either of a parallel group or of a split-mouth design;
• Presence of at least one experimental group in which APCs were clinically applied as an adjunct
to surgical procedures alone or in combination with bone grafting materials or GTR procedures
for the therapy of furcation defects;
• Presence of an appropriate control group, in which the same therapeutic procedures as those
employed in at least one experimental group were clinically applied for the treatment of furcation
defects, without the adjunctive effect of APCs;
• Patients included in the RCT should present with maxillary/mandibular Grade 2 or 3
furcation defects;
• Patients included in the RCT should have no systemic diseases nor taking medications that could
potentially influence the outcome of periodontal therapy;
• The follow-up period had to be at least 6 months.
4.4. Selection of Studies
Following the electronic search in all the respective databases, the records were imported into
EndNote 13 software (EndNoteX3; Thomas Reuters, New York, NY, USA) and the duplicates were
sorted to be removed from the pool of titles. A total of 153 titles and abstracts (if available) were
independently screened by two reviewers (MDF, SP) to exclude all articles clearly not meeting the
inclusion criteria. Of all the eligible articles, full texts were obtained and were thoroughly assessed.
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Only articles fulfilling the inclusion criteria were considered. In cases of disagreement between the two
reviewers, a third reviewer (LF) was consulted. Detailed reasons were stated for all excluded studies.
4.5. Data Extraction and Management
The relevant data of the included studies were extracted using an Excel spreadsheet (Microsoft,
Radmond, WA, USA). Data were independently extracted by two review authors (MDF, FG) and
recorded on predetermined spreadsheets. In case of missing or unclear information, the authors of the
included studies were contacted by email for providing clarification or missing information.
The following data were recorded for each included report:
• Patients’ demographic characteristics
• Study design and sample size
• Type of platelet concentrate used (PRP, PRF, PRGF, CGF)
• Follow up duration
• source of funding and study setting
• Outcome variables, relative to baseline and post-operative defect characteristics (probing pocket
depth (PPD), horizontal and vertical clinical attachment loss (HCAL, VCAL), horizontal and
vertical furcation depth (HFD, VFD)
4.6. Risk of Bias Assessment
Risk of Bias was assessed by two independent reviewers (ACD, AS) for all the included clinical
trials and the discrepancies were resolved by discussion and in consent with a third reviewer (MK). The
domains of the study were graded under high, unclear or low risk, based on the following categories:
Selection bias (random sequence generation and allocation concealment), performance bias (blinding),
detection bias (assessor blinding), attrition bias (incomplete outcome data), reporting bias (selective
reporting), sample size calculation and number of surgeons involved. Based on the domains, the
studies categorized as low risk of bias if all domains were at low risk; high risk of bias if two or more
domains were at high risk; or medium risk of bias if one domain were at unclear or high risk.
4.7. Data Synthesis
Data of the various outcomes were extracted from each included study. Parallel group and
split-mouth studies were combined in the meta-analysis of treatment effects. For all the outcomes,
mean differences and 95% confidence interval (CI) were used to summarize the results for each
included study. The meta-analysis was performed using Review Manager 5.3 software (RevMan 5.3,
Version 5.3.5 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) using
the fixed or random effects models, as appropriate. Fixed effects meta-analysis was used when the
heterogeneity was small (i2 < 60%, p > 0.05). When the heterogeneity was large (i2 > 60%, p < 0.05),
a random-effects model analysis was undertaken.
5. Conclusions
In conclusion, the evidence available in the literature for the beneficial effects of platelet
concentrates in periodontal furcation defects has been increasing in recent years. Platelet-rich plasma
and platelet-rich fibrin may be advantageously used as an adjunct to open flap debridement alone
and additional grafting procedures, while there is no evidence of an effect of APC when used in
combination with GTR, for the treatment of furcation defects.
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Abstract: In 2004, we developed autologous periosteal sheets for the treatment of periodontal bone
defects. This regenerative therapy has successfully regenerated periodontal bone and augmented
alveolar ridge for implant placement. However, the necessity for 6-week culture is a limitation.
Here, we examined the applicability of a human platelet-rich fibrin extract (PRFext) as an alternative
to fetal bovine serum (FBS) for the explant culture of periosteal sheets in a novel culture medium
(MSC-PCM) originally developed for maintaining mesenchymal stem cells. Small periosteum tissue
segments were expanded in MSC-PCM + 2% PRFext for 4 weeks, and the resulting periosteal sheets
were compared with those prepared by the conventional method using Medium199 + 10% FBS for
their growth rate, cell multilayer formation, alkaline phosphatase (ALP) activity, and surface antigen
expression (CD73, CD90, and CD105). Periosteal sheets grew faster in the novel culture medium
than in the conventional medium. However, assessment of cell shape and ALP activity revealed that
the periosteal cells growing in the novel medium were relatively immature. These findings suggest
that the novel culture medium featuring PRFext offers advantages by shortening the culture period
and excluding possible risks associated with xeno-factors without negatively altering the activity of
periosteal sheets.
Keywords: periosteal sheet; platelet-rich fibrin; growth; differentiation; bone grafting material
1. Introduction
Abundant growth factors and cytokines stored in platelet granules are released from activated
platelets in response to tissue injury. These soluble factors are involved in wound healing and tissue
repair [1]. In the 1990s, this essential role of platelets was exploited for regenerative therapy [2]
and since then, therapies using platelet concentrates have been widely applied in various fields of
regenerative medicine. In parallel with or even a little ahead of this therapeutic strategy, platelet lysates
(PLs) have been used as a substitute for fetal bovine serum (FBS) [3] for in vitro cell expansion
to reproducibly maintain cell proliferation [1]. Finding a possible alternative to FBS was strongly
motivated by two major reasons: (1) limitation of the variability of FBS owing to the increased demands
Int. J. Mol. Sci. 2019, 20, 1053; doi:10.3390/ijms20051053 www.mdpi.com/journal/ijms58
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and decreased production ability; and (2) wide variability between batches that may affect end-product
reproducibility, risks of pathogen contaminations, and ethical issues [1]. The quality of PLs also varied
by source; however, shortage and risks of unexpected contamination could be avoided with the use of
autologous platelets.
We have previously demonstrated a regenerative therapy with autologous periosteal sheets
exhibiting osteogenic properties [4] for alveolar bone regeneration in more than 120 clinical cases [5–7]
over the past 14 years on the basis of the evidence that osteogenicity, as well as osteoinductivity
and osteoconductivity, are maintained in this grafting material [4,8]. Periosteal sheets are routinely
expanded in vitro from small segments of alveolar periosteal tissues in the conventional medium
supplemented with 10% FBS. Although no adverse events related to xeno-factors have been
observed as a result of extensive washing with phosphate-buffered saline (PBS) prior to implantation,
other aforementioned concerns, such as availability and efficacy of FBS, still pose difficulties.
Furthermore, the requirement of a 6-week expansion period reduces the operational efficiency of
cell-processing facilities, thereby increasing the economic burden. Therefore, we aimed to develop
a xeno-free culture medium that may significantly shorten the period of expansion.
In a preceding study, we modified a chemically defined novel culture medium originally
developed for the maintenance of mesenchymal stem cells suitable for human adult periosteal cells.
This was accomplished by the addition of basic fibroblast growth factor (bFGF), platelet-derived
growth factor (PDGF), and dexamethasone. Additionally, we adopted the extract of platelet-rich
fibrin (PRFext) prepared from human peripheral blood samples to replace FBS. As the expansion of
periosteal sheets necessitates only a limited amount of FBS replacement and as this supplement should
be prepared in-house, we chose a more convenient way to obtain platelets and plasma instead of using
the protocol of PL preparation. We confirmed that this novel complete medium facilitated the growth
of periosteal sheets without causing genetic instability, as evident from karyotype testing. To test
compatibility, we compared cell growth and fundamental characteristics of periosteal sheets prepared
using the conventional culture medium (Medium199 + 10% FBS) and the newly modified stem cell
medium supplemented with 2% PRFext.
2. Results
2.1. Growth of Periosteal Sheets
Figure 1 shows the onset of cell outgrowth, which indicates the days required for the migration of
the first cell out of the original periosteum tissue segments. Some minor differences were reported
depending on individual samples; however, no statistical difference was observed between groups.
Cell outgrowth commonly occurred at 6–10 days of culture on average.
Figure 2 shows the photomicrographs of the periosteal cells that migrated out from the isolated
periosteum tissue segments. The cell density was maximum in the central region in cultures with
MSC-PCM + 2% PRFext (C), while the lowest density was observed in the cultures with conventional
Medium199 + 10% FBS (A). Differences in cell shape were observed in the peripheral region.
The majority of periosteal cells showed a typical spindle shape in the conventional medium, while their
shape was relatively branched in type, indicative of their immature phenotype [9–11]. These findings
are consistent with the results observed with MesenPRO-RS medium [8].
59
Int. J. Mol. Sci. 2019, 20, 1053
Figure 1. Effects of different culture media on the onset of periosteal cell outgrowth. The data
obtained from periosteum samples derived from four independent donors are shown. X-axis: types
of culture media. Statistical analysis was performed by Kruskal–Wallis one-way analysis of variance,
followed by Steel–Dwass multiple comparison test. No significant difference was observed between
the groups. N = 3, 4, 5, 6, or 9 replicates.
Figure 2. Photomicrographs of periosteal cells in the central and peripheral regions of periosteal sheets
cultured in different culture media. (A) Medium199 + 10% fetal bovine serum (FBS), (B) MSC-PCM + 4%
FBS, (C) MSC-PCN + 2% platelet-rich fibrin extract (PRFext). Bar = 50 μm. PTS: periosteum tissue segment.
Figure 3 shows the growth curves of periosteal sheets. Some individual differences were observed;
however, overall these data indicate that MSC-PCM + 2% PRFext was the most effective of all media.
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MSC-PCM + 4% FBS was equal or less effective than MSC-PCM + 2% PRFext, while the conventional
medium delayed the growth of periosteal sheets.
Figure 3. Effects of different culture media on the growth of periosteal sheets. The data obtained from
periosteum samples derived from four independent donors are shown. X-axis: time periods (weeks) of
explant culture. N = 2 (6 weeks), 3 (6 weeks), 4, 5, or 7 replicates. Statistical analysis was performed
by Kruskal–Wallis one-way analysis of variance, followed by Steel–Dwass multiple comparison test.
* p < 0.05 as compared with the control group (Medium199 + 10% FBS) at same time points. ** p < 0.05
as compared with the other experimental group (MSC-PCM + 4% FBS) at same time points.
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2.2. Phenotype of Periosteal Sheets
Figure 4 shows alkaline phosphatase (ALP) activity, a representative phenotypic marker of
differentiated osteoblasts, in fixed periosteal sheets. Safranin-O staining indicated the size of individual
samples. As the cell multilayer formation varied with different types of media, it is difficult to compare
ALP activity among groups.
Figure 4. Effects of different culture media on the alkaline phosphatase (ALP) activity and size of
periosteal sheets. Fixed individual periosteal sheets were first stained for ALP activity (positive:
dark blue-purple) and subsequently treated with Safranin-O (Saf.-O) for the evaluation of their sizes.
We used 60 mm culture dishes.
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Figure 5 shows cell multilayers and calcium deposit formation in the sagittal section of periosteal
sheets. The thickness of outgrown cell sheets varied in the presence of different types of culture
media. MSC-PCM + 2% PRFext was the most effective medium for cell multilayer formation.
Although cell growth in a horizontal plane is fundamentally different from cell growth in multiple
layers, the observed effect was, to some extent, consistent with the growth rate results shown in
Figure 3. By contrast, although calcium deposit formation largely relies on the nature of the original
periosteum tissue segments, the conventional medium generally induced diffused mineralization,
whereas MSC-PCM medium reduced it in limited regions.
Figure 5. Effects of different culture media on the thickness of periosteal sheets. In von Kossa staining,
calcium deposits were stained black. These data are representative of five independent experiments.
hematoxylin and eosin (HE) staining. Bar = 200 μm.
Figure 6 shows the distribution of PDGF-B, transforming growth factor beta 1 (TGFβ1),
and collagen type I in the outgrown cell sheets. PDGF-B or antigenically similar proteins were
not detected in any groups in Figure 6. The expression of TGFβ1 or similar proteins was slightly
positive in the periosteal sheets expanded in the conventional medium. However, collagen type I was
detected in all groups. As MSC-PCM + 2% PRFext produced the thickest cell multilayers, the volume of
collagen type I matrix was the most abundant in the periosteal sheets expanded in this culture medium.
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Figure 6. Effects of different culture media on the expression of platelet-derived growth factor-B
(PDGF-B), transforming growth factor beta 1 (TGFβ1), and collagen type I in the central region
of periosteal sheets (outgrowth area). Immunohistochemical staining with visualization using
3′-diaminobenzidine (DAB) (positive: dark brown). These data are representative of five independent
experiments. Bar = 50 μm.
Figure 7 shows the expression of the basic markers of mesenchymal stem cells, CD73, CD90,
and CD105, in the cells growing in periosteal sheets. Comparison was performed only between two
groups; namely, the conventional medium and MSC-PCM + 2% PRFext. Expression of CD105 was
lower in the newly developed medium than that in the conventional medium; however, no statistical
differences were observed.
Figure 7. Effects of different culture media on the expression of surface antigens. Only periosteal sheets
cultured with MSC-PCM + 2% PRFext were compared with the control sheets (Sample 21). X-axis: type
of surface antigens. Statistical analysis was performed using the Mann–Whitney rank-sum test and no
significant difference was observed between the two groups. N = 3 or 4 replicates.
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3. Discussion
FBS is still considered a “magical” supplement for the successful cultivation of cells, although the
associated disadvantages are well known. To improve the quality of the resulting cell-based products
and their therapies, animal-derived factors should be completely eliminated from culture media.
Several efforts have been directed toward the development of a chemically defined medium suitable
for adherent cell cultures. In the initial phase of our project, we aimed to develop such a chemically
defined medium or a medium free of animal components suitable for the cultivation of periosteal
sheets. In comparison with single cell cultures, however, periosteal tissues require stronger adhesion
systems that cannot be achieved by simply adding sufficient amounts of recombinant human adhesion
molecules, such as fibronectin and vitronectin, as evident from our preliminary studies. Instead, such
systems may be reproduced with the use of animal or human-derived sera. Therefore, we modified
our aim to develop a xeno-free medium.
At the beginning of the second phase, we developed and patented a new expansion method using
stocked human platelet-rich plasma (PRP) along with recombinant human bFGF to allow the growth of
periosteal sheets [12]. This method provides a consistent source of fully confluent periosteal sheets in
100 mm dishes within 4 weeks. However, a thin fibrin membrane also forms, covering periosteal sheets
that may cause easy detachment of periosteal sheets upon medium exchange. Thus, in the preliminary
study, we attempted to evaluate alternative ways to utilize the factors from platelet concentrates.
In industry, it may be convenient and economical to use pooled allogeneic PRP,
although complicated and costly extraction methods have to be introduced into the manufacturing
process. For the preparation of small-scale homemade autologous PRP extracts, by contrast,
the preparation protocol needs to be simple and cost-effective. The first choice is definitely platelet-rich
fibrin (PRF) exudate or releasate. However, as various major adhesion molecules were found to be
adsorbed on fibrin fibers in a preliminary experiment [Kawase et al., manuscript in submission],
we homogenized the minced PRF preparations to release these adhesion molecules and used the
obtained supernatant supplemented with small debris of fibrin fragments. This preparation protocol
is fast, less labor-intensive, and produced better results during the initial adhesion and growth of
periosteal sheets, even after reducing the content of PRFext to 2% (v/v).
The rapid growth induced by PRFext was not associated with the initial cell outgrowth, but was
related to the acceleration of cell proliferation after outgrowth. As illustrated in Figure 8 and previously
demonstrated [13], most periosteal cells are dead in the initial phase of culture, and the surviving cells
actively replicate and migrate out to form periosteal sheets. Our results indicate that the added PRFext
acted on cell outgrowth and subsequent cell proliferation, but not on cell turnover. The shortening of
the cell turnover phase may allow further reduction in the period of periosteal sheet preparation to
less than 3 weeks in the near future.
Figure 8. Phases in the process of periosteal sheet cultures.
As rapid proliferation needs to be balanced against genetic, phenotypic, and functional stability [1],
we examined the compatibility of periosteal sheets prepared using the new culture medium in
the validation stage of this study. Regarding genetic stability, the source of periosteal sheets,
i.e., the cells from alveolar periosteum, is at a relatively late stage of differentiation compared to
mesenchymal stem cells. In general, the genetic instability of cells correlates with their pluripotency
and multipotency [14,15]; therefore, the majority of periosteal cells may be relatively genetically
stable during expansion. In support of this speculation, we have previously demonstrated the least
probability of cell transformation in X-ray-irradiated periosteal cells [16]. Furthermore, the qualitative
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analysis of a limited number of cells in karyotype testing (preliminary study) revealed no abnormality
in the chromosomes from periosteal sheet samples at the end of the expansion period.
Regarding the rest of the criteria, the type of culture medium failed to have any significant
influence on the expression of the conventional surface markers of mesenchymal stem cells, i.e.,
CD73, CD90, and CD105 [17]. ALP expression and calcium phosphate deposition were, to some
extent, influenced by culture media. The addition of PRFext suppressed the spontaneous increase in
ALP activity and consequent calcium deposit formation observed in the periosteal sheets expanded
in Medium199 + 10% FBS. By contrast, MSC-PCM increased the accumulation of collagen around
periosteal cells and consequently increased the thickness of periosteal sheets with an increase in growth
rate. MSC-PCM induced maximum effects on sheet thickness in combination with PRFext.
Similar observations were recorded in a previous study using another stem cell medium,
MesenPRO-RS medium supplemented with 2% FBS [8]. Although the ALP activity and the ability to
form calcium deposits in vitro were lower, the periosteal sheets prepared with this medium showed
potent osteogenesis similar to that achieved with the conventional medium upon subcutaneous
implantation in animal models. Taken together with the evidence that collagen provides a platform
for mineral deposition [18], the periosteal sheets prepared with MSC-PCM + 2% PRFext may possibly
exhibit compatible osteogenesis.
The shortening of the preparation period is beneficial for both clinics serving this regenerative
therapy and patients receiving this therapy, in terms of cost, operation efficiency, and treatment
schedule. However, compatibility must be predefined and tested to ensure safety and efficacy of the
resulting periosteal sheets [1] prior to clinical application. As expected, the present study demonstrates
that the critical qualities of the periosteal sheet prepared with MSC-PCM + 2% PRFext are not negatively
influenced during the process of expansion. The process of blood collection from patients can be
estimated to be relatively low on the basis of predicted consumption as mentioned: for a medium
size (2−3 tooth width) alveolar ridge augmentation, approximately 30 periosteal sheets are usually
prepared. When 60 mm culture dishes are used, approximately 600 mL of the culture medium and
approximately 12 mL PRFext are required for the 4-week culture. Since a 10 mL whole-blood sample,
including 1 mL Acid Citrate Dextrose Formula-A (ACD-A), produces approximately 2.5 mL PRFext,
approximately 45 mL peripheral blood should be collected as a sufficient starting volume prior to the
explant culture. However, in case of smaller bone defects, such as periodontal bone defect, the volume
of blood required for the culture can be reduced to between one-fifth and one-tenth.
In addition, this xeno-free medium minimizes the risk of unknown pathogen contamination.
The newly developed MSC-PCM medium is exceptionally more expensive than the conventional
Medium199, but the total cost may be markedly reduced by choosing MSC-PCM + 2% PRFext.
Therefore, we proposed that this complete xeno-free medium may serve as a promising replacement
medium for the conventional FBS-containing medium in the preparation of periosteal sheets.
4. Materials and Methods
4.1. Preparation of PRFext
Blood was collected from six healthy and non-smoking volunteers aged 24–44 years (three females
and three males) using butterfly needles (21G 3/400; NIPRO, Osaka, Japan) and Vacutainer tubes
(Japan Becton, Dickinson and Company, Tokyo, Japan). To prepare the PRFext, the blood samples
were immediately (within approximately 2 min from blood collection) centrifuged by a Medifuge
centrifugation system (Silfradent S. r. l., Santa Sofia, Italy) [19,20]. The red thrombus (the fraction of
red blood cells) was eliminated with scissors and the resulting PRF preparations were minced using
scissors, followed by homogenization with sterile BioMasher (Nippi, Tokyo, Japan), as illustrated in
Figure 9 and as described previously [21]. The homogenized samples were centrifuged at maximum
speed to exclude fibrin matrix fragments. The resulting supernatant was stored at −80 ◦C until use.
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Approximately 2.5 mL PRFext can be prepared from 10 mL whole-blood sample, including 1 mL
ACD-A. The levels of PDGF-BB in the resulting samples usually ranged from 25 to 50 ng/mL [21].
Figure 9. Graphic summary of preparation of platelet-rich fibrin (PRF) extract.
The study design and consent forms for all the procedures (project identification code: 2015-2143)
were approved by the Ethics Committee for Human Subjects of the Niigata University School of
Medicine (Niigata, Japan) on 12 June, 2017, in accordance with the Helsinki Declaration of 1964 as
revised in 2013.
4.2. Explant Culture of Periosteum Tissue Segments to Form Periosteal Sheets
Six patients aged 20–44 years (four females and two males) in need of wisdom tooth extraction
participated in this study after providing written informed consent. Aliquots of periosteum tissues
were aseptically dissected from the buccal side of the retromolar region in the mandible of healthy
donors, washed thrice in Dulbecco’s PBS without Ca2+ and Mg2+, cut into small segments (~1 × 1 mm),
and plated on 60 mm dishes. After incubation for 15–20 min under dry conditions in a CO2 incubator,
the conventional medium (Medium199 supplemented with 10% FBS), MSC-PCM medium (Kohjin Bio,
Sakado, Japan) supplemented with 4% FBS, or MSC-PCM medium supplemented with 2% PRFext
was added to cover the bottom surface of the dish. All media were commonly supplemented with
25 μg/mL of L-ascorbic acid, 100 U/mL of penicillin G, 100 μg/mL of streptomycin, and 0.25 μg/mL
of amphotericin B (Invitrogen, Carlsbad, CA, USA). The volume of media was increased in a stepwise
manner as cell outgrowth proceeded.
4.3. Evaluation of Cell Outgrowth and Growth Rate
The onset of cell outgrowth, which indicates days required for the migration of the first cell out
of the original periosteum tissue segments, was evaluated using an inverted microscope once every
3 days. Frequent examination of cell outgrowth can sometimes lead to detachment of periosteum
tissue segments; hence, we did not perform a daily evaluation.
The growth rate was determined by measuring the lengths of the long (major) axis and short
(minor) axis. Periosteal sheets were plated on a light box and measured by a caliper.
4.4. Histological Determination of ALP Activity
For ALP staining, periosteal sheets were fixed with 10% neutralized formalin on dishes and
directly treated with an ALP staining kit (Muto Chemicals, Tokyo, Japan) for 4 h, followed by
counterstaining with Safranin-O [4].
4.5. Histological and Immunohistochemical Examination for Calcium Deposition, Growth Factor Expression,
and Collagen Accumulation
Periosteal sheets were gently detached using a cell scraper and immediately fixed with 10%
formaldehyde in 0.1 M phosphate buffer, pH 7.4, overnight. Fixed samples were dehydrated using
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an ethanol series (70%−100%) and xylene and embedded in paraffin. The samples were sagittally
sectioned at a thickness of 6 μm [4].
As previously described [20], the deparaffinized sections were subjected to antigen retrieval with
Liberate Antibody Binding Solution (Polysciences, Inc., Warrington, PA, USA) and blocked with Block-Ace
(Sumitomo Dainippon Pharma., Osaka, Japan) solution in 0.1% Tween-20-containing PBS. The sections
were probed with a rabbit polyclonal anti-collagen type I antibody (1:400; Bioss Inc., Boston, MA, USA),
anti-TGFβ1 antibody (1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), or anti-PDGF-B (1:200;
Santa Cruz) diluted in ImmunoShot Mild (Cosmo Bio, Tokyo, Japan) overnight at 4 ◦C, followed by
incubation in horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (Cell Signaling Technology,
Danvers, MA, USA). Immunoreactive proteins were visualized with a 3,3′-diaminobenzidine (DAB)
substrate solution (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD, USA).
The sections were alternatively stained with hematoxylin and eosin (HE) or silver nitrate
(von Kossa staining). For von Kossa staining, the sections were faintly counterstained with Kernechtrot
solution to provide a background stain [4].
4.6. Flow Cytometric Evaluation of CD73-, CD90-, and CD105-Positive Periosteal Cells
Cells were dispersed from cultured periosteal sheets with 0.05% trypsin + 0.53 mM
ethylenediaminetetraacetic acid (EDTA) solution (Invitrogen), washed twice with PBS, and suspended
in 0.1 mL PBS containing 0.1% bovine serum albumin (BSA) at a density of 1 × 106 cells/mL.
The cells were probed for 30 min at 4 ◦C with 5 μL of the following mouse monoclonal
antibodies: anti-CD73-fluorescein isothiocyanate (FITC) (IgG1) (BioLegend, San Diego, CA, USA),
anti-CD90-phycoerythrin (PE)/Cy5 (IgG1) (BioLegend), and anti-CD105-PE (IgG1) (BioLegend).
After being washed twice with PBS, the cells were analyzed by flow cytometry (Navios;
Beckman Coulter, Miami, FL, USA). Data analysis and histogram overlay were performed using Navios
Software (Beckman Coulter). For isotype controls, individual corresponding antibodies (all from
BioLegend) were used [8].
4.7. Statistical Analysis
The data were expressed as mean ± standard deviation (SD). For multigroup comparisons,
statistical analyses were performed to compare the mean values by Kruskal–Wallis one-way
analysis of variance, followed by Steel–Dwass multiple comparison test (BellCurve for Excel version
3.00; Social Survey Research Information Co., Ltd., Tokyo, Japan). For two group comparisons,
statistical differences were tested using the Mann-Whitney rank-sum test (SigmaPlot 12.5; Systat
Software, Inc., San Jose, CA, USA). Differences with P values of less than 0.05 were considered
statistically significant.
5. Conclusions
This preclinical study successfully validated the applicability of PRFext for FBS replacement
in explant cultures of periosteum tissue segments to form periosteal sheets. These findings were
established using the samples donated by healthy volunteers. For therapeutic use, however,
autologous periosteum tissue and PRFext must be employed for the preparation of periosteal sheets.
Thus, the efficacy of PRFext and the responsiveness of periosteum tissue may vary with individual
samples, and more careful measures should be adopted while evaluating the quality of periosteal
sheets prepared by this protocol.
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Abstract: Meniscal tears are the most common orthopaedic injuries, with chronic lesions comprising
up to 56% of cases. In these situations, no benefit with surgical treatment is observed. Thus, the
purpose of this study was to investigate the effectiveness and safety of percutaneous intrameniscal
platelet rich plasma (PRP) application to complement repair of a chronic meniscal lesion. This
single centre, prospective, randomized, double-blind, placebo-controlled study included 72 patients.
All subjects underwent meniscal trephination with or without concomitant PRP injection. Meniscal
non-union observed in magnetic resonance arthrography or arthroscopy were considered as failures.
Patient related outcome measures (PROMs) were assessed. The failure rate was significantly higher
in the control group than in the PRP augmented group (70% vs. 48%, P = 0.04). Kaplan-Meyer
analysis for arthroscopy-free survival showed significant reduction in the number of performed
arthroscopies in the PRP augmented group. A notably higher percentage of patients treated with
PRP achieved minimal clinically significant difference in visual analogue scale (VAS) and Knee injury
and Osteoarthritis Outcome Score (KOOS) symptom scores. Our trial indicates that percutaneous
meniscal trephination augmented with PRP results in a significant improvement in the rate of chronic
meniscal tear healing and this procedure decreases the necessity for arthroscopy in the future (8% vs.
28%, P = 0.032).
Keywords: meniscus; meniscus repair; meniscus tear; trephination; platelet-rich plasma; PRP; chronic
meniscal lesion; horizontal meniscal tear
1. Introduction
The menisci are known to play a pivotal role during normal functioning of the knee joint.
Their unique and complex chondral structure, as well as their biology, make treatment and repair very
challenging. The menisci increase joint stability, distribute load, absorb shock and provide lubrication
and nutrition to the remaining joint elements.
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Meniscal tears are considered the most common orthopaedic diagnoses. For many years,
arthroscopy was regarded as a “gold standard” in therapy with almost 4 million arthroscopies
for meniscus pathologies performed annually all over the world, thus representing a serious
socio-economic concern with relevant Health Care System costs [1]. Interestingly, more than 50% of
these surgeries are conducted in patients older than 45 years with degenerative meniscal lesions [2].
This type of injury is a slowly progressing phenomenon, typically involving horizontal cleavage of
the meniscal body with prevalence in the population reaching up to 56%. Interestingly, 61% of those
tears have no clinical symptoms of meniscal pathology (pain, aching, stiffness or oedema) [2]. These
data provided the background for studies analysing the efficacy of arthroscopy in chronic meniscal
lesion therapy. Several randomized clinical trials were performed and demonstrated no additional
benefit of partial meniscectomy to sham surgery [3]. These data introduced doubt into the current
practice and resulted in making clinical decisions more challenging. Additionally, meniscectomy
or partial meniscectomy results in rapid deterioration of articular cartilage and the development
of arthritis [4]. Despite the trend of meniscus tear repair and maintaining as much vital tissue as
possible [5] there is an inability amongst surgeons to restore anatomical and functional roles of the
repaired meniscus. Simultaneously, osteoarthritis progressively develops. These rationales shifted the
treatment protocols of chronic meniscal tears into the non-operative manner and motivated the search
for new therapeutic strategies.
There are several clinical trials that have provided evidence for the use of blood or bone marrow
derived products in the surgical treatment of meniscal pathology: the fibrin clot technique [6,7],
platelet-rich plasma (PRP) [8,9] or the bone marrow venting procedure [10,11]. There is, however, no
data in the literature evaluating the effect of blood derived products on healing of chronic meniscal
tears. Thus we designed a prospective, randomized, double-blind, parallel-group, placebo-controlled
study to investigate the effectiveness and safety of minimally invasive (percutaneous) intrameniscal
PRP application to complement repair of a symptomatic chronic meniscal lesion. We hypothesized
that intrameniscal injection of PRP with concomitant meniscal trephination would result in both an
improved healing rate and better functional outcomes.
2. Results
Follow-up ended on 15 January 2019. The median follow-up lasted for 92 weeks (54–157 weeks).
1 patient was lost to follow-up and 2 additional patients were excluded from analysis due to additional
procedures (ligament surgery and radio synovectomy) (Figure 1). All remaining patients were
functionally assessed at 3, 6, 12 months after the initial procedure. Patients undergoing arthroscopy due
to unacceptable quality of life were excluded from analysis of the PROMs. There were no significant
differences in baseline characteristics between the groups (Table 1).
Table 1. Baseline characteristics of study patients in the control and PRP-treated groups.
Control Group (n = 30) PRP-Treated Group (n = 42) P-Value
Age (years) 46 (27–68) 44 (18–67) P = 0.31
Sex (M:F) 19:11 22:20 P = 0.25
BMI (range) 28 (21–36) 27 (19–37) P = 0.27
Kellgren-Lawrence scale
(0 grade:1 grade:2 grade) 23:7:0 30:12:0 P = 0.79
PRP (PLT × 103/μL) 732 (220–1586) 823 (320–1659) P = 0.16
Meniscus (MM:ML) 30:0 41:1 P = 0.58
Data are presented as median (range) or mean ± standard error (confidence interval (CI) 95%) unless
otherwise indicated. BMI, body mass index; PRP, platelet rich plasma; PLT, platelets; MM—medial meniscus;
ML—lateral meniscus.
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Figure 1. Flow diagram of the trial.
2.1. Primary Outcome
Assessment of meniscal healing on MR arthrography was performed at week 33 (13–78) in both
groups (Table 2). Induction of the healing process within the meniscus was observed. The healing
rate of the meniscal tear, although not significant, was superior in the PRP augmented percutaneous
trephination repair group (11 fully and 4 partially healed menisci out of 25 assessed, 60%) than in the
control group (7 fully and 4 partially healed menisci out of 26 assessed). When considering cumulative
failure rate (arthroscopy and arthrography MRI), the success ratio was significantly better in PRP
augmented percutaneous trephination group (P = 0.04) (Table 2). In case of 10 patients (8 in the control
group and 2 in the PRP augmented group) subsequent arthroscopic meniscectomy or meniscal repair
was performed due to unacceptable clinical symptoms. The survival of the PRP injected meniscus
(arthroscopy free survival) was superior versus the control group (P = 0.032, Figure 2). No significant
influence of the number of injected platelets or fold increase in the number of platelets in PRP on
meniscal healing was detected.
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Table 2. Primary outcome assessment.
Cumulative Outcome (Assessed Using MRI and Arthroscopy) (P = 0.04)
Outcome PRP-treated group (n of menisci) Control group (n of menisci)
Healed 10 5
Partially healed 4 3
Failed 13 19
MRI (P = 0.41)
Outcome PRP-treated group (n of menisci) Control group (n of menisci)
Healed 11 7
Partially healed 4 4
Failed 10 15
MRI, magnetic resonance imaging; PRP, platelet-rich plasma.
Figure 2. Arthroscopy free survival of patients undergoing trephination of the meniscus with or
without PRP augmentation.
2.2. Secondary Outcomes-Pain
Baseline pain characteristics (VAS and KOOS-pain) of the patients did not differ significantly
between groups (Table 3). All patients presented an improvement in pain scores. The changes in VAS
and KOOS-pain exceeded minimal clinically important difference (MCID) value in majority of patients
(Table 4). We detected a significant difference level in the percentage of patients who benefited by at
least MCID in VAS score (39% vs. 65%, P = 0.046). No other significant changes were detected.
2.3. Secondary Outcomes-Function
Functional outcomes were measured with the IKDC subjective scale, WOMAC and the KOOS
subscales (symptoms, function in daily living [ADL], sport/recreation and knee related quality of
life [QOL]). Each parameter improved over time in both groups, exceeding the MCID values in vast
majority of patients. A significant difference in the percentage of patients who benefited by at least
the MCID value in the KOOS Symptoms subscale was detected (48% vs. 76%, P = 0.028). We noted
that the remaining KOOS subscales, IKDC score and WOMAC score were improved in both groups
(Tables 3 and 4).
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2.4. Complications
No peri- or post- procedure complications were noted among patients who participated in the
final follow-up.
Table 3. Patient-reported outcome measures (pain: VAS and KOOS-pain; function: IKDC, WOMAC,
KOOS: symptom, ADL, sport/recreation and QOL).















































































a For the control group vs. PRP group; Data are presented as mean ± standard error (CI 95%) unless otherwise
indicated. PROM, patient related outcome measures; VAS, visual analogue scale; WOMAC, Western Ontario and
McMaster Universities Osteoarthritis Index; IKDC, International Knee Documentation Committee; KOOS, Knee
injury and Osteoarthritis Outcome Score; ADL, activities of daily living; S/R, sport/recreation; QOL, quality of life.
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Table 4. Patient-reported outcome measures (pain: VAS and KOOS-pain; function: IKDC, WOMAC,
KOOS: symptom, ADL, sport/recreation and QOL).
Control Group PRP Group
PROM MCID Mean Change Improved by at Least
MCID [%]
Mean Change Improved by at Least
MCID [%]
P a P b
VAS 2 [12] 2.36 ± 0.0.09
(3.86–5.20)
39 3.62 ± 0.07
(2.82–4.43)
65 0.027 0.046
IKDC 16.7 [13] 33.66 ± 0.84
(25.95–41.36)
83 34.74 ± 0.55
(28.17–41.31)
78 0.48 0.48
WOMAC 11.5 [14] 21.77 ± 0.67
(15.65–27.90)




Pain 16.7 [13] 24.95 ± 0.62
(19.24–30.66)
65 29.50 ± 0.45
(24.18–34.81)
73 0.17 0.36
Symptoms 17.4 [13] 18.38 ± 0.82
(10.81–25.95)
48 27.93 ± 0.42
(22.89–32.96)
76 0.016 0.028
ADL 18.4 [13] 24.61 ± 0.74
(17.79–31.43)
57 26.27 ± 0.39
(21.67–30.87)
76 0.18 0.1
S/R 12.5 [13] 43.75 ± 1.12
(33.43–54.07)
83 34.65 ± 0.76
(25.57–43.74)
70 0.12 0.22
QoL 15.6 [13] 32.67 ± 1.06
(22.93–42.41)
70 28.43 ± 0.52
(22.23–34.64)
76 0.29 0.41
a For mean changes; b for % of patients improved by at least MCID. Data are presented as mean ± standard
error (CI 95%) unless otherwise indicated. PROM, patient related outcome measures; VAS, visual analogue
scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index; IKDC, International Knee
Documentation Committee; KOOS, Knee injury and Osteoarthritis Outcome Score; ADL, activities of daily living;
S/R, sport/recreation; QOL, quality of life; MCID, Minimal Clinically Important Difference.
3. Discussion
Meniscal healing has always been a major challenge for orthopaedic surgeons. All types of
meniscectomies can lead to an increase in the risk of osteoarthritis [15] and evidence comparing
the results of total and partial meniscectomy provide data on the beneficial effects of meniscus
preservation [16]. The rising problem in meniscal injury treatment is the substantial number of chronic
meniscal lesions. Recent studies comparing non-operative and arthroscopic treatment showed no
benefit of surgical treatment in large cohorts of patients [3,17]. Data provided by the European Society
of Sports Traumatology, Knee Surgery and Arthroscopy [18] or the guidelines published in the British
Medical Journal [19] showed no or poor clinical benefit of arthroscopy in the case of degenerative
meniscal lesions. In fact, arthroscopy was titled “the last resort” of treatment and applicable due to
failure of conservative management.
The most significant finding of this study was that percutaneous trephination with or without a
PRP boost induced the healing response of chronic meniscus tears. The process was augmented in
the PRP – treated group. Interestingly, our results also demonstrated that no full meniscal integrity is
necessary to obtain a clinically important difference in respect to PROMs. Additionally, we found that
the functional outcomes (KOOS Symptoms) and pain levels (VAS) scored higher in patients treated
with PRP-augmentation than in the control group.
For this study we used leukocyte- and platelet-rich plasma (L-PRP). Its fluid like state enables
delivery to the target site by needle injection. Once activated, L-PRP forms a gel and releases most
of the growth factors in the first few hours post injection until fully dissolved within 3 days [20].
It supports growth factors to act as an assembly of platelets and leukocytes in a complex matrix.
Although leukocyte and platelet rich fibrin (L-PRF), was shown to slowly release growth factors over a
period of about 7 days [21] providing optimal kinetics of a release, it forms a 3D matrix that cannot be
delivered via a minimally invasive way (e.g., intra-articular injection)
PRP has been shown to influence not only the process of meniscal healing in vitro and
in vivo [22,23] but also the treatment of other musculoskeletal injuries [24,25]. Some evidence has
been provided for the use of PRP in meniscal repair [8,9]. The authors found that clinical outcomes
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and healing rates were better with the introduction of PRP into the lesion at the end of surgery.
Griffin et al. performed a retrospective chart review with a minimum of 2 year follow-up and
failed to show any benefit of PRP augmentation [26]. However, the study was underpowered for
the primary and secondary outcomes. Another Study by Strümper, R. et al. demonstrated that
intra-articular autologous conditioned serum injection might be an effective treatment option for knee
pain associated with meniscal lesions [27]. The authors showed that surgery was avoided during the
6-month observation period and the Oxford Knee Score improved significantly from 29.1–44.3 in 83%
of patients. Interestingly, the structural findings on MRI, measured by Boston Leeds Osteoarthritis
Knee Score, also showed significant improvement. The limitations of the study were its retrospective
character and lack of control group analysis. We believe that an additional weak point of this study was
connected to not addressing perimeniscal capillary plexus (PCP) while performing the joint injection.
Trephination is a known technique usually employed during arthroscopy [28,29]. It involves the
formation of vascular access channels from the meniscus periphery (PCP) to the tear. This process
initiates bleeding into the meniscal lesion and subsequent tissue repair response. This simple technique
was showed to increase the meniscal healing rate while applied during a surgical procedure [30], most
probably by providing the injury site with both growth factors and mesenchymal stem cells.
The results of experimental studies support the hypothesis that PRP may improve meniscal
healing through activation of fibrochondrocytes present within the meniscus [31]. The process also
involves the activity of mesenchymal stem cells, which seem to be necessary for the repair of meniscal
lesions [23]. The PRP itself releases the “cytokine cocktail” of the healing cascade [25]. The main
growth factors are: platelet derived growth factor, platelet derived endothelial growth factor, vascular
endothelial growth factor, insulin like growth factor, platelet derived angiogenesis factor, transforming
growth factor-b, hepatocyte growth factor and others [32]. This release initiates the chemotaxis of
immunocompetent cells, inflammation, angiogenesis and as a consequence the process of synthesis of
the extracellular matrix and tissue remodelling. The PRP works at various levels for joint homeostasis.
Studies have shown that PRP application decreases catabolism while increasing anabolic activity
and observations have been made that catabolic activity in meniscus chondral tissue helps identify
patients who are at risk for progression of osteoarthritis [33]. Other processes, such as chondral
remodelling is promoted by PRP administration. Higher production of collagen II, matrix molecules
and prostaglandin has been observed in hyaline cartilage [34,35]. On the contrary, Lee et al. showed
on a rabbit model of a circular meniscal defect that PRP treatment failed to enhance the production
of meniscus cartilage. Additionally, it accelerated fibrosis and increased catabolic processes [36].
However, findings from in vivo and in vitro studies cannot be directly translated to clinical practice.
Increasing data provide evidence for the necessity of mesenchymal stem cells in delivering the
positive effect of PRP on healing of meniscal and hyaline cartilage defects [23,37] and the process of
chondrocyte differentiation [38]. PRP has been shown to enhance proliferation of stromal stem cells [39]
as well as their adhesion and migration [40]. This phenomenon is probably dependent on the release
of a growth factor cocktail and triggering of synovial tissue to create a more balanced intra-articular
environment. Recent studies link the synovium-derived stem cells to chondral regeneration, as they
possess chondrogenic potential and encouraging results have been shown for cartilage repair purposes
in experimental studies [41].
We hypothesize, that trephination, by creating multiple wounds and inducing intrameniscal
bleeding, starts the process of tissue repair with activation of synovial and blood derived stem cells,
which—in our study—are stimulated by addition of PRP. The combination of those two processes
allows for efficient meniscal tissue regeneration.
3.1. Strengths
This is the first study to employ percutaneous trephination of a chronic meniscal lesion with
or without PRP augmentation. The second strength is the study design itself, the randomized and
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blinded nature of this study and being adequately powered to detect differences in healing rates.
Lastly, independent evaluators were used for assessing of the outcomes.
3.2. Limitations
We acknowledge some limitations in this study. The study group was small, increasing the risk of
type II error. Additionally, some patients refused MRI arthrography due to its interventional character,
still their comfort of life improved significantly. Also, calculation of the primary outcome might have
been influenced by factors that could affect MRI images and their interpretation. There is also the
issue of heterogeneity within groups. Localization of the tear in medial or lateral compartments may
influence the primary outcome, as the biology of those menisci might differ. We find no statistically
significant differences between these groups but in the literature the results are mixed [42]. Additionally,
PROMs data have partially overlapping 95% confidence intervals, increasing the risk of type II error.
Moreover, it is still unknown which of the factors are solely responsible for the improved outcomes in
the PRP group. The rehabilitation protocol was uniform in all patients but we could not control those
differences that might have occurred in patients being treated in multiple outpatient centres. Lastly,
the observation period in this study allowed only for a short-term analysis.
4. Materials and Methods
4.1. Trial Design and Informed Consent
This was a parallel-group, superiority trial with equal randomization. The study protocol was
approved by an appropriate Institutional Review Board and was publicly accessible before enrolment
of the first patient. We performed the study in accordance with the ethical standards outlined in the
2013 revision of 1975 Declaration of Helsinki and we report the results according to the 2010 CONSORT
statement. The potential benefits and risks of meniscal trephination, PRP injection and follow-up were
explained to each study patient. All patients provided written informed consent for participation in
this study and no patient declined to participate. Clinical Trial Registration: The study protocol was
approved by Bioethics Committee at Centre of Postgraduate Medical Education (36/PB/2013 approved
on 29.05.2013) and was publicly accessible before enrolment of the first participant. The clinical trial
databases at cmkp.edu.pl-36/PB/2013, clinicaltrials.gov-NCT03066583.
4.2. Eligibility Criteria
Patients were recruited from a single public knee clinic at a tertiary care, university health centre
between 2016 and 2018 (Figure 1). 72 patients with chronic (horizontal) meniscal lesions were enrolled:
30 were randomized to undergo percutaneous trephination (control group) and 42 were randomized
to undergo percutaneous trephination with PRP injection at the repair site. Detailed inclusion and
exclusion criteria are presented in Table 5.
Table 5. Inclusion and exclusion criteria.
Inclusion Criteria Exclusion Criteria
skeletally mature patients aged 18–70 years
chronic horizontal tears on MRI
tear located in the vascular/avascular portion of the meniscus
single tear of the medial and/or lateral meniscus
arthritic changes (Kellgren-Lawrence scale >2)
discoid meniscus
axial leg deformity (valgus > 6 deg)- concomitant chondral defects (> 2 ICRS)
Inflammatory diseases (rheumatoid arthritis)
chondral defects above ICRS 2 on MRI
MRI, magnetic resonance imaging.
4.3. PRP and Thrombin Preparation
PRP and its activator (thrombin) was prepared as in Reference [9]. In this study we used
Red-L-PRPIIB-1 according to the new classification system [43]. PRP was prepared by a dedicated
laboratory assistant in the BL2 facility. Briefly, the PRP preparation procedure involved drawing
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of 120 mL of venous blood and centrifuging the blood using a refrigerated centrifuge in a two-step
process. First, the PRP layer was isolated, including a “buffy coat” and a small fraction of underlying
red blood cells (900 rpm × 9 min). Additional centrifugation and isolation of PRP was then applied
(3200 rpm × 15 min). The preparation was packed into sterile vials labelled with the patient ID. In
the study group, 6–8 mL of PRP solution was used, while in the control group, 6–8 mL of sterile 0.9%
saline was applied. Right before application, PRP was activated using 20 mM CaCl2 (Teva, Basel,
Israel) and 25 IU/mL autologous thrombin. It was then injected into the tear site of the meniscus with
a double chamber syringe. Platelets and leukocyte concentration were assessed for each sample.
4.4. Procedures
All procedures were performed by the same senior orthopaedic surgeon under ultrasound
guidance (R.K.) in the outpatient department. In brief, the PRP or control solution was prepared as
described above. Local anaesthetic was used. After identification of a horizontal tear via ultrasound,
the needle was introduced into the tear lesion (passing through the PCP, red zone, red-white zone and
white zone) with continuous injection of studied solutions (starting while in the PCP). 5–10 separate
needle introductions through all layers were performed. After discharge, patients were referred to
outpatient physiotherapy units and encouraged to follow a unified rehabilitation protocol. In short, all
patients wore a hinged knee brace for 4 weeks. Exercises with a range of motion from 0 to 90 degrees
for 6 weeks were encouraged. Weight bearing as tolerated was allowed - beginning from day 1. Early
quadricep muscle activation was initiated. At 6 weeks post procedure, a low-resistance stationary
bicycle and one-quarter body weight leg presses were initiated. Additional increases in low-impact
knee exercises were permitted as tolerated starting at 12 weeks post procedure.
4.5. Outcomes
The primary outcome was meniscus healing assessed using 1.5T magnetic resonance imaging
(MRI) arthrography with a dedicated knee coil (Siemens, Erlangen, Germany). Meniscus healing
was evaluated by two independent attending radiology consultants, who were blinded to the patient
allocation. We did not notice any intra-observer bias. Complete healing was considered when full
meniscus integrity was noted during MR arthrography (no intrameniscal contrast media). Partial
healing was considered with contrast media filling a defect between 1–3 mm. Healing failure was
considered when contrast media was detected within the meniscal body. Additionally, failure was
defined as performing arthroscopic meniscectomy or meniscal repair. Arthroscopy free survival
was analysed.
Secondary outcomes (patient reported outcome measures–PROMS) included pain assessment
with the visual analogue scale (VAS) and functional outcome assessment with the Knee injury and
Osteoarthritis Outcome Score (KOOS), Western Ontario and McMaster Universities Osteoarthritis
Index (WOMAC) and International Knee Documentation Committee Subjective Knee Evaluation
(IKDC) [12,44,45]. All secondary outcomes were assessed before the procedure and at 3, 6, 12, 24 months
post injection. Minimally clinical important difference (MCID) was assessed for PROMs [13,14,46,47].
Patients were closely monitored for complications. There were no changes to the protocol during
study duration.
4.6. Randomization
The randomization list for allocating patients to the study groups was generated using the “simple
randomization” function on the StatSoft GraphPad QuickCalcs web site (http://www.graphpad.com/
quickcalcs) [48]. We used sequentially numbered, opaque, sealed envelopes to conceal the allocation.
Patients were consecutively enrolled and assigned to the study groups. Intervention assignment was
performed during PRP preparation.
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4.7. Blinding
The patients, the data collectors and the assessors were blinded to the intervention type.
4.8. Statistical Analysis
We used the R statistical package (www.rproject.org) for statistical analyses [49]. Differences in
meniscus healing rates were assessed through analysis of a contingency table using Fisher’s exact test.
All categorical data were analysed using Fisher’s exact test. The VAS score, KOOS, WOMAC and IKDC
score were analysed using the two-tailed Mann-Whitney U test or unpaired t-test (after assessment for
parametric or non-parametric distribution using the Shapiro-Wilk test) [50]. Arthroscopy-free survival
was analysed using Kaplan Meyer plot and log-rank testing for statistical significance. Results were
considered statistically significant at a P-value < 0.05. Sample size was calculated for the primary
outcome (meniscus healing), with a two-tailed significance level at alpha = 0.05 and beta = 0.8, assuming
a difference in the meniscus healing rate of 15% between the study groups according to the method
described in Reference [51] and based on previous studies [52,53]. Minimum recruitment level was
estimated to be 28 patients per group. Assuming an attrition or non-compliance rate of 10% during the
study, we aimed to recruit at least 30 patients per group.
5. Conclusions
Our blinded, prospective, randomized, controlled trial on the role of PRP and percutaneous
trephination of the chronically torn meniscal tissue indicates that percutaneous trephination of
the meniscal tissue is an effective technique improving meniscal integrity as well as PROMs. The
augmentation of this technique with PRP results in a significant improvement in the rate of meniscal
healing (52% vs. 30%, P = 0.04). Importantly, this simple procedure seems to decrease the necessity for
arthroscopy in the future (8% vs. 28%, P = 0.032). This study showed that PRP augmentation could
provide significant and clinically important benefits. Further studies in this field are encouraged. The
risk of adverse events related to percutaneous trephination with augmentation with PRP is very low.
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Abstract: Background: Evidence is growing regarding the ability of platelet-rich plasma (PRP)
injections to enhance functional capacity and alleviate pain in knee osteoarthritis (OA). However,
heterogeneity in common practice regarding PRP preparation and biological content makes the
initiation of this activity in a hospital complex. The aim of this study was to document the efficacy of
a single PRP injection to treat knee OA and validate a routine care procedure. Methods: Fifty-seven
patients with symptomatic knee OA received a single injection of large volume of very pure PRP.
They were assessed at baseline and after one, three and six months, by measuring Knee Injury and
Osteoarthritis Score (KOOS), Observed Pain after a 50-foot walk test and Visual Analog Scale (VAS)
assessments. Magnetic Resonance Imaging (MRI) analysis was performed at baseline and six months
after the procedure. The objective was to recover 50% of responders three months after the procedure
using OMERACT-OARSI criteria. Results: A single administration of high volume pure PRP provided
significant clinical benefit for 84.2% of the responders, three months after the procedure. The KOOS
total score significantly increased from 43.5 ± 14.3 to 66.4 ± 21.7 six months after the procedure
(p < 0.001). Pain also significantly decreased from 37.5 ± 25.1 to 12.9 ± 20.9 (p < 0.001). No difference
was observed on MRI parameters. Conclusion: A single injection of large volume of very pure PRP is
associated with significant functional improvement and pain relief, allowing initiation of daily PRP
injection within our hospital.
Keywords: PRP; knee arthrosis; growth factors
1. Introduction
Osteoarthritis (OA) of the knee is a progressive joint disease involving the intra-articular (IA)
tibiofemoral and patellofemoral cartilage and all surrounding IA and periarticular structures [1]. In the
United States, symptomatic OA affects more than 50 million adults, resulting in annual costs exceeding
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$ 100 billion due to medical expenses and lost wages [2]. Non pharmacological approaches such as
exercise and lifestyle modifications are often associated with poor compliance [3] and pharmacological
therapies (including analgesics, non-steroid anti-inflammatory drugs and corticosteroid injections)
are not curative and induce side effects in the long term [4,5]. Hyaluronic acid (HA) injections were
described as more effective in the long term compared to corticosteroids injection [6] with highly
variable association with pain [7]. However, the American Academy of Orthopaedic Surgeons (AAOS)
clinical practice guidelines provide evidence against HA viscosupplementation injections in patients
with symptomatic knee OA [8]. This situation has led to the emergence of cell-based therapy options
also called orthobiologics. Among them, platelet-rich plasma (PRP) is defined as an autologous
plasma suspension of platelets, characterized by a platelet concentration higher than in physiological
blood [9] and able to release growth factors (GFs) involved in reparative and regenerative processes.
PRP has been the subject of increased clinical interest in the orthopaedic field and a recent meta
analysis indicates that, compared with HA and saline, an intra-articular PRP injection may have
more benefits in pain relief and functional improvement in patients with symptomatic knee OA at
one year post-injection [10], providing orthopaedic surgeons and rheumatologists a new validated
non-invasive option to improve knee OA related symptoms [11]. However, there is significant variation
in the production of autologous PRP, including heterogeneity in the harvesting method, the type of
anticoagulant used and the production method. Substantial differences in the content of platelets
concentrates produced by the various automated and manual protocols have been described [12,13]
and their consequences on clinical results in PRP therapy is currently being investigated [14,15].
Thus, the initiation of PRP injection activity within a hospital necessitates the selection of dedicated
material and the establishment of a precise patient care procedure which should take into account
recent recommendations from the AAOS regarding minimum reporting standards for clinical studies
evaluating PRP [16].
In this context, the aim of this study was to document the efficacy of a single PRP injection to treat
knee OA in routine care procedure. We assumed that PRP would allow to recover 50% of responders
three months after treatment, using OMERACT-OARSI criteria. We also analyzed the relationship
between clinical results and PRP composition through a precise biological characterization of the
injected PRP, including platelets, leukocytes and red blood cells (RBCs) counts.
2. Results
2.1. Characteristics of Patients
Out of 61 screened patients, 60 were injected and 57 were finally analyzed. One patient was
originally included in the study population but finally excluded before the injection. Three patients
were injected but could not be included in the analysis (one patient with lost follow up after one
month and two patients with misunderstanding in inclusion criteria) (Figure 1). Patients were aged
63.3 ± 9.6 years old and presented grade 2 (40.3%) and grade 3 (59.7%) knee OA according to the
Kellgren-Laurence scale (Table 1). 42 (73.7%) and 6 (10.5%) patients had previously had IA injection of
HA or corticosteroids, respectively.
Table 1. Baseline characteristics of patients included (n = 57) in statistical analysis.
Sex, male:female, n 24:33
Age, year, mean ± SD 63.3 ± 9.6
BMI, kg/m2, mean ± SD 25.4 ± 3.9
Symptom duration, mo, mean ± SD 8.4 ± 9.9
Kellgren Laurence Grade of knee OA grade 2: grade 3, n 23:34
Previous corticosteroids injection: HA injection, n 6:42
Flexion, ◦, mean ± SD 124.1 ± 10.3
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Table 1. Cont.
Extension, ◦, mean ± SD 15.0 ± 4.6
KOOS total score, mean ± SD 43.9 ± 14.6
KOOS other symptoms score, mean ± SD 56.0 ± 20.9
KOOS pain score, mean ± SD 51.3 ± 13.3
KOOS function in daily living score, mean ± SD 54.5 ± 17.1
KOOS sport and recreation score, mean ± SD 27.5 ± 19.0
KOOS quality of life, mean ± SD 30.3 ± 18.0
Observed Pain on 50-foot walk test (0–100), mean ± SD 38.6 ± 25.3
Previous week VAS arthrosis activity (0–100) 57.9 ± 18.4
Previous week VAS damages caused by arthrosis (0–100) 63.0 ± 19.3
Previous week VAS global health (0–100) 72.6 ± 16.2
SF-36 PCS (0–100) 37.1 ± 9.3
SF-36 MCS (0–100) 40.4 ± 8.9
SD, standard deviation; BMI, body mass index; mo, months; OA, osteoarthritis; HA, hyaluronic acid; KOOS,
Knee Injury and Osteoarthritis Score; VAS, visual analog scale; SF-36, Short Form Health Survey; PCS, Physical
Component Summary; MCS, Mental Component Summary.
Figure 1. Flow diagram of the clinical trial. M1, month 1.
2.2. Biological Characteristics of PRP
Table 2 summarizes the biological characteristics of injected PRP. The final injected volume was
8.8 ± 1.1 mL. The mean recovery rate in platelets was 68.3 ± 16.5%. The mean increases in platelets
and leukocytes compared with blood were 1.4 ± 0.4 and 0.1 ± 0.1, respectively. The percentage of
platelets was 96.2 ± 2.5% with low contamination from RBCs (3.7 ± 2.4%) and leukocytes (0.1 ± 0.1%).
The mean number of injected platelets was 2.5 ± 0.5 billion resulting in very pure PRP and a CCA rate
according to DEPA (Dose, Efficiency, Purity, Activation) classification [17].
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Table 2. Biological characteristics of platelet-rich plasma (PRP) (n = 57).
Mean ± Standard Deviation
Blood
Volume of whole blood collected, mL 18.0 ± 0.0
Red Blood Cells concentration, T/L 4.22 ± 0.65
Platelets concentration, G/L 197 ± 37
Leukocytes concentration, G/L 5.71 ± 1.22
PRP
Volume of PRP injected, mL 8.8 ± 1.1
Red Blood Cells concentration, T/L 0.01 ± 0.01
Platelets concentration, G/L 288 ± 95
Leukocytes concentration, G/L 0.22 ± 0.27
Quantity of injected Red Blood Cells, millions 92 ± 53
Quantity of injected Red Blood Cells (%) 3.7 ± 2.4
Quantity of injected Platelets, millions 2517 ± 812
Quantity of injected Platelets (%) 96.2 ± 2.5
Quantity of injected Leukocytes, millions 2 ± 2
Quantity of injected Leukocytes (%) 0.1 ± 0.1
Recovery rate in platelets (%) 68.3 ± 16.5
Increase factor in platelets 1.4 ± 0.4
Increase factor in leukocytes 0.1 ± 0.1
DEPA Classification CDA
2.3. Effect of Single Autologous PRP Injection in Knee OA
The main objective of the study was reached with 84.2% of OMERACT-OARSI responders at
three months. This result was stable with 82.5% and 80.7% of responders one and six months after the
injection, respectively. Single injection of PRP was effective in improving knee functional status with
a significant increase in KOOS total score from 43.5 ± 14.3 to 66.4 ± 21.7, six months after the procedure
(p < 0.001, Figure 2). Interestingly, this significant difference was observed already after one month
after the treatment and was reflected on all KOOS subscores (Figure 2 and Supplemental Table S1).
Assessment of pain through a 50-foot walk test also resulted in significant decrease of pain from the
baseline (37.5 ± 25.1) as of one month after the injection (20.2 ± 23.3; p < 0.001, Supplemental Table S1)
with a continuous effect until six months (12.9 ± 20.9; p < 0.001, Supplemental Table S1). Assessment
of damages caused by the arthrosis were also reduced from 62.3 ± 19.6 at baseline to 42.1 ± 42.5 at
six months with significant reduction at all follow-up (p < 0.001; Supplemental Table S1). Physical
component score from the SF-36 significantly improved at all follow-up (p < 0.001, Supplemental Table
S1). However, mental component score from the SF-36 did not change, which is consistent with the
lack of improvement relative to patients’ global health that was relatively good at the beginning of the
study (72.1 ± 16.0) (Supplemental Table S1). 78.9% of the patients and 80.7% of the rheumatologists
were either satisfied or very satisfied regarding the procedure six months after the injection. Evolution
of MRI parameters are presented in Table 3 without significant change six months after injection.
Regarding safety, four adverse events (AE) were reported in four patients. AE were shoulder pain in
two cases, acute pulmonary edema and peripheral arterial obstructive disease. None were considered
related to the study treatment.
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Figure 2. Evolution of KOOS total score and subscales. All follow-ups were statistically significant
in comparison to baseline (***: p < 0.001; see Supplemental Table S1). KOOS, Knee Injury and
Osteoarthritis Score. M1, month 1; M3, month 3; M6, month 6.
Table 3. MRI assessment pre-injection and six months post-injection of PRP (n = 49).
Pre-Operative 6 Months Post Injection p
Presence of edema
(number of patients)
Grade 0 23 26
p = 1Grade 1 18 13
Grade 2 6 10
Grade 3 2 8
Presence of joint effusion (number of patients)
p = 1
Grade 0 14 14
Grade 1 17 16
Grade 2 14 13
Grade 3 4 6
Articular thickness (mm, mean ± SD)
IFT-F compartment 1.16 ± 0.72 1.14 ± 0.77 p = 0.72
IFT-T compartment 1.67 ± 0.85 1.64 ± 0.89 p = 0.82
LFT-F compartment 1.60 ± 0.60 1.62 ± 0.60 p = 0.75
LFT-T compartment 2.08 ± 0.91 2.14 ± 1.01 p = 0.26
IFP compartment 2.27 ± 0.75 2.33 ± 0.77 p = 0.22
LFP compartment 2.61 ± 1.03 2.68 ± 1.06 p = 0.22
KOOS, Knee Injury and Osteoarthritis Score; I, internal; L, Lateral; FT, femorotibial; FP, femoropatellar; F, femur;
T, tibia.
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3. Discussion
Single administration of high volume of autologous pure PRP provided significant clinical benefit
to more than 80% of responders at three months according to OMERACT-OARSI definition, in patients
presenting knee OA in stage 2 or 3 according Kellgren–Laurence scale. These results are consistent
with meta-analysis results from Dai et al. indicating functional improvement and pain relief one year
after PRP injection [8]. Our study targeted patients similar to Dai et al. meta-analysis i.e., over 50 years
old, presenting stage 2 or 3 on the Kellgren–Laurence scale. However, the therapeutic schema was
different as the 10 randomized clinical trial (RCT) selected in that meta-analysis included multiple
PRP injections whereas one of the originality of our study was to perform a single large volume
PRP injection. Interestingly, only 3/10 of these RCT injected 8 mL whereas other studies injected 3
to 5.5 mL. From our point of view, PRP preparation for OA knee injection should take into account
the articular capacity of the knee in order to favor a better distribution of PRP throughout the joint.
It was recently recommended that the volume for knee-specific injection should be at 9 mL [18]. Thus,
the medical device used in this study was validated in order to reach this condition. It was also selected
to provide a pure PRP with limited contamination in RBCs and leukocytes and a platelets dose of
around 2.5 billion in accordance with the results of Louis et al. [19]. Indeed, this study demonstrates
that a single injection of very pure PRP (mean platelets dose ± SD of 2.4 ± 0.8 billion and platelets
purity of 91.4 ± 4.1%) offers a significant clinical improvement equivalent to a single HA injection.
This RCT also identified that higher platelets doses were correlated to higher levels of Transforming
Growth Factor-β1 and Platelets Derived Growth Factor-AB as well as with knee function impairment,
hence supporting limiting the injected dose of platelets. In our study, comparison between biological
characteristics of PRP injected between OMERACT-OARSI responders (n = 48) and non-responders
(n = 9) patients was performed without noticeable difference. This could be explained by (i) the small
number of non-responder patients, (ii) the high reproducibility of the PRP produced in this study
and (iii) the absence of GF quantification. This also suggests that this kind of correlation should be
performed in RCT to limit the impact of placebo effect in the interpretation of biological data. Despite
the excellent results of our study on pain and knee function, no statistical difference was observed
compared to baseline in the parameters assessed by MRI. These results are consistent with the study of
Buendia-Lopez et al. [20] who also assessed the articular thickness in all knee articular compartments
and reached a similar conclusion. However, Lisi et al. [21] used a different methodology where they
compared the number of patients with at least one grade improvement using MRI, according the
Shahriaree classification system [22], six months after PRP or HA injections. They describe a significant
difference with 16/31 patients reaching this improvement in PRP group and 8/31 in HA group,
suggesting that guidelines for MRI interpretation in the context of regenerative medicine are needed.
The major limitation of our study is the absence of a control group which is an important weakness
knowing the important placebo effect on arthrosis care. Indeed, it is important to recall that placebo
can relieve pain in OA patients (effect size of 0.51) or improve function and stiffness (effect size of 0.49
and 0.43), particularly when administered through injections [23]. The absence of a placebo group
was a conscious decision as many patients are discouraged to participate to a RCT involving PRP
whereas it is daily and routinely injected in several rheumatology and orthopedic departments. Also,
an adequately resourced RCT would require a higher number of patients and entail higher costs.
Finally, it would have been interesting to document efficacy and MRI parameters one year after the
injection, and extend the characterization of PRP to GF contents.
To conclude, our study indicates that a single injection of a large volume of very pure PRP is
associated with a responders’ rate of around 80%, up to six months after the injection, supporting the
initiation of daily PRP injection in OA patients in Saint Joseph hospital.
In light of the growing evidence of its benefit and taking into account the current complex and
heterogeneous context, a feasibility study according to AAOS guidelines would be desirable or even
mandatory, prior to initiating regular PRP injection in OA.
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4. Materials and Methods
4.1. Patients
To obtain a homogeneous study population, the patient suitability for inclusion was assessed
(after a first screening by a physician), according to the following inclusion criteria: Age between 20 and
80 years old, symptomatic knee osteoarthritis grade 2 or 3 in Kellgren–Lawrence scale and according
to the criteria of the American College of Rheumatology, axial deformity of the lower limb equal to
or lower than 5◦, at least moderate pain and difficulty to walk on a plain surface, ability to perform
rehabilitation exercises, articular pain > 6 months, Hemoglobin (Hb) >10 g/dL, negative pregnancy test
and written informed consent. The exclusion criteria were: Axial deformity of the lower limb over 5◦,
knee instability, important knee injuries or knee surgery less than 52 weeks before inclusion, Body Mass
Index >35, thrombocytopenia <150 G/L or >450 G/L, thrombopathy, Hb <10 g/dL, infectious disease
or positive serology to HIV, HCV, HBV and syphilis, actual chronic treatment by oral corticosteroid (or
last dose taken less than two weeks before), intra articular knee injection of corticosteroid less than
eight weeks before inclusion, intra articular knee injection of hyaluronic acid less than 24 weeks before
inclusion, NSAID or anti platelets treatment completed less than two weeks before inclusion, fever or
recent disease, auto immune disease, inflammatory arthritis, immune deficit, pregnancy and patient
under guardianship or involved in another clinical trial.
4.2. Study Design and Intervention
This monocentric prospective routine care trial was performed in the rheumatology department
of Saint Joseph Hospital between March 2016 and August 2018. Patients received a single injection
of PRP. After the injection, patients returned home with instructions to restrict movement of the leg
for at least 48 hours and to use paracetamol or ice on the injected area to relieve pain if necessary.
Non-steroidal anti-inflammatory drugs were prohibited during seven days following the injection.
During the follow-up, no treatment restriction was applied and subsequently a gradual resumption of
normal sport or recreational activities was tolerated.
The protocol was approved by the ethics committee and national health regulatory authority
(CPP Ile de France 1 authorization #14243ND, 15th November 2016). The study was carried out in
accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. All patients
gave written informed consent before their participation. The study was registered at clinicaltrials.gov
(NCT 03082430).
4.3. Autologous PRP Preparation Method
After a four-fold skin decontamination (antiseptic foaming solution, rinsing with sterile water,
drying, and alcoholic dermal antiseptic), a nurse collected 18 mL of blood by venipunture using
a 21-gauge needle filling one 20 mL syringe containing 2 mL of ACD-A (Fidia, Abano Terme, Itlay).
The blood was transferred into the Hy-tissue 20 PRP device (Fidia, Abano Terme, Itlay) before
centrifugation using the Omnigrafter 3.0 (Fidia, Abano Terme, Itlay) and PRP Large Volume Cycle
(3200 rpm during 10 minutes). All plasma was recovered using a 10 mL syringe through the Push-out
system. 300 μL of whole blood and each autologous PRP preparation were sampled to determine
platelets, leukocytes and RBCs concentrations using automated haematology blood cell analyzers
Beckman Coulter DxH 801 (Beckman Coulter, Miami, FL, USA) according to recent guidelines [24].
4.4. Injection
The intra articular knee injection was performed with a 21 Gauge needle after conventional skin
aseptic decontamination and under echographic control (HITACHI Aloka F37 Hitachi Aloka Medical
Systems, Tokyo, Japan).
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4.5. Evaluation Tools and Follow-Up
Patients were prospectively assessed at baseline and one, three, and six months after injection.
Evaluation included the Knee Injury and Osteoarthritis Score (KOOS), Observed Pain on 50-foot walk
test, Visual Analog Scale (VAS) assessments (0–100 mm scale) during the previous week regarding
arthrosis activity, damages related to arthrosis and global health. Quality-of-life was evaluated using
the 36-Item Short Form Health Survey (SF-36) which was divided into two summary measures:
The Physical (PCS) and Mental (MCS) Component Summary scores. Magnetic Resonance Imaging
(MRI) analysis was performed at baseline and six months after the procedure using 1.5T MAGNETOM
Aera and Avantofit (Siemens Healthcare, Erlangen, Germany). The presence of edema and joint effusion
was graded as follows: 0 (absence), 1 (low), 2 (moderate), 3 (severe). The highest articular thickness was
evaluated on same sequences for six compartments: Internal and lateral femoro-tibial compartments
on femur and tibial parts respectively and internal and lateral femoro-patellar compartments.
Patients and rheumatologists satisfaction were rated at six months on a 5-level scale: Not satisfied,
Few Satisfied, Moderately Satisfied, Satisfied and Very satisfied. Adverse events were recorded.
Primary endpoint measure was defined as the percentage of OMERACT-OARSI responders at three
months. OMERACT-OARSI criteria define responders patients if they satisfy either of the following
criteria: (i) High improvement (≥50% and absolute change ≥ 10) in pain domain (pain observed on
50-foot walk test) or function (KOOS function in daily living subscore) or (ii) improvement (≥20%
and absolute change ≥ 10) in at least 2/3 of the following domains: Pain, function or patient’s global
assessment (VAS assessment on arthrosis activity previous week).
4.6. Statistical Analysis
Data were analyzed according to the intention-to-treat principle. The continuous variables were
described by their mean and standard deviation. The categorical variables were described by their size
and percentage. Comparisons over time, between two or more time points, were done using statistical
test for repeated measurements. For situations involving two time points, we used Chi-square test,
or Fisher’s exact test if the expected count in any cell was <5 for categorical data and Wilcoxon’s for
continuous data. Correlation between covariates were quantified and tested using Pearson coefficient
correlation. Friedman’s test was used to consider trend over times. The tests were performed bilaterally
and were considered statistically significant when p-values ≤ 0.05. To deal with multiple testing in
trend analysis, we used Holm’s method to produce p-values adjusted. The statistical analysis was
performed with R software (version 3.1.0).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/6/
1327/s1.
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Abstract: Wrist osteoarthritis (OA) is one of the most common conditions encountered by hand
surgeons with limited efficacy of non-surgical treatments. The purpose of this study is to describe the
Platelet-Rich Plasma (PRP) mixed-microfat biological characteristics of an experimental Advanced
Therapy Medicinal Product (ATMP) needed for clinical trial authorization and describe the clinical
results obtained from our first three patients 12 months after treatment (NCT03164122). Biological
characterization of microfat, PRP and mixture were analysed in vitro according to validated methods.
Patients with stage four OA according to the Kellgren Lawrence classification, with failure to
conservative treatment and a persistent daily painful condition >40 mm according to the visual
analog scale (VAS) were treated. Microfat-PRP ATMP is a product with high platelet purity, conserved
viability of stromal vascular fraction cells, chondrogenic differentiation capacity in vitro and high
secretion of IL-1Ra anti-inflammatory cytokine. For patients, the only side effect was pain at the
adipose tissue harvesting sites. Potential efficacy was observed with a pain decrease of over 50% (per
VAS score) and the achievement of minimal clinically important differences for DASH and PRWE
functional scores at one year in all three patients. Microfat-PRP ATMP presented a good safety profile
after an injection in wrist OA. Efficacy trials are necessary to assess whether this innovative strategy
could delay the necessity to perform non-conservative surgery.
Keywords: wrist osteoarthritis; microfat; platelet-rich plasma; cell therapy; adipose tissue
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1. Introduction
Osteoarthritis (OA) of the wrist is one of the most common conditions encountered by hand
surgeons. It is a chronic non-inflammatory joint disease characterised by degenerative lesions of
the cartilage, which can result in major functional impairment including painful condition, and a
loss of strength and motion [1]. Its incidence is constantly increasing due to the ageing population
and sport-related traumatic injuries. Most of OA cases are post-traumatic and may be secondary to
scapholunate ligament tears leading to carpal disorganization (named scapholunate advanced collapse
or SLAC) or bone injury (sequelae of intra-articular distal radius fracture or scaphoid non-union
named scaphoid nonunion advanced collapse also known as SNAC). Idiopathic causes such as
idiopathic carpal avascular necrosis (Kienböck’s or Preiser’s disease) or congenital wrist abnormalities
(Madelung’s deformity) are rare, but can also lead to wrist OA [2,3].
The first line therapeutic measures are currently limited to symptomatic treatment: contention
by splints, analgesics and anti-inflammatory drugs [3,4] whereas, intra-articular injections of
corticosteroids or hyaluronic acid are used in common practice [3] without high levels of evidence.
Whereas, their use in other hand joints is still debated [5]. Surgery is indicated after conservative
treatment failure. The main objective is to ensure pain relief, while restoring strength and preserving
as much wrist motion as possible. Palliative wrist denervation is usually the first step of treatment due
to its lesser consequences on wrist mobility. However, it is inefficient in a quarter to more than a third
of cases [6,7]. The other surgical alternatives are: first row carpectomy, total or partial wrist arthrodesis
and sometimes prosthesis wrist arthroplasty. These palliative procedures require wrist immobilization,
intensive post-operative rehabilitation and can only preserve partial function of the wrist [8–13].
Thus, minimally invasive therapeutic alternative that could delay the use of these heavy and
non-conservative surgeries represent a medico-surgical challenge in management of wrist OA after
failure of well-conducted medical treatment. Recently, the emergence of biological therapies has led
to the evaluation of intra-articular injections of autologous Platelet-Rich Plasma (PRP) in treatment
of chondral degenerative diseases with satisfactory results [14–18]. Briefly, activated platelets release
growth factors (GF) with beneficial impacts on regenerative and reparative processes. In addition,
autologous adipose tissue has gained great interest because it represents a rich and convenient source
of cells for regenerative medicine. The stromal vascular fraction (SVF) cells constitute a heterogeneous
cell population, including a large proportion of mesenchymal multipotent stem cells (Adipose-derived
stem cells, ADSCs), which are located in the adipose tissue vasculature. Thus, the high abundance
of adipose tissue within the body, its high surgical accessibility, and the demonstrated multipotency
of ADSCs, especially towards the chondrogenic lineage [19–23], highlighted the potential of adipose
tissue-derived products for cartilage repair. Among them, microfat is simply obtained through
dedicated fat harvesting that uses a multi perforated cannula with holes of 1 mm allowing to harvest
smaller lobules of fat (around 600 μm) [24].
We previously described the safety profile of combining autologous microfat and PRP as a
mixed regenerative product injected in the carpus or the fetlock joint of sport horses presenting with
degenerative joint disease [25]. A significant lameness reduction, together with an early return to
compete were also indicative of potential efficacy. However, from a regulatory point of view, the
intra-articular use of PRP mixed-microfat was considered by the French National Agency for Medicines
and Health Products Safety (Agence Nationale de Sécurité du Médicament (ANSM)) as an Advanced
Therapy Medicinal Product (ATMP) according to the directive No. 1394/2007 from the European
Parliament and the European Council [26]. This classification is based on the non-homologous use of
microfat in the wrist joint. The consequences are that the preparation of the product should comply
with Good Manufacturing Practice (GMP), meaning it is relocated in a cell therapy facility, including
the achievement of process validation batches with outstanding characterization of the final product,
and definition of biological acceptance criteria. For safety concerns, ANSM also imposes a one-month
delay between the treatment of each of the three first patients for safety concerns.
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Here, we aimed to outline the phases of biological validation of a GMP-compliant PRP
mixed-microfat. ATMP performed prior to approval by the French Agency. We also report the
preliminary clinical results at 12 months with the follow-up obtained from the first three patients
enrolled in a clinical trial evaluating PRP mixed-microfat in wrist OA.
2. Results
2.1. Process Validation Batches
In the biological data characterising the experimental PRP, microfat and the mixed ATMP are
obtained from the process validation batches. As summarised in Table 1A–C, the PRP obtained
was a very pure PRP according to the DEPA (Dose Efficiency Purity Activation) classification [27]
with a mean ± SD of 97.4 ± 0.2 % platelets purity at the end of the preparation. Increase factor in
platelet concentration compared to whole blood was 2.0 ± 0.4. Platelet aggregation in response to
different inductors was considered effective for all conditions tested. All PRP preparations were free of
microorganisms, and presented stable biological characteristics at 3 h after the end of the preparation.
Production of microfat resulted in a macroscopically pure product with less than 10% of oily or bloody
phase with stable results at 3 h after the end of the production.
Table 1. Biological characteristics of PRP (A), microfat (B), and PRP mixed-microfat (C) obtained from
the analysis of GMP compliant process validation batches.
(A) T0 T + 3 h
Platelets Purity (%) 97.4 ± 0.2 97.4 ± 0.1
RBCs Contamination (%) 2.5 ± 0.1 2.5 ± 0.1
Leukocytes Contamination (%) 0.04 ± 0.04 0.03 ± 0.03
Potential Dose of Injected Platelets
(106/ 2 mL)
775.3 ± 35.8 766.7 ± 25.8
Increase Factor in Platelets 2.0 ± 0.4 2.0 ± 0.4
Platelets Aggregation Response (%)
ADP 5 μM 74.2 ± 9.8 69.0 ± 2.6
ADP 2.5 μM 55.5 ± 7.5 47.8 ± 1.9
Arachidonic Acid 0.5 mg/ mL 91.6 ± 3.5 87.5 ± 1.6
Collagen 3.3 μg/mL 90.1 ± 2.9 91.1 ± 2.4
Ristocetin 1.25 mg/mL 97.7 ± 2.5 96.9 ± 4.0
Microbiological Assay Free of germ (3/3) Free of germ (3/3)
(B) T0 T + 3 h
Macroscopical Aspect Absence of blood and oily phase (3/3) Absence of blood and oily phase (3/3)
Microbiological Assay Free of germ (3/3) Free of germ (3/3)
(C) T0 -
SVF Viability (%) 75.7 ± 1.3 -





VEGF 22.0 ± 30.1 -
PDGF 394.0 ± 128.1 -
FGF2 171.8 ± 83.1 -
TGF-β1 ND -
IL1-β 0.2 ± 0.1 -
IL-1RA 82.0 ± 73.3 -
IL-1RA/IL1-β ratio 443.3 ± 348.0 -
Results are expressed in mean ± SD except for microbiological assay, macroscopical aspect, and chondrocytes
differentiation. Red Blood Cells, (RBCs); Growth Factors, (GF); Stromal Vascular Fraction (SVF) * performed only on
two samples.
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PRP mixed-microfat manufacturing lead to a product containing 1.3 ± 0.6 million viable nucleated
Stromal Vascular Fraction (SVF) cells with a mean ± SD viability of 75.7 ± 1.3 %. ADSCs obtained
from the mixture were able to differentiate in chondrocytes under specific culture conditions compared
to control (Figure 1). Results of stability assays conducted at 3 h on PRP and microfat were similar to
t0 data. Finally, PRP mixed-microfat release detectable quantity of regenerative growth factors (VEGF,
PDGF, FGF2) whereas, only TGF-β1 was not. Interestingly, IL-1Ra/IL1-β ratio presented a mean ± SD
of 443.3 ± 348.0 suggesting a potential anti-inflammatory effect.
Figure 1. Macroscopic aspect of chondrocytes micromass obtained from adipose-derived stem cells
(ADSCs) derived microfat-PRP in the presence of chondrogenic differentiation media (A) or control
media (B). Red circles represent micromass with area > 0.05 mm2.
The final investigational product used for the clinical trial was then defined as two interconnected
5 mL syringes containing 2 mL of microfat and 2 mL of PRP that had to be injected within 3 h after the
end of manufacturing. Aspect of the final product delivered to the operating room and release criteria
from microfat and PRP were defined and validated by ANSM according to the results of process
validation batches and are listed in Figure 2.
Figure 2. (A) Microfat-PRP investigational Advanced Therapy Medicinal Product (ATMP) delivered
to the operating room for intra articular injection in radio-carpal joint (without labelling). (B) Release
criteria from PRP and microfat checked by the responsible pharmacist from the ATMP manufacturing
Department before delivery to the operating room.
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2.2. Preliminary Data from Clinical Trials
The first three patients were treated between June and August 2017 respecting a one-month delay
between each patient, as required by ANSM. Characteristics of patients and injected products are
described in Table 2.
Table 2. Patients and injected products characteristics obtained from the first three patients treated
with microfat-PRP ATMP.
Patient 1 Patient 2 Patient 3
Gender Female Female Male
Age, years 65 62 59
Dominant hand Right Right Right
Injured wrist Left Left Left
Etiology Radius fracture SLAC SLAC
Kellgren Lawrence grade 4 4 4
Seat(s) of osteoarthritis RC RC and IC RC
Volume of microfat PRP injected (mL) 2.7 4.0 3.8
Dose of injected platelets (106) 720.9 674.0 708.7
Platelets purity (%) 96.0 94.2 97.4
PRP microbiological assay Free of germ Free of germ Free of germ
Microfat microbiological assay Free of germ Free of germ Free of germ
R, Radiocarpal; IC, Intracarpal; SLAC, scapholunate advanced collapse.
There was 2.7 to 4 mL of mixture injected with a platelet dose around 700 million and a platelet
purity over 95%. Absence of pain was observed during injection (Visual Analog Scale: 0). All patients
were able to get back to their regular activities one week after injection. No serious adverse event was
recorded in these three patients. In addition, there was no infectious complication observed. The only
reported side effect was pain at the sites of the adipose tissue harvesting, which was systematically
reported at day seven in a postoperative visit and was relieved by grade 1 analgesics and completely
disappeared after one month. All three patients presented with at least a 50% decrease in pain
compared to baseline at three months. This effect was maintained until one year after the injection,
except for patient three. Disabilities of the Arm and Shoulder (DASH) improvement reached 11 points,
corresponding to the minimal clinically important difference (MCID) [28] for patient two and patient
three at three months and for all patients at six months. Patient-Rated Wrist Evaluation (PRWE)
improvement reached 14 points corresponding to MCID [29] since the third month after treatment for
all patients. These observations were stable until the last visit at one year. No significant improvement
was observed in grip strength and wrist range of motion during the follow-up. All three patients were
either satisfied or very satisfied after the procedure at all follow-up. Figure 3 summarises the results of
the pain Visual Analog Scale (VAS), DASH and PRWE scores up to one year.
Figure 3. Evolution of pain according to Visual Analog Scale (VAS), Disabilities of the Arm and
Shoulder (DASH) and Patient-Rated Wrist Evaluation (PRWE) scores at baseline, and months 3, 6 and
12 for patients 1, 2 and 3.
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3. Discussion
To our knowledge, this study is the first to report the use of a combined microfat-PRP product
as ATMP for joint injection in humans. Indeed, an introduction of adipose tissue in the joint was
considered as an ATMP, according to European regulation No. 1394/2007 due to the non-homologous
use of adipose tissue in the wrist joint. Thus, a set of accurate biological and pharmaceutical
characterisations of the final injected product was conducted, as requested by the regulatory French
Agency ANSM prior to any clinical trial authorization. Testing of the process validation batches
attested that the PRP mixed-microfat is a sterile product with limited contamination in Red Blood Cells
(RBCs) and leukocytes, preserved viability of SVF cells, chondrogenic differentiation ability in vitro
and high secretion of IL1Ra anti-inflammatory cytokine. Characteristics of the product were stable
upon 3 h after the end of the manufacturing.
These data allowed to obtain a clinical trial authorization for a phase I study with the constraint
to wait one month during the treatments of each of the three first patients for safety reason. The only
reported side effect was pain at the site of adipose tissue harvesting. Clinical results achieved MCID
for DASH and PRWE scores in all patients one year after injection. MCID is not clearly defined in the
literature for VAS scale, which measures pain for wrist OA. That said, VAS scale MCID for surgical
treatment of shoulder diseases is between 14 and 30 mm [30,31]. Interestingly, the three patients
reached a final improvement at one year of 51, 64 and 19 mm, respectively. The profile of patient three
is a matter of discussion, as he presented with an impressive improvement in pain and function up
until six months with a slight impairment in pain at one year. In contrast, patient 1 and 2 showed
progressive improvement up until one year after treatment. This was explained by a pain wrist crisis in
the weeks before the one-year evaluation. However, these subjective assessments were not supported
by the objective improvement in measures of strength or range of motion, and should therefore be
interpreted carefully.
Absence of adverse event is consistent with other published studies in the literature. Indeed,
no infectious or neoplasic complications related to the intra-articular injection of cell-based products
(including PRP, cultured ADSCs and/or minimally processed adipose tissue), has been reported to
date [15,32,33]. However, very few studies have been designed to address the upper limb, and mainly
concern the thumb carpometacarpal joint. Autologous intra-articular fat injection has been studied
for the treatment of the thumb carpometacarpal joint OA in two studies. Herold et al. assessed the
efficacy of the intra-articular injection of centrifuged adipose tissue in the treatment of rhizarthrosis.
They had significantly less pain and a better DASH score at all postoperative time points up until
the 12-month follow-up, when they analysed all of the patients together. However, severe patients
(grade 4) only presented a slight improvement in DASH score from 57 ± 23 to 51 ± 31 at 12 months
with a near return to preoperative value for VAS pain [34]. Kemper et al. [35] assessed the efficacy of
surgical arthroscopic debridement combined with autologous fat injections in the treatment of early
stages of thumb carpometacarpal osteoarthritis. They showed pain relief at rest, and under stress and
an improvement of the QuickDASH score after three to six months, which kept improving over two
years. These approaches differ from our procedure, as we used a dedicated harvesting device to obtain
small lobules of adipose tissue, also called “microfat” and presenting greater trophic and regenerative
qualities than adipose tissue harvested according to “standard” technique [36]. Furthermore, none of
these studies have associated PRP to improve the outcomes.
From a regulatory point of view, the preparation and injection of adipose tissue within these
two studies were performed in the same surgical procedure, which is simpler and faster than our
ATMP procedure. However, the strict application of European Regulation No. 1394/2007 [26] or from
the corresponding Food and Drug Administration guidance [37] considered that “regenerating or
promoting the regeneration of cartilage or tendon is not a basic function of adipose tissue which is
generally not considered a homologous use”. This question is still under debate, as some countries
believe the entire procedure can be performed routinely in the operating room and more precision and
harmonisation from national and international governing bodies are urgently needed. Nevertheless,
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the manufacturing of our innovative therapy remains simple, conservative, and minimally invasive
and can be performed in a one-day surgery including two consecutive surgeries under local anesthesia.
As ATMP production must occur in accordance with the pharmaceutical industry GMP, production
costs have increased. However, we were aware that the microfat-PRP ATMP had to be manufactured
within a few hours, to anticipate potential sustainability for public institutions in the future. This point
should be considered from a cost-effectiveness perspective.
Regarding the mechanism of action, the association of microfat and PRP could be interesting in
order to potentiate trophic and regenerative effects on damaged cartilage sites. From a theoretical point
of view, the combination of these two products, which are respectively rich in autologous multipotent
stem cells and growth factors, aims to create an optimal environment for cartilage cells regeneration.
Furthermore, microfat could play the role of scaffold limiting PRP resorption [38,39]. However, this
regenerative potential could only be confirmed by the use of appropriate magnetic resonance imaging
of the wrist.
The major limitation of this study is the absence of a control group, which is an important
weakness knowing the substantial placebo effect in arthrosis care [40]. Furthermore, due to the low
number of patients assessed (only three patients), no statistical analysis was conducted.
4. Material and Methods
4.1. Obtention of Human Tissues and Regulatory Approval
For the process of validation batches, human peripheral blood and abdominal adipose tissue
were harvested from three healthy volunteers (42, 33 and 31-year-old females who were not taking any
drugs) during esthetic liposuction and after the collection of written informed consent collection.
The clinical trial was approved by the ethics committee (authorization for AMIPREP trial #16-65
from Comité de Protection des Personnes Sud Méditerranée #1 received 22nd of August 2016) and
the ANSM (authorization for AMIPREP trial #160879A-12 received 28th of April 2017) and registered
in Clinicaltrials.gov website (NCT03164122 and EudraCT #2016-002648-18). All experiments were
conducted in the Cell Therapy facility (authorization #ETI/14/O/005) of our university hospital in
compliance with Good Manufacturing Practice.
4.2. PRP Preparation
After seven steps of skin decontamination (antiseptic foaming solution, rinsing with sterile water,
drying, antiseptic foaming solution, rinsing with sterile water, drying and alcoholic dermal antiseptic),
18 mL of blood was collected by venipuncture using a 21-gauge needle filling one 20 mL syringe
containing 2 mL of ACD-A (Proteal, Barcelona, Spain). The blood was transferred into the Orthopras
20+ ® device (Proteal, Barcelona, Spain) before centrifugation using the Omnigrafter III ® (Proteal,
Barcelona, Spain) at 3200 rpm over 10 min. The PRP was recovered using the Push Out system and 2
mL of PRP was sampled in a 5 mL syringe.
For process validation batches, the following analyses were performed on the PRP: cell counting,
platelet aggregation test and microbiological assay at t = 0 (immediately after manufacturing) and
t = 3 h (claimed shelf life with storage at 18–24◦C).
Cell counting and microbiological assay were performed on clinical trial PRP batches.
4.2.1. Blood and PRP Cell Counting
300 μL from whole blood and each PRP preparation were sampled to determine platelets,
leukocytes and red blood cells counts using automated haematology blood cell analyzers Sysmex
XN-10 (Sysmex, Kobe, Japan) in accordance with recently published guidelines [41].
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4.2.2. Platelets Aggregation Test
Platelets aggregation was assessed by light transmittance aggregometry (LTA) on a four-channel
APACT 4004 aggregometer (Elitech, France). To obtain homologous Platelet-Poor Plasma (PPP) as
negative control, 1.8 mL of PRP was centrifuged at 2500× g during 10 min. Maximal (peak) platelet
aggregation (%) induced by ADP 5 μM, ADP 2.5 μM, collagen 3.3 μg/mL, ristocetin 1.25 mg/mL,
arachidonic acid 0.5 mg/mL was measured in PRP.
4.3. Microfat Preparation
After seven steps of skin decontamination, harvesting the adipose tissue was performed either
in the abdominal area (process validation batches) or in the subcutaneous adipose area of the inner
side of the knees (clinical trial batches) after local anesthesia. The microfat harvesting technique
was performed using a Hapifat® kit (Benew Medical, Melesse, France). Briefly, a St’rim cannula was
both connected to a 10 mL syringe and a purification Puregraft 50® bag through a Fat Lock System®.
Adipose tissue was then purified two times using 1:1 rinsing with saline solution [42] allowing for the
elimination of fluid excess, lipid phase, blood cells, and fragments through filtration by the Puregraft
bag membrane. Finally, 2 mL of microfat was sampled in a 5 mL syringe.
For process validation batches, following analyses were performed on microfat: assessment of
macroscopic aspect and microbiological assay at t = 0 and t = 3 h.
For clinical trial batches, following analyses were performed: assessment of macroscopic aspect
and microbiological assay.
4.3.1. Macroscopic Assessment of Microfat
The 5 mL syringe containing 2 mL of microfat was placed vertically allowing sedimentation of
oily and bloody phases, considered as contaminants. Quantification was performed visually using
syringe graduations by an experimented technician. Contamination lower than 25% of the final volume
(0.5 mL) in oil and/or blood was expected.
4.3.2. Microbiological Assay
250 μL of PRP or microfat were sampled in Bactec culture bottles (Peds Plus Aerobic/F and Plus
Anaerobic/F culture vials, containing each 40 mL of medium). The Bactec method (Becton Dickinson,
Sparks, MD, USA) uses a computer-controlled incubation/detection system. The media used contained
proprietary factors designed to inactivate a wide variety of antibacterial and antifungal agents [43].
Bactec culture bottles were incubated at 37 ◦C for a total of 10 days, and automated readings were
taken every 10 min. Detection of organisms resulted in an audible alarm and automatic recording of
time to detection.
4.4. Microfat-PRP Mixture
The two 5 mL syringes were connected and mixed by gently shaking the two syringes back and
forth ten times to obtain a final product of 4 mL of a homogeneous mixed product.
For process validation batches, following the analyses performed on Microfat-PRP: SVF viability
and cell content, ability to differentiate in chondrocytes, GF release.
For clinical trial batches, following analyses were performed: GF release.
4.4.1. Stromal Vascular Fraction (SVF) Extraction
From 2 to 4 mL of mixture were sampled for SVF extraction. SVF was purified from the
Microfat-PRP mixture by collagenase digestion (0.25 U/mL, NB5, Heideberg, Germany) at 37 ◦C
with 5% CO2 for 45 min. Total viable nucleated cell recovery and cell viability were determined using
the Nucleocounter NC100 instrument (ChemoMetec, Denmark).
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4.4.2. Chondrocytes Differentiation
ADSCs were isolated following SVF cells plating in a 25 cm2 flask in the following proliferation
media (45% DMEM / 45% HAMS-F12/ 10% fetal bovine serum (Gibco, Thermo Fisher Scientific,
Waltham, MA, USA)), GlutaMAX® (100×, Gibco) gentamicin (Panpharma Luitré, France) penicillin
G (Panpharma Luitré, France), fungizone (Bristol-Myers Squibb, New York, NY, USA) for ADSCs
proliferation. At 80% confluence, ADSCs were trypsined and plated in 24 well-plate in either a
chondrocyte differentiation media (StemPro®, Thermo Fisher Scientific, Waltham, MA, USA) or
proliferation media (considered as control media) at the concentration of 80,000 cells/5 μL. At 10 days,
cells were washed using DPBS Ca++/Mg++-free medium (Life Technologies, Carlsbad, California,
USA), coloured with 0.015% Alcian Blue 8GX (Sigma-Aldrich, Saint-Quentin-Fallavier, France) to
stain glycosaminoglycan cartilage and fixed in 60% ethanol/40% acetic acid to observe chondrocytes
micromass. Standardized photographs were taken using a Canon Eos 50D (Canon, Tokyo, Japan) with
a 100 mm F2.8 Macro lens. All micromass area ≥0.05 mm2 were quantified using NIH ImageJ software
and compared with the control group.
4.4.3. Microfat-PRP Growth Factors Release Measurement
The microfat-PRP mixture (500 μL) was placed in a 48-well collagen coated plate (CellAffix,
APSciences, Columbia, MD, USA) and incubated for 30 min at 37◦C with 5% CO2 to allow contact
with collagen. After this incubation, 500 μL of non supplemented DMEM (Gibco, Thermo Fisher
Scientific, Waltham, MA, USA) was added to the mixture and incubated for 24 h at 37 ◦C with 5%
CO2. After 24 h the samples were centrifuged (Multifuge Heraus 3 S-R centrifuge, Thermo Scientific,
Indianapolis, IN) at 1500 rpm for 5 min to remove microfat, and samples were stored at −80 ◦C until
used for analysis. A combination of 6 cytokines and growth factors (Vascular Endothelial Growth
Factor, Interleukin-1 Receptor antagonist, Fibroblast Growth Factor 2, Interleukin-1β, Transforming
Growth Factor β1, Platelet Derived Growth Factor AA-BB or AB-BB) were measured using a Magpix
instrument (Luminex xMAP Technology, Luminex Inc., Austin, TX, USA) allowing simultaneous
measurement of the different analytes in small sample volume.
4.5. Patients
According to the Kellgren and Lawrence classification [44] and with the informed written patient
consent, males and females between 18 to 75 years of age who suffered from radio-carpal OA stage
four were enrolled. OA resulted from post-traumatic malunion of an articular distal radius fracture
or SLAC or SNAC. Only patients that failed conservative treatments (analgesics, anti-inflammatory
drugs, splinting, and physiotherapy), defined as having a persistent daily painful condition > 40 mm
according to VAS, and that would have otherwise been a candidate to surgery were included.
4.5.1. Surgical Procedure and Injection
Operative procedure included two consecutive surgical steps performed under local anesthesia
in the same day. The first step consisted of lipoaspiration for microfat and harvesting the blood
sample. Lipoaspirate and the blood sample were transported in sterile bags to the authorized ATMP
manufacturing Unit. Microfat and PRP were prepared as described above and two interconnected
syringes were sent back to the operating room within 2 h after harvesting. The second step consisted
of the injection of PRP mixed-microfat. Before the intra-articular injection, microfat and PRP were
pooled together by making ten transfers between the two connected syringes. After local anesthesia
subcutaneously on the dorsal side of the wrist with xylocaine (10 mg/mL) without adrenaline, 4 mL of
microfat and PRP was injected using a 16 gauge needle into the radio-carpal joint under X-ray guidance
(Ziehm Solo FD, Ziehm Imaging GmbH, Nürnberg, Deutschland). An analgesic immobilization by a
specific cast involving compression, contention and cryotherapy (IGLOO®) was immediately put in
place for seven days.
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4.5.2. Clinical Assessment
The primary endpoint was the safety of the treatment evaluated by the occurrence of adverse
events up to one month after the injection (visits at Day 7 and Month 1). Secondary endpoints were
the following criteria at 3, 6 and 12 months: subjective pain rating according to VAS (0–100 mm),
functional evaluation according to the DASH and the PRWE scores, objective wrist strength measured
by dynamometry, and the objective wrist range of motion measured using a goniometer. Patient’s
satisfaction was rated on a 5-level scale: Not satisfied, Few Satisfied, Moderately Satisfied, Satisfied,
and Very satisfied.
4.6. Statistical Analysis
Data are presented as mean ± standard deviation except for microbiological assay (presence/free
of germ), chondrocytes differentiation (number of micromass formed compared to control),
macroscopic aspect of the microfat (presence/absence of contaminants > 25%). The increase factor
in platelets was obtained by dividing the concentration of platelets in PRP by the concentration in
whole blood. Doses of platelets in PRP were obtained by multiplying the volume of PRP injected by
the corresponding concentration. Platelets purity was obtained by dividing the quantity of platelets in
the PRP by the sum of platelets, red blood cells and leukocytes. No statistical analysis was performed
due to the low number of samples or patients described in the study.
5. Conclusion
The present report demonstrates the feasibility to manufacture, control, and inject a PRP
mixed-microfat investigational ATMP and its short-term good tolerance for wrist OA. However,
only a greater number of patients documented will improve the safety of the procedure. If this
endpoint is met, efficacy trials could then be implemented to define whether this non-invasive strategy
can be proposed in selected patients with a history of wrist OA with drug-refractory failure, and be
advantageous compared to invasive and non-conservative surgical wrist procedures.
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Abstract: Matrix-assisted autologous chondrocyte transplantation (MACT) for focal articular
cartilage defects often fails to produce adequate cartilage-specific extracellular matrix in vitro
and upon transplantation results in fibrocartilage due to dedifferentiation during cell expansion.
This study aimed to redifferentiate the chondrocytes through supplementation of blood-products,
such as hyperacute serum (HAS) and platelet-rich plasma (PRP) in vitro. Dedifferentiated
monolayer chondrocytes embedded onto collagen type I hydrogels were redifferentiated through
supplementation of 10% HAS or 10% PRP for 14 days in vitro under normoxia (20% O2) and hypoxia
(4% O2). Cell proliferation was increased by supplementing HAS for 14 days (p < 0.05) or by
interchanging from HAS to PRP during Days 7–14 (p < 0.05). Sulfated glycosaminoglycan (sGAG)
content was deposited under both HAS, and PRP for 14 days and an interchange during Days 7–14
depleted the sGAG content to a certain extent. PRP enhanced the gene expression of anabolic markers
COL2A1 and SOX9 (p < 0.05), whereas HAS enhanced COL1A1 production. An interchange led to
reduction of COL1A1 and COL2A1 expression marked by increased MMP13 expression (p < 0.05).
Chondrocytes secreted less IL-6 and more PDGF-BB under PRP for 14 days (p < 0.0.5). Hypoxia
enhanced TGF-β1 and BMP-2 release in both HAS and PRP. Our study demonstrates a new approach
for chondrocyte redifferentiation.
Keywords: articular cartilage; cartilage repair; redifferentiation; collagen hydrogels; biologics;
hyperacute serum; platelet-rich plasma
1. Introduction
The articular cartilage of the synovial joints, being avascular and limited for endogenous repair
capacity, consists of sparsely distributed specialized cells called chondrocytes embedded within its
extracellular matrix (ECM), which provide the cartilage with remarkable mechanical and low friction
properties. A traumatic injury or anomalous loading to the joint results in a cartilage defect in the
short-term. For full articular cartilage defects, cell-scaffold-based tissue engineering approaches, such
as the matrix-assisted autologous chondrocyte transplantation (MACT), are some of the standardized
treatment methods among many others. MACT involves a two-step surgical intervention by isolating
a cartilage biopsy from the non-load bearing site for obtaining and expanding autologous chondrocytes
in vitro onto 2D substrates in order to attain sufficient cell populations and then further embedding
it onto biological scaffolds and transplantation [1]. The autologous chondrocytes are expanded
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both under 2D and 3D conditions in the presence of autologous human serum (HS) supplemented
along the growth medium [2]. Chondrocyte dedifferentiation is a well-known phenomenon that
occurs during 2D expansion, and redifferentiation occurs when cultured on a 3D scaffold [3]. Most
often, studies indicating redifferentiation potential on scaffolds utilize fetal calf serum (FCS) and not
autologous HS. MACT involves a clinical approach and thereby the use of autologous HS for culturing
cell-scaffold constructs. However, supplementing HS does not necessarily redifferentiate in many
settings and instead leads to a fibrocartilaginous phenotype usually marked by an increased type I
collagen expression with no or less type II collagen expression [4]. Various cell sources other than
autologous chondrocytes are investigated for cartilage repair, including bone marrow mesenchymal
stem cells, adipose tissue derived mesenchymal stem cells, synovium-derived mesenchymal stem cells
and infrapatellar fat pad stem cells. These sources of cells are advantageous for the low donor site
morbidity and in obtaining higher cell yield.
HS and platelet-rich plasma (PRP) are blood products. The latter has gained attention over the
last two decades for use in cell-culture supplements to expand bone marrow or adipose-derived
mesenchymal stem cells (MSCs) [5] and for its advantage over the autologous source. Both autologous
and allogeneic pooled PRP have been shown to maintain the stemness and concomitantly support
differentiation of MSCs into the osteogenic, chondrogenic and adipogenic lineages. PRP constitutes
a milieu of growth factors, chemokines/cytokines, proteases/antiproteases, adhesive proteins,
trophic factors, small molecules, and catabolic/anti-catabolic factors [6]. In the clinical context,
leukocyte-free PRP is used as intra-articular injections in patients with knee joint degeneration enrolled
for randomized controlled trials (RCTs). It provides symptomatic pain relief for up to 12 months,
noticed through local adverse inflammation reactions initially after multiple PRP injections, which
diminishes over time [7–9]. Ex vivo expansion of bone marrow MSCs using autologous PRP has
been proposed as and treatment option for articular cartilage defects in a case study with repair,
less pain, and mobility but no RCTs have further progressed in this regard [10]. Several in vitro
studies investigating the biological effects of leukocyte-free PRP on porcine and human articular
chondrocytes observe an increase in both proliferation and differentiation [11–13]. Discrepancies
among PRP preparations and the mode of activation remains a concern owing to the uncertainty of
biological effects and clinical outcomes. A recent alternative derivative of platelet-rich fibrin (PRF) is
hyperacute serum (HAS) and HAS which has been consistently reported for its regenerative capacity by
increasing the cell proliferation capacity, as reported for chondrocytes [14], bone-marrow mesenchymal
stem cells [15], and in an ex vivo model of bone ischemia recently [16]. HAS involves the activation of
the natural coagulation cascade by a single-step centrifugation process, and its chemical composition
comprises serum proteins, albumin, growth factor, and cytokines. Advantages of HAS over PRP
include: there is no cellular reminiscence, it is free from fibrinogen and there is no over-concentration
of the plasma content.
An important consideration when using biological scaffolds to regenerate the articular cartilage
extracellular matrix is the interaction between chondrocyte and its surrounding niche. In this study,
we aimed to test PRP and HAS as an alternative to replace HS for in vitro supplementation in the
culture of MACT constructs, namely the collagen type I hydrogel used herein under normoxic/hypoxic
conditions. We evaluated the effect of supplementing chondrocytes with HAS and PRP and observed
the changes to chondrogenic markers encoding the synthesis of ECM and proteoglycan content.
Subsequently as the next approach, we cultured chondrocytes with HAS for seven days and
interchanged to PRP during Days 7–14. This way we hypothesized to achieve cell proliferation with
HAS and an interchange to PRP would enhance the ECM synthesis. Dedifferentiated chondrocytes
were obtained by expansion on 2D substrates for 14 days and subsequently cultured onto collagen
hydrogels for another 14 days. Redifferentiation was assessed by analyzing anabolic cartilage matrix
gene expression and glycosaminoglycan production as the critical evaluation criteria. Furthermore,
the secreted anabolic growth factors and catabolic inflammatory cytokines responsible for modulation
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of the dedifferentiated or redifferentiation fate were measured in the cell-construct culture supernatant
using ELISA.
2. Results
2.1. HAS Increases Chondrocyte Proliferation and Accumulates sGAG Content but PRP Enhances Anabolic
Markers of the Cartilage Extracellular Matrix
The rate of proliferation over the course of chondrocyte redifferentiation analyzed on Days 7 and
14 revealed that PRP inhibited the proliferation over Days 0–14 with no change in cell numbers from
the initial seeding density. HAS increased the cell number by three-fold on Day 7 (p < 0.0019) and by
eight-fold as compared to PRP (p < 0.0001) (Figure 1A). DMMB assay quantification of the sulfated
glycosaminoglycan (sGAG) illustrated that the total amount of sGAG per construct was enhanced
under both HAS and PRP (Figure 1B). The total sGAG content normalized to total dsDNA content
denotes an increase in HAS on Day 7 as compared to in PRP (p < 0.0121) (Figure 1C).
The redifferentiation potential of the monolayer dedifferentiated chondrocytes embedded in
collagen type I hydrogels was assessed for the anabolic/catabolic chondrocyte markers of gene
expression. Chondrocytes cultured for 14 days with PRP showed higher expression of COL2A1 on
Days 7 (p < 0.05) and 14 (p < 0.0.5) (Figure 1E) and of SOX9 on Days 7 (p = 0.0428) and 14 (p = 0.0396)
(Figure 1F) than in HAS. Concomitantly, the expression of COL1A1 had a seven-fold increase in HAS
during Days 7–14 (p < 0.0404), whereas no COL1A1 expression was observed in PRP at both time
points (Figure 1D). MMP3 was downregulated as compared to Day 0 in both groups (Figure 1G).
MMP13 and VCAN were upregulated in PRP during Days 7–14, whereas, in HAS, MMP13 and VCAN
were downregulated during Days 7–14 (Figure 1H,I).
2.2. An Interchange in Supplementation from HAS to PRP Enhances Proliferation but Depletes Anabolic
Markers of the Cartilage Extracellular Matrix Marked by High Upregulation of MMP13
To achieve both proliferation and redifferentiation of the chondrocytes, an interchange from HAS
to PRP during Days 7–14 was performed. The interchange did not arrest cell proliferation (Figure 2A),
and the total sGAG content was significantly higher over 14 days (p < 0.0238) (Figure 2B). The total
sGAG content normalized to total dsDNA content over 7–14 days was decreased by one-fold, denoting
a depletion of the sGAG content (Figure 2C).
The anabolic/catabolic chondrocyte markers of gene expression indicated a seven-fold decrease
in COL1A1 expression (p < 0.05) over 14 days indicating dedifferentiation (Figure 2D). Interchange
during Days 7–14 did not enhance the COL2A1 expression (Figure 2E), but SOX9 increased by two-fold
(p = 0.0952) (Figure 2F). MMP3 was significantly downregulated on Day 14 (p < 0.0476) and VCAN
was downregulated by three-fold. MMP13 was significantly upregulated by 20-fold (p < 0.0238),
suggesting that MMP13 upregulation could result in depletion of the extracellular matrix markers and
the sGAG content.
2.3. Chondrocytes Secrete More Anabolic Growth Factors and Less Catabolic Inflammatory Cytokines When
Supplemented by PRP under Normoxia
ELISA quantification of inflammatory cytokine secretion levels under normoxic conditions
(20% O2) revealed that the chondrocytes secreted higher levels of IL-6 under HAS as compared
to the controls; however, in the PRP group, IL-6 secretion was significantly reduced by 10-fold during
Days 7–14 (p < 0.0446) (Figure 3A). IL-1β levels under PRP were less in the chondrocytes when
compared to HAS at 14 days, but no significant difference was observed (Figure 3B). Quantification
of anabolic growth factors revealed that PDGF-BB levels secreted by chondrocytes had a two-fold
increase in the PRP group during Days 7–14 (p < 0.0312) as compared to HAS (Figure 3C). Lower IGF-1
levels were secreted by the chondrocytes than observed in the controls (Figure 3D). BMP-2 was present
in a higher amount in both the HAS and PRP controls but the chondrocytes did not secrete BMP-2
under HAS supplementation. Under PRP supplementation, chondrocytes secreted high BMP-2 levels
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on Day 7, which decreased significantly by Day 14 (p < 0.0496) (Figure 3E). No significant differences
were observed in the TGF-β1 levels among all groups (Figure 3F).
Figure 1. Analysis of: cell proliferation (A); total sGAG quantification (B); and sGAG/DNA
quantification (C). Differences in relative expression of chondrogenic markers for COL1A1, COL2A1,
SOX9, MMP3, MMP13, and VCAN (D–I) as determined by reverse transcriptase quantitative
real-time PCR of chondrocytes cultured in hyperacute serum (HAS) and platelet-rich plasma (PRP)
under normoxia (20% O2). Significant difference at * p < 0.05, ** p < 0.01, **** p < 0.0001; n = 6
biological replicates.
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Figure 2. Analysis of: cell proliferation (A); total sGAG quantification (B); and sGAG/DNA
quantification (C). Differences in relative expression of chondrogenic markers for COL1A1, COL2A1,
SOX9, MMP3, MMP13, and VCAN (D–I) as determined by reverse transcriptase quantitative real-time
PCR of chondrocytes cultured in hyperacute serum (HAS) for seven days and interchanged to
platelet-rich plasma (PRP) during Days 7–14 under normoxia (20% O2). Significant difference at
* p < 0.05; n = 6 biological replicates.
2.4. Secretion of BMP and TGF-β1 by Chondrocytes Is Enhanced by Both HAS and PRP Supplementation
under Hypoxia
ELISA quantification of inflammatory cytokine secretion levels under hypoxic conditions (4% O2)
revealed that the chondrocytes secreted higher levels of IL-6 under HAS as compared to the controls but
in the PRP group IL-6 secretion was significantly reduced by seven-fold during Days 7–14 (p < 0.0348)
(Figure 4A). Lower IL-1β levels under PRP were less secreted by the chondrocytes as compared to HAS
at 14 days, but no significant difference was observed (Figure 4B). Quantification of anabolic growth
factors revealed that PDGF-BB levels secreted by chondrocytes increased two-fold in the PRP group
during Days 7–14 (p < 0.0496) as compared to HAS (Figure 4C). Lower IGF-1 levels were secreted by
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the chondrocytes than observed in the controls (Figure 4D). The above factors were secreted similarly
as seen under normoxic conditions. Differences from normoxia were observed in BMP-2 and TGF-β1,
where BMP-2 was consistently secreted over 14 days in both PRP and HAS (Figure 4E). Similarly,
TGF-β1 was secreted consistently under PRP but decreased over 14 days under HAS. No significant
differences were observed between the groups (Figure 4F).
Figure 3. Analysis of determined catabolic inflammatory cytokines (IL-6 (A); and IL-1β (B)) and
anabolic growth factors (PDGF-BB (C); IGF-1 (D); BMP-2 (E); and TGF-β1 (F)) secreted by the
chondrocytes during the culture period of 7 and 14 days under normoxic conditions (20% O2).
Significant difference at * p < 0.05; n = 6 biological replicates.
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Figure 4. Analysis of determined catabolic inflammatory cytokines (IL-6 (A); and IL-1 β (B)) and
anabolic growth factors (PDGF-BB (C); IGF-1 (D); BMP-2 (E); and TGF- β1 (F)) secreted by the
chondrocytes during the culture period of 7 and 14 days under hypoxic conditions (4% O2). Significant
difference at * p < 0.05; n = 6 biological replicates.
3. Discussion
MACT in specific systems utilizes in vitro expansion for engineered cartilage constructs for
cartilage repair. We investigated blood products as a natural mixture of bioactive molecules on
the chondrocyte microenvironment. Our objective was to assess the redifferentiation potential of
dedifferentiated chondrocytes cultured in collagen type I hydrogels for 14 days under supplementation
of HAS and PRP in the culture media under normoxia/hypoxia and an interchange from HAS to
PRP during Days 7–14. Cell growth was enhanced only by supplementing HAS, and an interchange
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from HAS to PRP led to enhancement of cell growth. However, the redifferentiation of chondrocytes
was achieved only by supplementing PRP for the entire 14-day culture. Proteoglycan accumulation
was observed under all conditions, but an interchange led to a decrease in the content at 14 days.
Chondrocytes secreted higher pro-inflammatory cytokine IL-6 at seven days under all conditions
but reduced at 14 days under PRP. The IL-1β secretion was comparatively lower than IL-6 secretion.
The anabolic growth factor secretion of PDGF-BB was higher in PRP at both 7 and 14 days, while IGF-1
remained at same levels under all conditions. Under hypoxia, TGF-β1 and BMP-2 were higher in PRP
than in normoxia and vice versa in HAS. The highest magnitude of gene expression encoding cartilage
matrix synthesis, namely COL2A1 and SOX9, occurred when supplementing PRP for 14 days, but an
interchange from HAS to PRP did not support the synthesis.
MACT involving culture of autologous chondrocytes is often cultured under cell culture medium
supplementation of autologous human serum (HS) as a gold standard, but there is not much clarity
on the subsequent redifferentiation of monolayer expanded dedifferentiated chondrocytes to MACT
constructs for transplantation. Autologous human serum in cell culture supplementation for MACT
is known for its progressive proliferation capacity [2], but the MACT constructs very often result in
a fibrocartilage tissue formation upon implantation, rather than a hyaline cartilage tissue formation.
Discrepancies in analogy with regard to different serum preparations have not been investigated in
many of the previous studies articulating MACT constructs. In recent years, several in vitro studies
have demonstrated the redifferentiation potential of chondrocytes by platelet derivatives [14,17].
We found different effects on chondrogenesis with different formulations of platelet and serum
derivatives wherein our study, PRP inhibited the cellular growth in specific to collagen hydrogels,
but matrix turnover markers were enhanced. This mimics the natural environment of chondrocytes
as articular cartilage under normal conditions maintains a low matrix turnover and is resilient to
proliferation and end-stage differentiation [18]. This result is coherent with several reports that indicate
that chondrocytes are involved in the process of proliferation during cell cycle phase or committed
to the differentiated state [19–21]. Liou et al [22] recently reported that PRP promotes proliferation
of mesenchymal stem cells from bone marrow and infrapatellar fat pad in hydrogel encapsulated
cultures. This effect could be specific to mesenchymal stem cells and inapplicable to chondrocytes
in hydrogels.
Low oxygen tension between 1% and 5% O2 is reported to maintain the chondrogenic phenotype
during cell expansion and maintain the matrix metabolism in 3D constructs [23–25]. However,
not all commercially available MACT systems utilize hypoxic conditions for MACT procedures.
A few systems, e.g., NeoCart®, apply 2% hypoxia in a bioreactor together with hydrostatic pressure
stimulation. On the one hand, obtaining clinically sufficient cell numbers without monolayer expansion
continues to be a challenge. On the other hand, restoring the functional properties of articular cartilage
is insubordinate in tissue-engineered cartilage. To tackle the limitation in increasing cell number while
simultaneously enhancing the chondrocytes to resuscitate its matrix synthesis activity in a short culture
period within the MACT constructs, an interchange of supplementation of HAS for the proliferation
of cells switched to PRP for matrix synthesis was tested in our study. The interchanging of culture
conditions, however, did not favor the hypothesis, as proliferation achieving matrix synthesis did not
occur, which was indicative of higher MMP13 upregulation after the interchange. The fact that MMP13
is temporarily and not permanently active in articular cartilage as well as its higher activity, based
on the congregation of several factors such as insulin-like growth factor (IGF-1), which subsequently
results in abnormal homeostasis and breakdown of the proteoglycans [26,27].
Chondrocyte dedifferentiation results from the failure of metabolic imbalance to sustain the
anabolic/catabolic equilibrium during synthesis of the ECM involving a multitude of anabolic and
catabolic cytokines/growth factors [28]. PRP constitutes a natural milieu of growth factors/cytokines
and embodies as an alternative cell culture supplementation to avoid chondrocyte dedifferentiation
for MACT procedures. Our study is consistent with other studies where PRP concentrated platelets
release the cytokines/growth factors from their α-granules [29,30]. Sundman et al [31] compared
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the concentrations of anabolic and catabolic growth factors/cytokines in the cellular composition of
leukocyte-rich and leukocyte free PRP, and determined that leukocyte-rich PRP (Lr-PRP) released
higher levels of catabolic cytokines such as IL-1β, and a higher concentration of platelet content in
Lr-PRP released more anabolic growth factors such as TGF-β1 and PDGF-AB. Contrary to the above-
mentioned statement, our study involving leukocyte-poor PRP (Lp-PRP) released less IL-1β associated
with less TGF-β1 and PDGF-BB. Remarkably, the chondrocytes secreted higher levels of TGF-β1 and
PDGF-BB with no increase in IL-1β when supplemented with Lp-PRP. We found an increased secretion
of BMP2 by the chondrocytes during the culture period under hypoxic conditions in HAS, which was
more in PRP supplementation, as well as the stable release of TFG-β1 throughout the culture time.
BMP2 was observed to disappear during monolayer expansion, and the addition of BMP2 was superior
to TGF-β1 in preventing chondrocyte dedifferentiation [27]. BMP-2 has been strongly correlated with
hypoxia on expression of the matrix gene COL2A1, which is tightly controlled through the p38MAK
pathway [32]. However, we did not observe differences in matrix gene expression and the sulfated
glycosaminoglycan content between normoxic and hypoxic conditions. This could be attributed to
the fact that there might be a prevalence of hypoxia gradients inside the collagen hydrogel. Future
investigations should decipher the hypoxia levels and make them more precisely controllable.
This limitation to our current study includes the lack of histological characterization for additional
confirmation of the matrix synthesis and remodeling. Deciphering the underlying signaling mechanism
between secreted growth factor and cytokines on the ECM turnover would have provided more
insights on the effect of PRP and HAS. Taken together, these factors have been considered for
future investigations. The current state of the art for cartilage repair envisions on a broad range
of tissue engineering strategies and towards this direction a compliant GMP structure can expedite
the production of tissue engineered implants and biologics at the premises of the surgical facility.
Towards this context additive manufacturing technologies such as 3D bioprinting are advantageous as
biomaterials for MACT procedures can be controlled for a high degree of porosity with hierarchical
anisotropic architecture for cells to produce collagen fibers vertically, which subsequently helps during
the phase of matrix remodeling.
4. Materials and Methods
4.1. Ethics
The local ethical committee of Lower Austria approved the study protocol on 1st January 2013
(approval No. GS4-EK-4/249-2013). All subjects gave written informed consent in accordance with the
Declaration of Helsinki.
4.2. Isolation and Culture of OA Chondrocytes
Human osteoarthritic cartilage was obtained from the surgical wastes of 12 donors undergoing
total knee arthroplasty (60 ± 3 years old) after written informed consent was given. The cartilage
pieces from the superficial zone areas where no cartilage loss occurred were determined then rinsed in
phosphate buffered saline (PBS) and minced into fine pieces. Chondrocytes from the articular surface
of the cartilage were isolated by enzymatic digestion, as previously reported [4]. Chondrocytes were
seeded at a density of 10,000 cells/cm2 and expanded in a growth medium (GIBCO® DMEM/F12
GlutaMAX™-I, Invitrogen, Vienna, Austria) containing 2.5 μg/mL Amphotericin B and 0.1 mg/mL
streptomycin (Sigma, Steinheim, Germany) with 10% FCS (PAA Laboratories GmbH, Linz, Austria). All
further experiments were performed on passage 1 chondrocytes to reduce the point of dedifferentiation
over passaging.
4.3. Preparation of Hyperacute Serum and Platelet-Rich Plasma
Whole blood was collected from 15 individual healthy male and female blood donors (36 ± 10 years
old) after written informed consent was given. HAS was prepared by centrifuging whole blood onto 9 mL
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silicon coated blood collection tubes (VACUETTE® z serum clot activator, Greiner bio-one, Kremsmünster,
Austria) at 1770 g for 10 min. The top layer containing the supernatant was removed and the resulting
fibrin clot (middle layer) was separated from the tube by discarding the bottom part containing red blood
cells. The fibrin clot was gently squeezed with a non-absorbable sterile material in a petri dish to extrude
HAS. HAS was pooled from the individual 15 blood donors and stored at −80 ◦C. Leukocyte poor PRP
(lpPRP) was prepared by transferring whole blood from the same donors onto 9 mL EDTA coated blood
collection tubes (VACUETTE® K3EDTA, Greiner bio-one, Kremsmünster, Austria) and centrifuged at
440 g for 10 min. The platelet enriched plasma (middle layer) along the poor platelet plasma (top layer)
was further transferred to 15 mL falcon tubes leaving the leukocytes and RBC region and secondary
centrifugation at 1770 g for 10 min was performed. The resulting lpPRP was pooled from individual
donors and stored at −80 ◦C. Pooled lpPRP enclosed on average 1 × 106 platelets/mL.
4.4. Re-Differentiation of OA Chondrocytes by Supplementing Hyper Acute Serum and Platelet-Rich Plasma
Ten milligrams of collagen type I solution (BD Biosciences) were diluted to a final concentration
of 2.5 mg/mL in a neutral buffer containing 10× PBS, ultra-pure distilled water, and 1 N NaOH with
a final pH of 7.4. Passage 1 dedifferentiated chondrocyte were encapsulated onto collagen type I
hydrogels at a density of 40,000 cells/cm2 at 4 ◦C and left to polymerize at 37 ◦C/5% in a CO2 incubator
for 30 min. Post-polymerization constructs were re-differentiated in growth medium supplemented
with either 10% HAS or 10% PRP for 7 and 14 days under normoxia (20% O2) or hypoxia (4% O2).
Another set of experiments were performed where constructs were redifferentiated in a growth
medium supplemented with 10% HAS until 7 days and switched to medium supplementation with
10% PRP post for Days 7–14 under normoxia (20% O2) or hypoxia (4% O2).
4.5. Real-Time Quantitative PCR
Collagen gel-chondrocyte constructs were collected and digested with 120 units/mL
collagenase in a serum-free medium for 30 min to release the cells. The RNA was isolated
using the High Pure RNA Isolation kit (Roche Diagnostics GmbH, Mannheim, Germany) in
accordance with the manufacturer’s instructions. The mRNA was reverse transcripted with
a First Strand cDNA Synthesis Kit (Roche Diagnostics GmbH, Mannheim, Germany), and cDNA
samples were amplified with RT-qPCR in a cycler. GAPDH was used as an endogenous external
reference gene, and the ΔΔCt method was used to evaluate the relative expression level of
mRNA for each target gene. The values are depicted with the Day 0 monolayer dedifferentiated
chondrocyte as a control. The following human primers were used in this study: GAPDH
(forward (F) 5′-CTCTGCTCCTCCTGTTCGAC-3′; reverse (R) 5′-ACGACCAAATCCGTTGACTC-3′),
COL2A1 (F, 5′-GTGTCAGGGCCAGGATGT-3; R, 5′-TCCCAGTGTCACAGACACAGAT-3′),
COL1A1 (F, 5′-GGGATTCCCTGGACCTAAAG-3′; R, 5′-GGAACACCTCGCTCTCCAG-3′), SOX9
(F, 5′-TACCCGCACTTGCACAAC-3′; R, 5′-TCTCGCTCTCGTTCAGAAGTC-3′), VCAN (F,
5′-GCACCTGTGTGCCAGGATA-3′; R, 5′-CAGGGATTAGAGTGACATTCATCA-3′), MMP3 (F,
5′-CAAAACATATTTCTTTGTAGAGGACAA-3′; R, 5′-TTCAGETATTCGCTTGGGAAA-3′), MMP13
(F, 5′-TTTCCTCCTGGGCCAAAT-3′; R, 5′-GCAACAAGAAACAAGTTGTAGCC-3′).
4.6. Sulfated Glycosaminoglycan (sGAG) and DNA Quantification
Constructs were collected on Days 7 and 14, frozen at −80 ◦C and lyophilized at 20 ◦C to
evaporate the water content and measure the produced matrix content. sGAG quantification was
achieved by treating constructs overnight with 25 U/mL proteinase K enzyme at 56 ◦C. Enzyme
inactivation was then performed at 90 ◦C for 10 min. One hundred microliters of the supernatant
were frozen at −80 ◦C for DNA quantification and the resultant solution was transferred to ultra-free
filter reaction tubes of 0.1 μm pore size (Millipore, Billerica, MA, USA) and centrifuged at 12,000 g for
min. sGAG was measured through complexation and decomplexation with a 1.9 dimethyl methylene
blue solution (DMMB). The absorbance was measured at 656 nm in a plate reader. The DNA content
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was measured fluorometrically using the Quant-iT™ PicoGreen® assay (Molecular Probes, Vienna,
Austria) in accordance with the manufacturer’s instructions (excitation wavelength 480 nm; emission
wavelength 528 nm).
4.7. Growth Factor and Cytokine Quantification
The above supernatant constructs were collected every 2 days during total media exchange and
pooled until Day 7 or Day 14 of incubation as experimental end time points for an enzyme-linked
immunosorbent assay (ELISA). The 10% HAS and 10% PRP served as internal controls to the constructs
supplemented with 10% HAS and 10% PRP. ELISA kits were used to measure the production of human
IGF-I (Quantikine®, R&D Systems, Abingdon, UK), PDGF-BB, TGF-β1, BMP-2, FGF-18, IL-1β, and
IL-6, and quantified according to the manufacturer’s instructions and measured for absorbance at
450 nm in a microplate reader.
4.8. Statistical Analysis
Non-parametric Mann–Whitney two-tailed U-test was performed for comparisons between two
datasets at a time. Multiple comparisons were performed using non-parametric Kruskal–Wallis test
followed by Dunn’s multiple comparisons test. All data are presented as the mean ± SEM. Significance
level was set at p < 0.05. All statistical analyses were performed using the GraphPad Prism software
(Graphpad Prism Software Inc., San Diego, CA, USA).
5. Conclusions
The current study showed that; (i) PRP supplementation over 14 days to collagen-gel chondrocyte
constructs enhances the anabolic gene expression markers of cartilage regeneration; (ii) an interchange
from HAS to PRP achieves proliferation of chondrocytes but impairs matrix anabolic metabolism; and
(iii) hypoxic conditions favor increased secretion of TGF-β1 and BMP-2 by chondrocytes compared to
normoxia under both HAS and PRP. Our study proposes a step towards the continual improvement of
the existing MACT procedure based on in vitro culture conditions specific to collagen type I hydrogels
by instructing the embedded chondrocytes to produce hyaline-like cartilage upon transplantation.
Further strategies should be developed for embedding autologous chondrocytes with rapid eTnzymatic
digestion post arthroscopy in a PRP-augmented collagen hydrogel, aimed at a one-step cartilage
repair procedure.
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Abstract: Autologous blood derived products, such as platelet-rich plasma (PRP) and platelet-rich
fibrin (PRF) are widely applied in regenerative therapies, in contrast to the drawbacks in their
application, mainly deriving from the preparation methods used. Eliminating the disadvantages of
both PRP and PRF, hyperacute serum (HAS) opens a new path in autologous serum therapy showing
similar or even improved regenerative potential at the same time. Despite the frequent experimental
and clinical use of PRP and HAS, their protein composition has not been examined thoroughly yet.
Thus, we investigated and compared the composition of HAS, serum, PRP and plasma products
using citrate and EDTA by simple laboratory tests, and we compared the composition of HAS, serum,
EDTA PRP and plasma by Proteome Profiler and ELISA assays. According to our results the natural
ionic balance was upset in both EDTA and citrate PRP as well as in plasma. EDTA PRP contained
significantly higher level of growth factors and cytokines, especially platelet derived angiogenic and
inflammatory proteins, that can be explained by the significantly higher number of platelets in EDTA
PRP. The composition analysis of blood derivatives revealed that although the preparation method of
PRP and HAS were similar, the ionic and protein composition of HAS could be advantageous for
cell function.
Keywords: hyperacute serum; platelet-rich plasma; blood derived products; composition
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1. Introduction
Autologous blood derived products, particularly platelet concentrates, are widely applied
nowadays in different regenerative therapies which include wound healing, orthopedics, and
dentistry [1–5]. Platelet derived growth factors are able to enhance soft and hard tissue regeneration
by increasing cell migration and proliferation, and decreasing the rate of inflammation [6,7]. The most
commonly used platelet concentrate products are PRP (platelet-rich plasma)—also known as first
generation blood product—and PRF (platelet-rich fibrin), which is known as second generation blood
product. PRP has a wide range of application in wound healing, cartilage, bone, musculoskeletal
regeneration, oral surgery, dentistry, and cosmetics [8–13]. Moreover, PRP has been successfully applied
in treating endometriosis, chronic skin ulcer and vitiligo in earlier studies [14,15]. Nevertheless, there
are some drawbacks of using PRP [16]. For example, the lack of uniformity in PRP preparation
methods [4,17] which is mainly caused by the treatment of blood with different anticoagulants like
EDTA and citrate, which are the most preferred ones in PRP preparation. The information in the
literature on the optimal anticoagulant for PRP preparation is contradictory. On the basis of previous
studies, both EDTA and citrate (sodium citrate, acid citrate dextrose) have a negative effect on the
balance of ionic content in the plasma fraction because of their chelating mechanism [18]. Higher
platelet numbers can be obtained by using EDTA compared to citrate [19,20], however the mean
platelet volume (MPV)—which is a marker of platelet function—can be higher than citrate using
EDTA [20]. Other studies have claimed that platelet aggregation was inhibited more efficiently by
using EDTA than acid citrate dextrose solution [19]. Using EDTA, spontaneous platelet activation can
be avoided because EDTA has a stronger complex capacity with divalent cations than citrate. For the
activation of citrate and EDTA, PRP thrombin and calcium–chloride or temperature activation can be
used. [21] The addition of bovine thrombin during PRP preparation may lead to cross-reaction with
human factor Va causing bleeding disorder, but it is more effective than activating PRP by repeated
freezing and thawing [16].
With PRF the major disadvantages of PRP can be avoided. In addition, growth factors and
cytokines are released from platelets over a longer period of time, whereas in PRP these factors are
released immediately into the site of application [22,23]. Nevertheless, PRF is not capable of replacing
PRP in all therapeutic areas because of its compact three-dimensional structure, which hinders its
application as an injection [24–26]. Consequently, PRF is mainly used for replacing injured tissues in
oral and dental surgery, orthopedics, and wound healing [27–31].
SPRF (serum from platelet-rich fibrin) or HAS (hyperacute serum) was developed to avoid the
limitations of both PRF and PRP. The preparation method is the same as in the case of PRF, but the
serum is squeezed out from the PRF clot at the end of the procedure [32]. Thus, it does not contain any
anticoagulant or thrombin, and the final product is liquid. Based on our previous results, HAS has a
better cell proliferative effect on mesenchymal stem cells, osteoblasts, and osteoarthritic chondrocytes
compared to EDTA PRP [33]. Furthermore, HAS promotes MSCs lineage shift towards the osteoblastic
line and results in a better preserved bone marrow structure in bone marrow explants compared to
EDTA PRP treatments [32,34].
Despite the positive results of HAS in cell proliferation and migration, the composition of HAS has
not been reported so far. However, angiogenic proteins were measured earlier both in HAS and PRP by
Proteome Profiler, showing that EDTA PRP has more angiopoietic components, whereas HAS has more
anti-angiopoietic components [35]. In the present study we investigated and compared the composition
of HAS, PRP, blood serum, and plasma to understand the differences in the cell proliferative and
regenerative effect of HAS and PRP. In the laboratory tests EDTA and citrate anticoagulated PRP were
also compared. However, due to the more homogenous blood fraction separation that was achieved
using EDTA, and based on the earlier cell culture experiments, the semi-quantitative and quantitative
analysis was only done with PRP that was anticoagulated with EDTA in order to allow consequent
results and interpretation.
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2. Results
First, we measured the concentration of relevant metal ions, inorganic phosphate, the activity of
ALP enzyme, and the quantity of cellular blood components in the serum and plasma samples by a
general laboratory test. EDTA and citrate PRP were activated by thrombin and CaCl2 with heparin
together to prevent coagulation, thus the chelation capacity of both K3EDTA and sodium citrate was
reduced in PRP.
The concentration of calcium ions was significantly higher in EDTA and citrate PRP, and lower
in EDTA and citrate plasma compared to the serum fractions. Both anticoagulants effectively chelate
calcium and citrate is more effective in forming complexes with magnesium ions. The level of potassium
ions was higher in EDTA plasma fractions due to the potassium content of K3EDTA. The concentration
of copper, zinc, and iron ions was also significantly lower in EDTA plasma and EDTA PRP due to the
chelating ability of K3EDTA. Sodium ion concentration was increased due to the sodium content of
citrate while phosphate content was only significantly influenced using citrate PRP. The activity of
ALP enzymes was also reduced significantly because EDTA naturally chelates Mg2+ and Zn2+ which
have a crucial role in the structural stability of ALP enzyme (Figure 1A).
Figure 1. Quantitative determination of the concentration of relevant ions and the activity of alkaline
phosphatase (ALP) enzyme (A) and the number of red blood cells, leukocytes and platelets in the serum
and plasma fractions (B), n = 4. The significance level was p > 0.05, where * means that p is between
0.01 and 0.05, ** means that p is between 0.01 and 0.001, and *** means that p is lower than 0.001.
Sodium citrate has a weaker complex capacity with divalent cations than EDTA, thus the ion
content of citrate plasma fractions was not influenced significantly except calcium ions, which were
added both to citrate and EDTA PRP for activation. Cellular blood components were measured before
activating PRP because activated platelets might have been disrupted. The number of leukocytes was
the highest in citrate PRP and the standard error of mean was high in the case of EDTA and citrate
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PRP as well. The number of platelets was higher in EDTA PRP compared to citrate PRP. The platelet
number was extremely low in EDTA and citrate plasma, serum and HAS. Mean platelet volume (MPV),
which is a marker of platelet function, was similar in EDTA and citrate PRP. (Figure 1B). For further
examination EDTA plasma and PRP were used because a higher number of platelets could be isolated
by EDTA than citrate with similar MPV values. Furthermore, EDTA enabled the most homogenous
separation and therefore EDTA was used as an anticoagulant in our previous studies where the cell
proliferation rate of different cell types was investigated.
For mapping the composition of serum, HAS, EDTA plasma, and PRP (Figure 2A), 138 different
known cytokines and growth factors were screened using antibody-based dot-blot assays. The results
were presented as relative values compared to the positive control for the secondary antibody. From
the 138 cytokines and growth factors selected as known paracrine mediators of tissue regeneration,
vascularization or inflammation, 82 proteins were neglected (AU < 2%) thus 56 proteins (AU > 2%) are
presented in Figure 2A [35]. The whole data set containing the 138 cytokines and growth factors is
shown in Table S1. We observed a general trend that the overall concentration of active molecules was
the highest in PRP, followed by HAS, plasma, and serum, respectively (see in Figure 2A and Table S1).
There were clear differences in the proteome profiler patterns of the blood derivatives, although the
proteome profiler is not reliable enough for quantitative measurements and for the statistic comparison
of the blood derivates. Thus, on the basis of these results and the literature [6,36–39] we set out to
quantify the key inflammation related cytokines and proteins with ELISA or Luminex assays.
Figure 2. Semi-quantitative Proteome Profiler analysis of serum, hyperacute serum (HAS), plasma,
and platelet-rich fibrin (PRP). On the bar chart proteins exceeding 2% (AU) of the total protein content
(A) are presented. The level of the top 10 angiogenic proteins and cytokines are presented on a heat
map. (B) The level of the proteins is expressed in % compared to the combined arbitrary unit of ANG
that was considered to be 100%. n = 8.
For quantitative protein analysis, Luminex and ELISA assays were used where systemic
pro-inflammatory molecules, complement system molecules, platelet-derived inflammation,
angiogenesis related molecules, and anti-inflammatory molecules were investigated. Lipocalin-2,
EMMPRIN (CD147), Osteopontin, IL-17A, and Chitinase-3-like protein 1 (CHI3L1) are similarly present
in all blood derivates. While CD97 and Myeloperoxidase (MPO) were higher in serum derivates,
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ALCAM was higher in plasma derivates. The concentration of CD40L was elevated in PRP compared
to HAS, and CRP was significantly higher in plasma than in HAS and PRP (Figure 3A). From the
complement system we measured C5a that showed the highest levels in plasma and C1qR1 which was
highly elevated in all cases (Figure 3B).
Figure 3. Concentration of systemic pro-inflammatory molecules (A) and complement system related
molecules (B) in blood derivatives, n = 8. The significance level was p > 0.05, where * means that
p is between 0.01 and 0.05, ** means that p is between 0.01 and 0.001, and *** means that p is lower
than 0.001.
Platelet-derived pro-inflammatory cytokines and growth factors showed a very clear pattern: they
were higher in PRP compared to other blood derivatives. In contrast, the fibrin/fibrinogen level was
high both in plasma and PRP compared to serum and HAS, as the latter two were already coagulated
and the clot was removed (Figure 4A). The anti-inflammatory cytokine IL-1RA was elevated in PRP and
HAS. Angiopoietin-1 showed the highest level in serum but was present in all other blood derivatives
in effective concentrations (Figure 4B).
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Figure 4. The concentration of platelet-derived inflammatory molecules (A) and anti-inflammatory
molecules (B) in blood derivatives, n = 8. The significance level was p > 0.05, where * means that
p is between 0.01 and 0.05, ** means that p is between 0.01 and 0.001, and *** means that p is lower
than 0.001.
3. Discussion
In the present study we investigated and compared the composition of different blood derivatives,
especially EDTA, citrate PRP and HAS. On the basis of the literature PRP has excellent regenerative
effects in numerous clinical applications, such as bone and cartilage regeneration, in osteoarthritis, in
dental and oral surgery, or in musculoskeletal regeneration [8,9,11,40]. However, there are numerous
drawbacks in the application of PRP mainly caused by certain steps of the preparation methods which
are not present in the preparation of HAS [19,20].
First, the blood derivatives were analyzed by laboratory tests, where the number of cellular
blood components, the concentration of relevant ion contents and the activity of ALP enzymes were
measured. The concentration of ions, such as iron, copper, and zinc which are all influenced by the
chelating mechanism of EDTA, were significantly lower, whereas potassium was higher in PRP and
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plasma because K3EDTA was used as an anticoagulant. The upset of the natural ionic balance due
to EDTA PRP treatment may result in unexpected side effects when using it inside injured and/or
inflamed tissue. As EDTA chelated both Zn2+ and Mg2+ the activity of ALP enzymes was reduced
significantly. ALP has an important role in bone healing and regeneration, thus the reduced enzymatic
activity has a negative effect in the case of injecting PRP into an osteoarthritic or injured joint [41].
The ionic balance of citrate PRP was much better, except for calcium ions which were added to PRP for
platelet activation, and sodium because of the addition of sodium citrate. However, a significantly
lower number of platelets could be isolated using citrate than EDTA, and the number of leukocytes
was also much higher in citrate PRP.
The standard error of mean was high, indicating that the level of red blood cells and leukocytes
in the samples depend mainly on the preparation method. During the preparation of HAS, the red
blood cell containing fraction was cut away from the bottom of the PRF clot, while in case of PRP
preparation, plasma fraction was removed by pipetting it carefully from the top of the red blood cell
containing fraction. Using this isolation procedure, the PRP fraction contains some red blood cell
fraction. The plasma isolation procedure is more complicated when citrate is used as an anticoagulant
because the plasma and red blood cell fraction overlaps after centrifugation and the boundary could
not be defined in a uniform manner. The mean platelet volume was similar in EDTA and citrate PRP,
which indicates that platelet function was not influenced significantly by EDTA in our experiments.
Using citrate, much better ionic composition can be achieved while the composition of blood shaped
elements is much less favorable than EDTA PRP. On the basis of these results, and because only EDTA
PRP was used in our previous studies for proteome profiler and luminex analysis, only EDTA PRP
and plasma were used.
The level of angiogenic proteins [35] and cytokines was screened by semi-quantitative proteome
profiler analysis. This method is not accurate enough for statistic comparison but was sufficient to
determine that the overall concentration of proteins was the highest in EDTA PRP, followed by HAS,
plasma, and the lowest was in serum. For quantitative protein measurement, inflammation-related
molecules were chosen based on the proteome profiler results and relevant scientific literature [37–39].
The level of those molecules which are derived from systemic sources and are not affected by the
preparation protocols, including MPO, ALCAM, CRP, Lipocalin-2, EMMPRIN, Osteopontin, IL-17A,
CHI3L1, CD97, CD40L, was similar. From the elements of the complement system, C5a was present in
the highest level in plasma, while C1qR1 was present in a similar concentration in all cases indicating
that it was already activated after blood drawing regardless of the processing method. Platelet-derived
pro-inflammatory cytokines and growth factors were all the highest in EDTA PRP compared to the
other blood derivatives except for fibrinogen, which was high both in plasma and EDTA PRP compared
to serum and HAS. This was due to the fibrin clot being separated from both HAS and serum after
coagulation. Analyzing the concentration of anti-inflammatory cytokines in the samples, IL-1RA was
elevated in EDTA PRP and HAS, and angiopoietin-1 was elevated in serum only. Interestingly the
platelet-derived molecules were not increased in HAS or serum, although in both cases platelets are
activated and release cytokines. This is probably due to the fact that serum is deprived of platelets
and it contains only molecules which the platelets actively secrete. This is closer to the physiological
conditions than disrupting all platelets and mixing their content into the plasma, as in the case of
EDTA PRP activated by thrombin and calcium-chloride for example. The composition analysis of
blood derivatives revealed that although the preparation method of EDTA PRP and HAS are similar,
and they are typically considered interchangeable in clinical settings, there are marked differences.
Most strikingly EDTA PRP contains excess EDTA, and as a consequence imbalanced ionic composition,
higher growth factor content, and elevated pro-inflammatory cytokine content is present compared
to HAS. According to previous results, EDTA PRP contains more angiogenic factors as well [31].
On the basis of our results so far, HAS eliminates the disadvantages of PRP preparation, such as
the addition of EDTA, citrate, thrombin, or calcium chloride, which may cause side effects inside
an injured tissue. HAS is free from activated platelets, which may be the reason why EDTA PRP is
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more pro-inflammatory than HAS. The presence of pro-inflammatory cytokines could further enhance
inflammation in injured tissues. Further benefits of using HAS instead of EDTA PRP is the better cell
proliferative effect on mesenchymal stem cells, osteoblasts, and osteoarthritic chondrocytes than EDTA
PRP based on our previous results [32,34,35].
4. Materials and Methods
4.1. Isolation of Blood Derivates
Blood samples were obtained from healthy donors of both genders aged 24–45 years under IRB
approval (IRB approval number 33106-1/2016/EKU, 12.07.2016.). The preparation method of serum,
hyperacute serum, plasma and platelet-rich plasma is shown in Figures 5–8.
Figure 5. For serum isolation, whole blood was obtained from donors in VACUETTE® 9 mL Z Serum
C/A tubes (Greiner Bio-One, Kremsmünster, Austria). Blood was allowed to clot for 30 min (a) and
centrifuged at 1710× g for 5 min at room temperature (b). The supernatant formed after centrifugation
is called serum (c,d).
Figure 6. For hyperacute serum isolation, a whole blood sample was obtained from healthy donors
(28–45 years) in VACUETTE® 9 mL Z Serum C/A tubes (Greiner Bio-One) (a) and it was immediately
centrifuged at 1710× g for 5 min at room temperature (b). After centrifugation two layers were formed
in the tubes. The top layer was the platelet-rich fibrin clot and the bottom layer contains red blood cells
(c). PRF (platelet-rich fibrin) as removed using sterile forceps in a biosafety cabinet (d), red blood cells
at the bottom of the fibrin clot were cut away (e) and the clot was placed onto a 110 mm long, 75 mm
wide custom-made plastic grid with 5 mm diameter holes on it. It was sterilized in an autoclave before
use (f). The hyperacute serum was squeezed out from the PRF clot using a sterile spatula (g,h) [24].
127
Int. J. Mol. Sci. 2019, 20, 721
Figure 7. For PRP isolation, whole blood was obtained from donors in VACUETTE® 9 mL K3 EDTA
blood collection tubes (Greiner Bio-One) and VACUTTE 3.5 mL sodium citrate 3.2% blood collection
tubes (Greiner Bio-One) (a) then centrifuged at 1710× g for 5 min at room temperature (b). The
supernatant formed after centrifugation is called plasma (c,d).
Figure 8. For PRP isolation, whole blood was obtained from donors in VACUETTE® 9 mL K3 EDTA
blood collection tubes (Greiner Bio-One) and VACUTTE 3.5 mL sodium citrate 3.2% blood collection
tubes (Greiner Bio-One) (a) then centrifuged at 320 g for 12 min at room temperature (b). The
platelet-rich layer above the buffy coat was aspirated and transferred into a 15 mL tube (c,d) and
centrifuged at 1710× g for 10 minutes (e). The resulting platelet pellet was resuspended in the same
volume as the isolated hyperacute serum from the same donor (f). PRP was activated by 10 IU thrombin
and 10 mg calcium-chloride (Sigma-Aldrich, St. Louis, MO, USA) in case of both EDTA and citrate
tubes (g,h).
4.2. Laboratory Testing of Blood Derivates
A Sysmex XN-1000 Sa-01 cell counter was used for the quantitative determination of red blood
cells, leukocytes and platelet number in the serum and plasma fractions. The concentration of ions,
that may interfere with EDTA and sodium citrate (calcium, magnesium, copper, zinc, iron, sodium,
phosphate, and potassium) and the activity of ALP enzymes were measured using a Beckman Coulter
AU5800 automated laboratory machine (n = 4).
4.3. Comprehensive Protein Analysis
In order to quantify the cytokine and angiogenesis-related protein content of EDTA PRP and
plasma serum a HAS Proteome Profiler Human Angiogenesis Array Kit (55 protein, R&D Systems,
#ARY007) (R&D Systems Inc., Minneapolis, MN, USA) [35] and Proteome Profiler Human XL Cytokine
Array Kit (102 protein R&D Systems, #ARY022) were used according to the manufacturer’s instructions.
Some cytokines were included in both the Proteome Profiler Human Angiogenesis Array Kit and
Proteome Profiler Human XL Cytokine Array Kit, in these cases we used the mean of the results.
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In total, 138 different cytokines were measured by the two different kits. Proteome Profiler individual
protein levels were measured as spot intensities on the blots using Fiji Image J 1.47 (South Bend, IN,
USA) and Adobe Photoshop CC 2015.5 software (San Jose, CA, USA). The results were expressed in %
compared to the arbitrary unit of the highest AU value, which belonged to ANG. Thus, the combined
protein level of ANG among the samples was considered to be 100% (n = 8).
4.4. Quantitative Protein Measurement by Multiplex Immunoassay and ELISA Assays
The key proteins, where clear differences were found during the proteome profiler measurements,
were quantified using custom Human Magnetic Luminex Assay (CHI3L1, C5a, EGF, CD40L, VEGF,
CRP, Il-17a, Osteopontin, Angiopoetin, IL-1RA, EMMPRIN, Lipocalin-2, Pentraxin-3, PDGF-AA,
PDGF-BB) (R&D Systems Inc.) or ELISA assays (MPO, ALCAM, CD97, C1qR1, TGF-beta, Fibrinogen,
Thrombospondin-1, CXCL-5) (Abcam, Cambridge, UK) (n = 8)
4.5. Statistical Analysis
One-way analysis of variance (ANOVA) was performed with a Tukey post hoc test to compare
differences between the groups. The significance level was p > 0.05, where * means that p is between
0.01 and 0.05, ** means that p is between 0.01 and 0.001, and *** means that p is lower than 0.001. Prism
7 software (Irvine, CA, USA) was used for statistical analysis. Data are presented as mean ± SEM.
5. Conclusions
General trends can be observed in the composition changes of the blood products that were
investigated. These trends are based on the characteristics of the additives and the steps of the
production methods. For the preparation of PRPs calcium-chloride, thrombin, citrate or EDTA is
added, which has a negative effect on the composition of these blood products. The exact mechanism
of HAS on cells is not regenerative, only acts as a supplement but with the use of HAS the negative
effects originating from the PRP’s preparation methods can be circumvented, while maintaining the
beneficial influence of PRP on cells and tissues in vitro. Our further aims include comparing the effect
of HAS, EDTA and citrate PRP in clinical studies, whicht can be differ from the in vitro results.
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Abstract: Platelet rich plasma (PRP) is blood plasma with a platelet concentration above baseline.
When activated, PRP releases growth factors involved in all stages of wound healing, potentially
boosting the healing process. To expand our knowledge of the effectiveness of PRP, it is crucial
to know the content and composition of PRP products. In this study, growth factor quantification
measurements of PRP from burn patients and gender- and age-matched controls were performed.
The PRP of burn patients showed levels of growth factors comparable to those of the PRP of
healthy volunteers. Considerable intra-individual variation in growth factor content was found.
However, a correlation was found between the platelet count of the PRP and most of the growth
factors measured.
Keywords: platelets; burns; growth factors; platelet rich plasma; quantification
1. Introduction
Platelet rich plasma (PRP) is produced from blood plasma, and results in a platelet concentration
above baseline. When PRP is activated, platelets release their growth factors, such as platelet-derived
growth factor (PDGF), fibroblast growth factor (FGF), transforming growth factor β (TGF-β), epidermal
growth factor (EGF), and vascular endothelial growth factor (VEGF). These growth factors are involved
in all stages of wound healing. Improved wound healing qualities have been attributed to PRP, by the
multitude of growth factors delivered to a wound [1].
There are numerous types of PRP products and preparation methods. An even larger number
of different application areas exist, varying from sports medicine and orthopedics to chronic and
acute wounds, as well as aesthetic applications. These are described in an extensive body of
literature; however, most studies advocating the use of PRP comprise case reports and patient cohorts.
Randomized controlled trials are rare, and systematic reviews repeatedly fail to show strong conclusive
evidence of the effects of PRP [1–3]. This could be partly due to the great variability of PRP products,
namely, variability in preparation protocols; different composition (with/without leukocytes and
fibrin content); variability in platelet baseline count and PRP yield, growth factor content per platelet;
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and finally activation and application methods. Furthermore, for all the different applications, the most
desirable number of platelets and amount of growth factors that should be used are unknown.
Recently, a new classification system for PRP was proposed by Harrison et al., in an effort to
systematize studies done on PRP [4]. This paper also emphasizes the importance of quality control of
the platelet preparations. To expand our knowledge of the effectiveness of PRP, it is essential to know
the content and composition of the PRP products. Growth factor quantification still seems the best
type of quality control of PRP, since platelet count and growth factor quantification do not appear to
correlate in a consistent way [5,6]. A recent systematic review of commercial PRP separation systems
showed a large heterogeneity in the concentrations of platelets, leukocytes, and growth factors [7].
One of the inclusion criteria of this systematic review was that the studies had to investigate ‘healthy
volunteers.’ This is somewhat curious, because autologous PRP is mostly applied in patients and not
healthy volunteers. An extensive search of the literature was carried out; however, we could not find
studies describing the quantification of PRP content in actual patients.
In burn patients, the use of PRP has been ascribed potential positive effects on burn wound
healing [1,8]. The current study was part of a recent randomized trial, which failed to show significant
added value of PRP in acute burns [9]. In addition to the variables in PRP in general described
above, a few more can be added for burn injury. Burn injury has a severe impact on the internal
physiology of patients [10], and platelet counts show a distinct pattern post-burn injury, with a nadir
at day 3, a peak around day 14, followed by a gradual return to normal values [11], thus affecting
the baseline platelet count from which the PRP is produced. Since platelets are the core ingredient of
PRP, it is crucial to know if and how the quality of the PRP could be affected by the burn injury. In a
recent study, it was found that the platelets in burn patients were not overly activated and remained
functional and not deprived of growth factors; however, this was tested in platelets in whole blood
samples [12]. The current study investigated the quality of PRP, classified as L-PRPIIB-1 according to
the new classification system, which implicates leukocyte-rich PRP, activated before application (II),
with a mean platelet count between 900–1700 (B), and prepared with a gravitational centrifugation
technique (1) [4], from burn patients compared with age and gender matched healthy controls.
2. Results
2.1. Demographics and Hematology
The demographics and hematology results are listed in Table 1. By chance, the patients included
were sampled on longitudinal days post-burn injury (Figure 1). The platelet counts follow the known
time course post-burn injury as has been described, with only patient 3 still having a lower count than
expected. A possible explanation could be that this patient suffered the largest burn [11].
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2.2. Platelet Concentration Ratio
The mean ratio of platelet concentration from whole blood platelet to PRP was 4.44 (SD1.04 range:
2.5 to 5.9) (Figure 1). There was no difference between patients and volunteers, 4.7 vs. 4.2 respectively
(p = 0.78 Mann–Whitney Test).
Figure 1. Platelet count in whole blood versus platelet count platelet rich plasma (PRP), in patient
group and in volunteer group; the platelet concentration factor is depicted underneath the arrow;
under patient group the post- burn day is shown.
2.3. Growth Factor Content
No significant difference was found in mean growth factor content between PRP from burn
patients and that from matched healthy controls (Mann–Whitney tests: transforming growth factor β
(TGFβ-1) (mean patient 57,542 pg/mL vs. volunteers: 45,389 pg/mL) p = 0.2; TGFβ-2 (mean patients
1292 pg/mL vs. volunteers 934 pg/mL) p = 0.2; TGFβ-3 (mean patients 21 pg/ml vs. volunteers
21 pg/mL) p = 0.9; platelet derived growth factor (PDGF-AA) (mean patients 36,327 pg/mL vs.
volunteers 32,113 pg/mL) p = 0.4; PDGF-BB (mean patients 56,031 pg/mL vs. volunteers 44,566
pg/mL) p = 0.5; vascular endothelial growth factor (VEGF) (mean patients 701 pg/mL vs. volunteers
756 pg/mL) p = 0.8; epidermal growth factor (EGF) (mean patients 73 pg/mL vs. volunteers 60 pg/mL)
p = 0.7; fibroblast growth factor (FGF-2) (mean patients 224 pg/mL vs. 220 volunteers pg/mL) p = 0.8),
nor in growth factor per platelet ratio (data not shown).
There was a noticeable correlation between platelets in PRP and growth factor concentration, when
volunteer 5 (which was considered an outlier, because it was more than 2SD outside the mean ratio)
was eliminated, except for VEGF and FGF (Figures 2–4 and Supplemental Figures S1–S5) Spearman’s
rho correlation tests: TGFβ1 R = 0.95, p = 0.008; TGFβ-2 R = 0.9, p = 0.001; TGFβ-3 R = 0.8 p = 0.02;
PDGF-AA R = 0.9, p = 0.002; PDGF-BB R = 0.8, p = 0.008; VEGF R = 0.3, p = 0.4; FGF-2 R = 0.1, p = 0.7;
EGF R = 0.7, p = 0.03).
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Figure 2. Growth factor quantification per platelet count in platelet rich plasma (PRP) for transforming
growth factor β (TGFβ1).
Figure 3. Growth factor quantification per platelet count in platelet rich plasma (PRP) for platelet
derived growth factor (PDGF) AA.
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Figure 4. Growth factor quantification per platelet count in platelet rich plasma (PRP) for vascular
endothelial growth factor (VEGF).
3. Discussion
In this study it was shown that PRP of burn patients, L-PRPIIB-1, according to the new
classification system [4], had comparable levels of growth factors to that of the same type of PRP of
healthy volunteers. This is despite the systemic effects that burn injury has on the physiology of burn
patients. This is relevant additional information to the main RCT, of which the current study was
a part [9], that showed that the addition of PRP to the treatment of burn wounds did not result in
improved graft take and epithelialization, nor in better scar quality. Only minor beneficial effects in
certain subgroups were seen. From the current study, it can be concluded that the lack of substantial
clinical effect of the PRP in acute burns does not seem to be explained by a general lack of available
growth factors in the PRP of burn patients.
We did find a considerable variation in growth factor concentrations, which is in accordance with
the literature on PRP products [7]. More research is required to determine an optimum platelet and
growth factor concentration for burns, as well as for other applications. There is some consensus on
the minimum platelet counts required in PRP; it is generally advocated that a minimum platelet count
of 0.8–1 × 106/μL should be obtained, however, there is no compelling evidence for this. Interestingly
enough, we found a correlation between the platelet count in PRP and most of the growth factors
measured. This has not always been demonstrated in previous studies [5,6]. The platelet count in
PRP did not correlate with the outcome in sub-analyses of the main RCT, of which the current study
was a part [9]. Nevertheless, platelet count can potentially be used as a quality control parameter for
future research, since it is far more feasible to routinely determine the platelet count in PRP than it is to
analyze growth factors. We recommend that further research be done to confirm this finding.
A limitation of this study is that only a small cohort of patients was tested, so the results should
be considered preliminary. Furthermore, subgroup analyses were not feasible. The effect of gender
and age could not be studied; this may influence the growth factor content, as has recently been
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suggested [6]. Nor could the effect of the percentage total body surface area burned (TBSA %) or
timing of the post-burn injury be clarified. It would also have been very interesting if we had been
able to correlate the growth factor content with the clinical outcome in the RCT; however, this was not
realistic in this small adjunct study.
In conclusion, in this preliminary study, burn patients have a comparable platelet growth factor
content in L-PRPIIB-1 to that of matched healthy volunteers. In accordance with the literature,
considerable individual variation in growth factor content was found; however, a correlation between
growth factor concentration and platelet count in PRP was seen.
4. Materials and Methods
This study was performed as a sub-study (amendment NL28331.094.09) of a randomized
controlled trial (ISRCTN14946762) performed in the burn center of Beverwijk, the Netherlands, which
compared autologous platelet-rich plasma with standard treatment for burn wounds [9]. All ethical
committee and institutional permissions were obtained to recruit five consecutive patients, who were
already included in the main RCT, after additional informed consent had been obtained, between
December 2011 and March 2012. The PRP was prepared with the Gravitational Platelet Separation
System (GPS-III system, Biomet Merck Biomaterials, Darmstadt, Germany). The instructions of the
manufacturer were strictly followed. For details of the trial and preparation methods see previous
report [9]. From 27 ml blood from five patients, we prepared PRP with an additional GPS-III mini-kit.
We matched the patients by gender and age with five healthy volunteers and also prepared PRP with a
GPS-III mini-kit.
A small amount of PRP and non-citrated whole blood (WB) was collected in an EDTA (ethylene
di-amine tetra-acetic acid) tube, and analyzed for baseline measurements, using the Cell-Dyn Sapphire
2 hematology analyzer (Abbott Diagnostics Division, IL, USA). The platelet, erythrocyte, and leukocyte
counts were determined.
The PRP was activated with autologous thrombin according to the manufacturer’s protocol (i.e.,
PRP:thrombin = 10:1) and incubated for one hour at room temperature to mimic clinical application
as accurately as possible. Activated PRP was centrifuged (10,000× g at 4 ◦C for 15 min), clots were
removed, and supernatants were collected and stored at −80 ◦C until further analysis. Magnetic bead
panel Milliplex MAP kits (EMD Millipore, Billerica, MA, USA) were used to analyze FGF-2, EGF,
VEGF, TGFβ-1, TGFβ-2, TGFβ-3, PDGF-AA, and PDGF-BB. Separate kits were used to analyze TGFβ
and PDGF. All the kits were used according to the manufacturers’ protocol. The Milliplex MAP kits
were measured using Bio-Plex 200 (Bio-Rad, Hercules, CA, USA) and the data were analyzed using
Bio-Plex manager software.
For statistical analyses, SPSS statistics 21(IBM) software was used. For the comparison of means,
a Mann–Whitney test was used. Correlation was tested with the non-parametric Spearman’s rho test.
Significance was set at p ≤ 0.05.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/2/
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Abstract: The role of platelet-rich plasma (PRP) in promoting the healing of bone fractures has not
yet been clearly stated. The aim of this prospective clinical study was to evaluate the effectiveness of
plasma rich in growth factors (PRGF, a PRP derivate) in the treatment of naturally-occurring bone
fractures in dogs. With this objective, sixty-five dogs with radius/ulna or tibia/fibula bone fractures
were randomly divided into two groups (PRGF and saline solution (SS) groups) and checked at
days 0, 7, 14, 21, 28, 35, 42, 49, 56, 60, 63, 70, 120, and 180. All the fractures were treated with an
external skeletal fixation, and pain was controlled with Carprofen. Healing was evaluated by physical
examination, limb function, radiography, and by a Likert-type owner satisfaction questionnaire.
A faster fracture healing was observed in the PRGF group, with statistically significant differences
with respect to the SS group. Swelling at the fracture site was significantly greater at day 14 and
28 in animals injected with PRGF, and more pain on palpation was found in the area at day 28.
The injection of PRGF in acute bone fractures accelerates bone healing.
Keywords: PRGF; Carprofen; dog; fracture; bone healing
1. Introduction
Plasma-rich growth factors (PRGF) are currently being used to promote bone healing in
reconstructive surgeries [1–3]. In canine models, several experimental studies have published the
effect of this platelet rich plasma derivate in osteoarthritis with differing results [4–7]. Platelets are
very important in the wound healing process [1]; they rapidly arrive at the wound side and begin the
coagulation process. In addition, they release multiple wound-healing growth factors and cytokines
within 10 min [1–3]. Platelets are viable for seven days and will continue to release growth factors into
the tissue during this time [8].
The use of PRGF is based on the assumption that higher platelet concentrations release significant
quantities of growth factors, which aids in bone healing [9–11]. Specifically, growth factors are thought
to be a contributing factor in bone regeneration and in increasing vascularization, which are vital
features of the bone-healing process [6].
Treatments with PRGF have given excellent clinical results in oral and maxillofacial surgery in
humans [9,12], and in bone and cartilage healing in animal studies [7,13,14]. Growth factors have also
Int. J. Mol. Sci. 2019, 20, 1075; doi:10.3390/ijms20051075 www.mdpi.com/journal/ijms141
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been used in the treatment of large wounds and skin defects in burn patients [15–17]. However, some
controversial results can be found in the cited literature; therefore, the effectiveness of this technique
requires further research.
To the authors’ knowledge, articles discussing fresh fractures and delayed fracture healing are
very scarce [18,19]. In the veterinary field, no publications were found regarding the use of PRGF
in fractures.
In this study, the dogs used were clinical patients, but also clinical animal models. In the present
study, we hypothesize that treating canine bone fractures with PRGF would accelerate bone healing.
Thus, the aim of this clinical trial is to evaluate the use of PRGF in the treatment of naturally occurring
bone fractures in dogs.
2. Results
A total of 68 dogs were initially evaluated; however, only 43 met the necessary requirements to be
included in the study.
The dogs were randomly assigned to either PGRF or SS groups. Twenty dogs were included in
the PRGF group (47%) and 23 in the SS group (53%). The results for each dog belonging to either the
PRGF or the SS groups are summarized in their respective tables (Tables 1 and 2).
The mean weight for each group was 16.27 kg for the PRGF group and 13.07 kg for the SS group.
Mean age was 40.85 and 57.17 months, respectively, with no statistical differences between groups in
these parameters (p ≥ 0.08).
During the study, all the animals received Carprofen as a rescue analgesia at least one time during
the first seven days except for 2 and 4 patients in the PRGF and SS groups, respectively, with no
statistical differences between groups (p ≥ 0.05).
The time (mean ± SD) for implant removal was 41.3 ± 11.73 days in the PRGF group and 49 ±
12.12 days in the SS group. This difference was statistically significant (p = 0.03) (Figure 1).
Figure 1. Boxplot corresponding to the days of implant removal for both PRGF and SS groups. Mean
time was significantly higher in the SS group.
The time when full weight support was detected was 22.1 ± 13.64 days and 25.47 ± 14.9 days
in the PRGF and SS groups, respectively; however, this difference was not statistically significant
(p = 0.45). All animals were sound within six months post-surgery.
Swelling in the fracture site was present in both groups up to day 14 without statistically significant
differences between the groups. Between days 14 and 28, swelling was still present in the PRGF group
(p < 0.048).
The joint movement evaluation showed almost 100% joint mobility without differences between
groups in any of the checking periods.
The evaluation of pain on palpation showed statistically significant differences at day 28 between
groups, where pain was still present in the PRGF group (p = 0.041).
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No significant differences were found in the assessment of owner satisfaction at implant removal,
with a satisfaction between 4 (24% in PRGF, 25% in SS) and 5 (76% in PRGF, 75% in SS).
Complications were recorded. One dog suffered gastroenteritis, and three dogs had pins become
loose in the PRGF group. The same number of complications occurred in SS group (Tables 1 and 2).
3. Discussion
In the present study, the beneficial effect of PRGF in acute ulna/radius and tibia/fibula fracture
healing has been proven, achieving a faster healing compared with controls. However, in all cases,
a primary and non-complicated healing was present.
To the authors’ knowledge, there is no published clinical research discussing the use of PRGF in
fractures in a canine model. Experimentally, some studies proved there was faster bone regeneration
when PRGF or other autologous platelet concentrates were applied [20,21]. In human medicine, there
was only one clinical study evaluating the healing of fresh fractures using PRGF with no positive
effect [18]. On the contrary, a clinical case with a delayed union fracture treated with autologous PRGF
showed a favorable healing and concluded to be a safe technology for patients [19].
PRGF has also been used by other authors in combination with other therapeutics, showing
positive results. Ya-dong Zhang et al. [22] proved that the use of PRGF combined with a degradable
bioactive borate glass promotes functional bone repair. On the other hand, other authors [4] found no
effect of PRGF on non-grafted implants in dogs; nevertheless, we cannot compare these results with
our study because a different process was used to obtain the PRGF: using thrombin (100U/mL) to
stimulate growth factor release rather than calcium chloride.
It is known that Carprofen is suitable alone or in combination with other NSAIDs for the control
of pain and swelling in dogs [23,24]. Gastrointestinal inflammation and ulceration are among the most
common side defects reported in the literature [25]. In our study, there were only two animals with
gastroenteritis, and they responded positively to the conventional treatment.
In the present study, it has been observed that the surgical application of PRGF at the fracture site
is associated with increased swelling and oedema during the first days, probably due to the activation
of angiogenesis and cell activation [26]. The enhancement of the arrival and formation of blood vessels
increases heat, pain, and redness of the area. This swelling associated with oedema has been effectively
treated with oral Carprofen.
In any case, increased swelling did not affect the animals’ gait nor the functional ability of the
joint. In this sense, some papers reported the inhibitory effect of interleukins, which may be attributed
to PRP [27]. This effect may be related to a reduction of acute pain in the fracture site, even though the
activation of angiogenesis may cause an increased perception of discomfort and inflammation [26].
Thus, even if the application of PRGF increases oedema and swelling on the area, the limb’s function
was minimally affected during the first days.
Good results have been obtained using PRP to accelerate bone fusion [28]. In our case, the group
receiving the PRGF injection presented an earlier implant removal, which is in agreement with those
who state that chemotactic and mitogenic effect on mesenchymal cells (stem cells) and osteoblasts
accelerate bone healing [29,30].
A rapid return to functionality is crucial for quick and correct healing; when the limb bears
weight, a transmission of forces takes place that stimulates osteoinduction. Likewise, early activity
boosts vascularization and avoids muscle atrophy, which are factors that clearly activate bone healing.
Moreover, the Carprofen helped to control pain and acute swelling at the fracture site, facilitating an
earlier return to functionality [29]. This shows that swelling control and post-surgical analgesia are
fundamental for early functionality of the affected limb and represent an important parameter to be
assessed by the pet owners.
Regarding external fixation, all the animals showed limb weight bearing 48 h after surgery. Very
few complications arose in relation to the use of external skeletal fixation. One animal presented
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a secondary infection, which is a usual side effect, and only six animals presented pin loosening. Other
studies show a larger number of cases presenting pin loosening as the most frequent complication [31].
The present study has three main limitations. First, the use of dogs with a wide weight range
potentially limited results that are more accurate. A narrow weight range could provide more reliable
and accurate results, at least for a specific weight range. Second, a biomechanical analysis of gait could
provide full objective results regarding limb function. Third, statistical analysis of the variable “swelling
at the fracture site” could provide more accurate results if it is considered a continuous variable instead
of categorical, avoiding detection, performance, and reporting biases; however, the presence of
hematoma or callous formation at the fracture site could potentially hinder precise measurements.
4. Materials and Methods
A multicentric study was designed and formed by four surgeons in four different veterinary
clinical centers.
4.1. Animal Model
A total of 68 dogs were evaluated. The follow-up of the animals took place until six months
after treatment. The inclusion criteria required the presence of a fresh, single, closed fracture and the
absence of significant muscular soft tissue damage or abrasions.
The exclusion criteria for the present study were the following:
• Animals presenting concurrent systemic disease (Leishmania spp., Ehrlichia spp., etc.).
• Animals with hematological disorders.
• Animals with multiple fractures.
• Animals with internal lesions due to traumatism.
• Animals with open fractures or with significant damage to the surrounding soft-tissue.
• Animals with a significant weight loss or functional disabilities due to the treatment or other
non-related causes.
• Animals needing different concurrent fixation methods due to the nature or clinical features of
the fracture.
Fractures were classified according to the affected bone. In order to acquire similar healing
conditions during the study, only tibia/fibula and radius/ulna fractures were included because of
their poor vascularization due to their small surrounding muscular mass. The individual data of each
dog for the PGRF and SS groups are summarized in Tables 1 and 2, respectively.
4.2. Fracture Treatment
All fractures were treated with conventional open or closed reduction and external fixation.
The external skeletal fixation configuration frame was the most appropriate for each fracture, using
type IIa or type IIb [32]. In all cases smooth pins of different diameters, connecting bars, and Meynard
clamps were used.
After an initial clinical examination, animals were randomly assigned to one of the following
groups depending on the treatment received:
• PRGF group: A single infiltration of PRGF in the fracture site during the surgery.
• SS group: A single infiltration of saline solution in the fracture site during the surgery.
All groups were treated with morphine (0.2 mg IM every 6 h), and Carprofen 4 mg/kg IV
(Rimadyl®, Zoetis®, Spain) for 24 h. Cephalexin was administered as a post-surgery antibiotic.
After 24 h, the owners were allowed to give Carprofen (4 mg/kg/day) as a rescue analgesic
if their pet presented clear signs of distress or discomfort. This fact should be reported during the
clinical follow-up.
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4.3. PRGF Preparation
For the present study, the extraction, isolation, activation, and administration model of the PRGF
was standardized in all clinics following Anitua´s technique [9]. Briefly, 20 mL of blood were aseptically
collected in four 4.5 mL citrate tubes, then centrifuged during 8 min at 460 G. Care has to be taken to
avoid the buffy coat. Before the infiltration, the PRGF was activated with 5% of its volume with 10%
calcium chloride. This obtained PRP derivate is enriched in platelets 2-fold over peripheral blood and
less than 0.2 leucocytes × 106/mL.
4.4. Evaluation
The limb function was evaluated on days 0 (pre-surgery), 7, 14, 21, 28, 60, 120, and 180 after
the treatment began. This parameter was assessed by the same researcher evaluating animals when
standing (1: weight-bearing; 2: no weight-bearing; or 3: no limb support), by observing swelling on
the fracture site (0: presence or 1: absence), pain on palpation (0: presence or 1: absence), and joint
movement (1: <40%; 2: 40–70%; 3: 70–90%; or 4: >90%).
The same radiologist, unaware of the group of treatment, patient, and surgeon involved, examined
all radiographs. Each radiograph was evaluated by a stage score of 1–5 points (1: not visible callus
formation; 2: barely visible callus formation; 3: scattered, not homogeneous callus; 4: uniform, mature
callus formation; 5: very active, hyperthrophic callus formation). Radiographical examination started
for each dog at day 21 and for every two weeks thereafter until the animal reached stage 2; beyond
this period, radiographs were taken weekly, coinciding with the checkpoints for the other parameters.
When a final score of 4/5 was achieved, implant removal was performed and recorded. The researcher
who performed the evaluation of limbs and who read the radiographies were blind to the given
treatment (PGRF or SS).
The use of the rescue analgesic and the presence of side effects were registered by the owner.
The level of owner satisfaction with the clinical outcome of their pets during the first 28 days and at
implant removal was evaluated with the following questionnaire referring to the level of satisfaction
measured with a Likert-type scale (Table 3).
Table 3. Likert-type questionnaire of satisfaction for dog owners at time of implant removal.
How do you consider the lameness of (name of the pet) has progressed?
Excellent Good Average Fair Poor
5 4 3 2 1
Do you think the treatment given to (name of the pet) has been effective?
Strongly agree Agree Neutral Disagree Strongly disagree
How Do You Think (Name of the Pet) has Responded to the Treatment?
Excellent Good Average Fair Poor
5 4 3 2 1
4.5. Statistical Analysis
Statistical analysis was performed with the computer program SPSS 18® for Windows® (IBM
Co., Chicago, IL, USA). A value of p < 0.05 was considered statistically significant. The descriptive
study of the population was shown as the mean ± SD. To determine the differences between the
groups for non-categorical variables (weight, age, and total doses of Carprofen), a Kruskal–Wallis
and Mann–Whitney test was done. To determine the effect of PRGF on implant removal time,
a Kaplan–Meier curve and a log-rank test were used. The impact evaluation of total doses of Carprofen,
age, weight, and bone fractured, within time to implant removal, a multivariable analysis was made
using a Cox regression. Categorical variables (evaluation when walking, evaluation when standing,
swelling, pain on palpation, joint movement, use of the recue analgesic, owner satisfaction, and
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presence of side effects) were assessed using crosstabs with chi square, contingency coefficient, or the
Fisher’s exact test used when necessary in each variable.
The experimental procedure was approved by the ethics committee of the Research Institute in
Biomedical and Health Sciences (ULPGC, Spain). The owners were informed about the aims of the
study, and a written consent was required before including their pets in the study.
5. Conclusions
The use of PRGF for bone repair accelerates fracture consolidation and simultaneously promoted
healing, achieving clearly shorter implant removal times.
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Abstract: The morpho-functional recovery of injured skeletal muscle still represents an unmet need.
None of the therapeutic options so far adopted have proved to be resolutive. A current scientific
challenge remains the identification of effective strategies improving the endogenous skeletal muscle
regenerative program. Indeed, skeletal muscle tissue possesses an intrinsic remarkable regenerative
capacity in response to injury, mainly thanks to the activity of a population of resident muscle
progenitors called satellite cells, largely influenced by the dynamic interplay established with different
molecular and cellular components of the surrounding niche/microenvironment. Other myogenic
non-satellite cells, residing within muscle or recruited via circulation may contribute to post-natal
muscle regeneration. Unfortunately, in the case of extended damage the tissue repair may become
aberrant, giving rise to a maladaptive fibrotic scar or adipose tissue infiltration, mainly due to
dysregulated activity of different muscle interstitial cells. In this context, plasma preparations,
including Platelet-Rich Plasma (PRP) and more recently Platelet-Poor Plasma (PPP), have shown
advantages and promising therapeutic perspectives. This review focuses on the contribution of
these blood-derived products on repair/regeneration of damaged skeletal muscle, paying particular
attention to the potential cellular targets and molecular mechanisms through which these products
may exert their beneficial effects.
Keywords: fibrosis; myoblasts; myofibroblasts; myogenesis; Platelet-Rich Plasma (PRP); Platelet-Poor
Plasma (PPP); satellite cells; skeletal muscle regeneration; stem cell niche; regenerative medicine
1. Introduction
Skeletal muscle can be considered as the largest organ of the human body, accounting for 40–45% of
the total body mass, responsible for generating forces that guarantee breathing and movement. In addition,
it represents an important metabolic and endocrine organ [1,2]. The incidence of skeletal muscle injuries
as a consequence of trauma (e.g., sport injuries), inherited genetic diseases (e.g., muscular dystrophies),
pathology (cancer and endocrinological disorders) or systemic conditions such as aging is very high
worldwide, thus representing a serious socio-economic concern with relevant Health Care System
costs [2,3]. Indeed skeletal muscle damage is the most common cause of severe long-term pain and
physical disability, restricting patient daily living activities and imposing lost working days.
It is well known that skeletal muscle tissue possesses an intrinsic remarkable regenerative
potential, which, however, becomes compromised in the case of severe and extended damage.
In particular, it has been reported that skeletal muscle tissue is able to compensate for up to 20%
of muscle mass loss but beyond this threshold the restoration of the native muscle tissue structure and
function cannot be achieved [2].
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Traditional therapeutic options for the treatment of damaged muscles include RICE (Rest,
Ice, Compression and Elevation) treatment, rehabilitation therapies, corticosteroid administration
and, in the worst conditions, even reconstructive surgical intervention. The progress of scientific
research, that allowed a deeper understanding of the cellular and molecular mechanisms driving
skeletal muscle tissue repair/regeneration, together with the advances of regenerative medicine and
biotechnology, pushed the development and application of alternative and innovative strategies to
promote or improve muscle repair/regeneration, such as cell-based therapy with different kinds
of stem cells [4–10], tissue engineering [11,12] and Low Level Laser Therapy (LLLT—more recently
termed Photobiomodulation) [13–15].
However, none of the therapeutic options so far adopted has proved to be resolutive and
satisfactory; in addition, the most innovative therapeutic strategies, despite the encouraging elicited
outcomes, still bear several criticisms hindering their clinical application for regenerative purposes.
For more detailed information readers are referred to recent reviews [2,9,10] focusing on this topic,
which is beyond the aim of this review.
Based on these considerations, the development of new effective treatments for skeletal muscle
injury represents a priority and an urgent need. A current scientific challenge remains the identification
of appropriate factors capable of limiting muscle degeneration and/or potentiating the endogenous
muscle regenerative program. In this context, plasma preparations, including Platelet-Rich Plasma
(PRP) and more recently Platelet-Poor Plasma (PPP), have shown several advantages and promising
therapeutic perspectives.
This review, besides giving an updated description of the main cell types driving skeletal muscle
repair/regeneration, focuses on the contribution of PRP and PPP on repair/regeneration of damaged
skeletal muscle, paying particular attention to the cellular and molecular mechanisms through which
these blood-derived products may exert their beneficial effects.
2. Adult Skeletal Muscle Repair and Regeneration: Role of Satellite and Non-Satellite Cells
It has been clearly proven that adult skeletal muscle tissue possesses a remarkable ability to
regenerate in response to focal injuries. This is mainly thanks to the activity of a small population
of resident mononucleated myogenic precursors, called satellite cells, whose name depends on
the unique anatomical location at the periphery of a skeletal myofiber, beneath the surrounding
basal lamina in intimate association with the myofiber sarcolemma, and in close proximity to
capillaries and neuromuscular junction [16–20]. In healthy skeletal muscles, satellite cells are
mitotically quiescent and transcriptionally inactive; in this dormant state they express the paired
box transcription factor Pax7, necessary for their survival and function, and the myogenic transcription
factor Myf5 (~90% of quiescent satellite cells) but not the myogenic regulatory factors, namely MyoD
or myogenin [21,22]. In injured muscles, in response to signals coming from damaged myofibers
and infiltrating inflammatory cells (neutrophils and macrophages), satellite cells become activated,
giving rise to a progeny of proliferating Pax7, Ki67, Myf5 and MyoD positive adult myoblasts which
subsequently, down-regulating Pax7 and expressing myogenin and MRF4/Myf6, differentiate into
skeletal myocytes that finally either fuse with each other, forming nascent syncytial contractile
myofibers, and fuse with injured myofibers, thus repairing the damage [21]. There is evidence
indicating that a small percentage of satellite cells are true stem cells, capable of self-renewal, thereby
ensuring the replenishment of the basal pool of resident satellite cells that are recruitable in the case of
muscle re-injury [16,23,24].
The behavior and the fate of satellite cells are largely influenced by the dynamic interplay
established with components of the surrounding microenvironment, which changes under homeostatic
conditions (quiescent state) and during regeneration (activated state) [25]. This microenvironment
includes the so called “immediate satellite cell niche” and the microenvironment beyond the immediate
niche [16]. The immediate satellite niche represents the microenvironment where the satellite cells
reside. It consists of several signaling molecules diffusing between the satellite cell and the myofiber,
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different extracellular matrix (ECM) components, satellite cell and myofiber surface-associated
receptors for mediating cell-to-cell or cell-to-ECM interactions or binding different regulatory factors,
and receptors present in the basal lamina to sequester inactive growth factor precursors secreted by
either satellite cells and myofibers, serving as a local reservoir to be rapidly activated during muscle
injury [16,26,27]. The microenvironment beyond this niche comprises the local milieu and the systemic
milieu. The local milieu may be identified by the muscle fascicle wrapped by perimysium, consisting
of other myofibers surrounded and connected to each other by endomysium sheath, a heterogeneous
population of interstitial cells in the stroma between the myofibers [28–30], blood capillaries together
with their secretable factors and associated pericytes and mesoangioblasts [31,32] and motor neuron
endings. The main interstitial cells types are represented by fibroblasts, mesenchymal stem/stromal
cells (MSCs) including fibro-adipogenic progenitors -FAPs- [33], telocytes (CD34+/vimentin+ stromal
cells with a small cell body and distinctive extremely long, thin and moniliform cytoplasmic
extensions called telopodes alternating slender segments—podomeres- with dilatations-podoms) [34],
Abcg2+ side population (SP) [35], skeletal muscle-derived CD34+/45− (Sk-34) myogenic endothelial
progenitors [36], interstitial stem cells positive for stress mediator PW1 expression and negative for
Pax7 expression termed PICs [37], integrin β4 interstitial cells.
The systemic milieu includes the entire muscle belly along with bones and surrounding skeletal
muscles, the immune cells and circulating growth factors, interleukins/chemokines and hormones.
The dynamic and collaborative interaction between satellite cells and the different cell types of
the surrounding microenvironment, becomes crucial for a proper execution of the essential events
of repair/regeneration process. Indeed, in contrast to the quiescent conditions, in the activated ones,
many cells are found close to satellite cells exerting a supportive role for their functionality. On the
other hand, this cell interaction is bidirectional since satellite cells can influence the behavior of
interacting cells [20,38].
The cells supporting satellite cell-mediated regeneration in the activated niche may include several
cell types.
Pro-inflammatory phagocytic macrophages (M1) and anti-inflammatory pro-regenerative macrophages
(M2) have been demonstrated to promote proliferation and differentiation of myogenic precursors
respectively, via both paracrine and juxtacrine signaling [39–42]. The ability of macrophages to rescue
myoblasts and myotubes from apoptosis has also been demonstrated [43].
Fibroblasts-myofibroblasts and FAPs are the major contributors to the deposition and remodeling of
the transitional ECM after a muscle lesion, required to rapidly restore tissue integrity [44]; on the other
hand the capability of fibroblasts to promote myoblast proliferation and differentiation and to enhance
satellite cell renewal as well as pro-myogenic function of FAPs has been documented [38,45–49].
Telocytes have been supposed to play a “nursing” role in satellite cell-mediated regeneration.
By means of their telopodes they connect with each other via homocellular junctions, or with
neighboring cells including satellite cells via heterocellular ones, thus forming a three-dimensional
network in the interstitium: telocytes might act as a guidance stromal scaffold able to carry signals
over long distances, driving satellite cell proliferation, migration and differentiation after their
recruitment [34]. In addition, telocytes may modulate satellite cell function in a paracrine manner by
the release of extracellular vesicles containing myogenic factors (e.g., Vascular Endothelial Growth
Factor, VEGF, or microRNAs) [4,34,50,51].
Capillary endothelial cells secrete different paracrine factors strongly stimulating growth of
myogenic progenitors and/or protecting them from apoptosis [19,52,53], whereas periendothelial
cells including pericytes are crucial for the re-entry of satellite cells into quiescence at the end of
the regeneration process and myofiber growth [54,55].
In addition, motor neurons and Schwann cells secreting neurotrophic factors including Insulin
Growth Factor (IGF)-1, Nerve Growth Factor (NGF), Brain-Derived Growth Factor (BDNF) and Ciliary
Neurotrophic Factor (CNTF) may contribute to the modulation of satellite cell/myoblast viability,
proliferation and fusion [16,20,29,56,57].
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Furthermore, in regulating satellite cell quiescence, activation, proliferation and differentiation
an essential role is played by ECM factors (both of basal lamina and of interstitial matrix) including
specific ligands, soluble factors sequestered within the matrix, as well as by the mechanical properties
of ECM itself as extensively discussed in the review by Thomas and co-workers [27].
Many works have demonstrated that, in addition to satellite cells, other cell types residing
within muscle or recruited via circulation may contribute to muscle regeneration thanks to their
inducible myogenic potential [58]. These so-called myogenic non-satellite cells include: the interstitial
Abcg2+SP [35,59–61], skeletal muscle-derived CD34+/45− (Sk-34) cells (likely a subpopulation of SP
with more pronounced myogenic potential) [36], PICs [37], mesoangioblasts and pericytes [31,62–64],
integrin β4 interstitial cells, CD133+ human skeletal muscle derived and blood- derived stem
cells [65–67]. However, if these cells represent an independent source of muscle progenitors undergoing
unconventional myogenic differentiation or if they give rise to satellite cells, remains to be elucidated.
Moreover, also the molecular mechanisms guiding the lineage switch of these muscle interstitial or
circulating cells in the regenerating environment are still unclear [28,29]. Based on all of this evidence,
it appears clear that, for an effective restoration of muscle structure and function, collaborative
and temporally coordinated juxtacrine and paracrine interactions among many myogenic and
non-myogenic cells, are required.
Unfortunately, in case of severe and extended damage, with an intense and persisting
inflammatory reaction or in disease settings, the muscle repair may become aberrant, occurring
with a maladaptive fibrotic scar or adipose tissue infiltration, or even with heterotopic ossification,
mainly as a consequence of dysregulated activity and number of fibroblasts and mesenchymal
progenitors [3,33,49,68–70], which hamper the muscle regenerative response. Moreover, a critical
event that must be considered for the achievement of a regenerating functional muscle tissue after
injury is the re-establishment of neuromuscular junctions for the new myofibers, which is mandatory
to prevent muscle wasting [71].
On the basis of these considerations, improving the functionality of satellite and non-satellite
myogenic cells either directly or by acting on their microenvironment (e.g., modulating the
inflammatory response or MSC functionality thus limiting fibrosis or muscle fatty deposition) as
well as nerve regeneration, could represent the final goal of effective therapeutic strategies for efficient
muscle regeneration.
3. Plasma Preparations: Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP)
3.1. Definition and Biological Properties
PRP and PPP can be defined as a plasma fraction with a concentration of platelets respectively
above and below baseline levels in whole blood. Unfortunately, so far, no univocal guidelines
are available for these plasma preparations and protocols show a high variability among authors,
thus leading to plasma fractions differing in terms of concentration of blood cells (platelets and
leukocytes) and content and type of cytokines and growth factors. For a detailed and updated
overview of the different methods of plasma fraction collection, of the commercially available PRP
systems and of PRP classification, the readers are referred to several excellent reviews [72–75]. In any
case, the rationale for using plasma fractions, in particular PRP, for regenerative purposes in different
areas of medicine [76–81] including musculoskeletal and sport medicine [82–85], relies on the fact that
they represent a cost-effective reservoir of numerous biologically active molecules, holding a strong
potential for improving tissue healing and regeneration [86–89]. Moreover, the prompt availability
from whole blood of patients and thus the autologous source of these blood products, posing no
risks of disease transmission or immunogenic reactions [90,91], as well as the ease of administration,
represent additional advantages for their clinical use. Furthermore, recent findings demonstrating the
safety and favorable outcomes of the application of allogenic PRP to treat musculoskeletal conditions
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have opened new perspectives for off-the-shelf PRP therapy for all patients for whom the use of
autologous PRP would not be recommended [92,93].
3.2. Contribution of PRP to Skeletal Muscle Repair/Regeneration
Some studies have reported positive outcomes after administration of PRP in patients with
injured skeletal muscles, without negative side effects. Indeed, patients/athletes with acute muscle
strains after PRP intralesional injections combined with a rehabilitation treatment, exhibited an earlier
“return to play”, faster pain relief without a significant increase of the re-injury risk in short and long
term, when compared to patients undergoing a rehabilitation program only [94–98]. Improvement of
inflammatory state, reduction of fibrotic scar size and parenchymal recovery was also demonstrated
in PRP-treated muscle lesions [94,99–101]. However, despite the encouraging findings, these studies
do not reach sufficient statistical significance to support the adoption of PRP therapy for skeletal
muscle injury in clinical routine, as recently extensively discussed [83,84,102–104]. Therefore, further
human studies, to ascertain and validate the effective therapeutic benefits of PRP for skeletal muscle
regenerative purpose, are strongly required.
On the other hand, a large body of experimental evidence supporting the contribution of PRP to
the morpho-functional recovery of damaged skeletal muscles comes from studies carried out in animal
models. Although these studies cannot be directly validated or extrapolated to human species, they do
provide a robust and instructive scientific background to design and perform clinical investigations.
In particular, PRP injections into skeletal muscles of rats or mice subjected to different traumatic
injuries (incision, laceration, contusion or lengthening/eccentric contractions) or to cardiotoxin
injection or into ischemic muscles, have been demonstrated to contribute to the muscle healing
process: (i) by modulating the inflammatory response including the increase in M2 macrophage
cell recruitment to the injury site and function [105–108]; (ii) by generating a myogenic response, as
evaluated by satellite cell activation, increase of the expression of different myogenic regulatory factors,
modulation of the expression of muscle specific microRNAs and activation of myogenic signaling
pathways leading to myofiber formation [105,106,109–113]; (iii) by attenuating the impairment of
myocytes mitochondrial function determined by muscle damage and improving their endogenous
antioxidant defense system [114]; and (iv) by protecting cells from apoptosis [108,111].
In addition, the reduction of type-I collagen deposition and scar formation (fibrosis) [106,
110,112,113,115–118] the enhancement of angiogenesis [106,110,112,116,117] and a faster functional
recovery [108,109,113,118,119] have been also observed after PRP application on damaged muscles.
Takase and co-workers [120] recently demonstrated also the ability of PRP to prevent fatty
degenerative changes of rotator cuff muscles in a rat rotator cuff tear model, when administered
into subacromial space.
3.3. Impact of PRP on Satellite Cells and on Myogenic and Non-Myogenic Interstitial Cells
The cellular and molecular mechanisms that could mediate the beneficial pro-regenerative and
anti-fibrotic effects of PRP-derived growth factors on muscle tissue healing have been investigated in a
growing number of in vitro studies.
Satellite cells may represent a direct target of PRP action. Indeed, the capability of PRP
to positively influence the behavior of primary myoblasts—human skeletal myoblasts [116,121],
human pre-plated muscle derived-progenitor cells [122], rabbit myogenic progenitor cells [123],
rat intrinsic skeletal muscle cells [124]—or satellite cell-derived myoblast line namely murine C2C12
myoblasts [120,121,125,126] and human CD56+ myoblasts [127] by promoting their activation and
proliferation [116,120–127] and protecting them from apoptosis [116] has been demonstrated.
Among the different growth factors within PRP, Platelet Derived Growth Factor (PDGF) [122],
has been identified as a key factor mediating PRP-induced mitogenic response, whereas the
involvement of others—demonstrated to be contained in PRP [86–89]—has been proposed on the basis
of previous studies investigating their effects on myoblast cell line or primary muscle stem cells, such
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as VEGF [4,128], Hepatocyte Growth Factor (HGF) [129] or IGF-1 [130]. The involvement of PDGF and
VEGF in mediating the PRP effects may be also presumed on the basis of the recent study of Scully
and co-workers [131] showing that platelet releasate is capable to drive C2C12 myoblast proliferation
and terminal differentiation, as well as the commitment to differentiation of myofiber-derived stem
cells, at least in part via PDGF and VEGF signaling pathways.
However, it must be pointed out that the effects of the combination of different growth factors
(such as PRP) may be completely different from the ones elicited by the single growth factors, based
on the proved antagonistic or synergistic cross-talk between diverse growth factor-mediated signaling.
In addition, primary cultured skeletal muscle cells treated with PRP have also shown an increased
motility/migratory ability associated with an up-regulation of different focal adhesion proteins and
F-actin cytoskeleton remodeling [132]; these findings are of particular interest given that migration of
satellite cells and of satellite derived-myoblasts is a crucial process in muscle regeneration by which
the cells reach the injured site.
In line with these findings, our research group has recently shown that PRP used as single
treatment, positively influenced C2C12 myoblast viability and proliferation in the same manner
of standard culture media containing animal sera, by promoting the activation of AKT-mediated
signaling, as well as the activation of cultured murine satellite cells isolated from single skeletal muscle
fibers [133].
In this paper, we also demonstrated that PRP treatment induced C2C12 myoblasts to enter and
progress into the myogenic program by stimulating MyoD, myogenin, α-sarcomeric actin expression
as standard differentiation culture media containing animal sera did, accordingly to a previous
study [127]. The pro-myogenic effect of PRP was also recently demonstrated by the study of McClure
and co-workers [126] where C2C12 myoblasts cultured on PRP embedded ECM mimicking scaffold,
exhibited a PRP-dose dependent increase in myogenin and myosin heavy chain protein expression,
mediated by ERK1/2 signaling activation. In addition, our study reported that PRP promoted
also the C2C12 myoblast expression of matrix metalloprotease (MMP)-2 [133] whose function has
been reported to be required for satellite cell activation [134–136], for basal lamina degradation
and, at the elongation stage of the myogenic differentiation process, for completing the successive
myoblast cell migration and fusion [6,27,137,138] thus supporting the pro-myogenic effect of PRP.
These latter results concerning differentiation seem to question findings in the literature showing a
reduction or even inhibition of myogenic differentiation of myoblasts cultured with PRP [120,121,125].
These contradictory PRP-elicited biological responses may be attributed to different experimental
settings and more likely to the heterogeneity of PRP preparation techniques and formulations used,
which may contain interplaying pro-myogenic growth factors—such as IGF-1 [130], HGF [129] and
β-Fibroblast Growth Factor (FGF) [125,139]—and anti-myogenic ones—such as Transforming Growth
Factor (TGF)-β [140]—in different concentrations and proportions. In addition, the different PRP
dosages used may account for the discrepancy in the literature on whether PRP hampers or improves
differentiation, when considering the dose-dependence of some myogenic cell responses as well as the
timing of PRP application [116,121,125,126,132,133].
Another very interesting finding of our recent work [133] is the ability of PRP to satisfactorily
support and stimulate in vitro viability, survival and proliferation of MSCs. Taking into consideration
the close morpho-functional relationship between satellite and the interstitial stromal cells, in particular
the reported supportive juxtacrine and paracrine role of different stromal cell types for satellite cells,
our results may suggest that the muscle resident stromal cells could also benefit from the treatment with
PRP. In other words, PRP might indirectly promote satellite cell-mediated regeneration by potentiating
the nursing role of interstitial MSCs.
PRP may impact indirectly on satellite cells also by favoring the appearance and functionality of
pro-regenerative macrophage phenotype (M2) within the healing niche on the basis of recent in vitro
studies, evaluating the effects of different PRP preparations on human monocyte-derived cells [141,142]
and also being consistent with the findings of in vivo research [106].
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On the other hand, PRP could also affect the myogenic potential of the so-called non-satellite
myogenic cells. In this line, Li and co-workers [122] have reported that pericytes, isolated from
post-mortem human skeletal muscle biopsies, exhibited an enhanced proliferative ability when
cultured with PRP as compared to standard culture media while maintaining their in vitro myogenic
differentiation capability and in vivo myogenic potential.
Interestingly, we have recently demonstrated the capability of PRP to prevent the transition
of fibroblasts into myofibroblasts, the main drivers of tissue scarring [143] via VEGF-A/VEGF-A
Receptor-1-mediated inhibition of TGF-β1/Smad3 signaling [144]. These findings, in accordance with
other studies [145,146], may contribute to the identification of the cellular and molecular mechanisms
responsible for the observed reduction in the fibrotic response achieved after injections of PRP in
damaged skeletal muscles [106,110,112,113,115–118]. Such reduction is necessary for the recreation
of a more hospitable and conductive microenvironment for muscle progenitor functionality and for
axonal growth/regeneration and muscle re-innervation [147] and eventually for a complete tissue
morpho-functional recovery. On the other hand, the ability of different PRP-derived factors to positively
influence Schwann cell function in vitro and to assist peripheral nerve repair/regeneration in vivo
has been documented [148–151], thus allowing us to include Schwann cells in the list of the potential
cell targets of PRP in the skeletal muscle tissue during tissue repair/regeneration (Figure 1) and to
suggest that promotion of muscle re-innervation may represent an additional benefit exerted by PRP
for damaged muscles.
Figure 1. Schematic drawing representing the potential cell targets of PRP during skeletal muscle
repair/regeneration, which may mediate its beneficial effects.
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3.4. Impact of PPP on Skeletal Myogenesis
PPP, long regarded as the waste product of PRP and used a sham treatment [109], has recently
been demonstrated to exert a beneficial effect on myogenesis. In particular, Miroshnychenko and
co-workers [121] showed that PPP, differently from PRP, reduced the proliferation rate of human
primary skeletal muscle myoblasts but led to a significant induction of differentiation of these cells
into the myogenic pathway and myotube formation. The same cell responses were elicited by a
modified preparation of PRP, by means of a second spin to remove platelets, suggesting that the
beneficial effects of PRP on myogenesis can be mostly due to plasma per se. Indeed, although
PPP by its definition contains a very low concentration of platelets and therefore smaller quantities
of growth factors, it still represents a reservoir of bioactive molecules (such as PDGF, IGF-1) [87],
which may be responsible for the observed pro-myogenic effects on myoblasts. This research is in
line with previous studies showing the effectiveness of PPP in evoking biological responses from
different cell types involved in the healing process of several tissues, namely fibroblast migration
and ECM remodeling [152,153], periodontal ligament stem cell differentiation towards osteoblastic
phenotype [154], tenocyte proliferation and collagen production [155], endothelial cell differentiation
towards angiogenic cells [156] and macrophage anti-inflammatory activity [157]. Miroshnychenko
and co-workers [121] conclude that PPP and platelet deprived-PRP may be more appropriate to
promote skeletal muscle regeneration than the traditionally formulated PRP, probably containing a
greater quantity of platelet- derived factors detrimental for myoblast differentiation such as TGFβ-1.
However, this laboratory evidence does not seem to have received a large consensus from the current
literature [103,109].
Therefore, although PPP may hold promise for skeletal muscle injuries, further investigations to
assess the exact growth factors contained in this kind of plasma formulation and especially to validate
the impact of PPP on myogenic precursors, as well as to disclose its role on skeletal muscle tissue
regeneration in vivo are absolutely required. Moreover, to date, no clinical studies evaluating the effect
of PPP on skeletal muscle have been conducted.
4. Conclusions and Further Directions
Plasma preparations and especially PRP have been demonstrated to hold a strong therapeutic
potential for the healing of injured skeletal muscle tissue due to their ability to potentiate the
endogenous mechanisms of tissue repair/regeneration while contributing to limit the aberrant
responses such as fibrosis. Nevertheless, despite these encouraging outcomes, evidence from animal
studies and even more from human ones, are not still sufficient to attain the effective clinical translation
of these blood products for skeletal regenerative purpose. Therefore, further investigations are
necessary to validate the regenerative potential of these blood derivates and ultimately drive medical
decisions. On the other hand, it must be considered that some human and animal studies have reported
limited effectiveness or inefficacy of a PRP therapy for damaged skeletal muscle in terms of tissue
regeneration and recovery of functionality, or even an exacerbation of the fibrotic response [158–168].
The main reason for these conflicting results certainly could be due to individual-based variations
and muscle lesion type and severity but is most likely due to the great heterogeneity of the injected
available products and application timing. Therefore, standardization of PRP preparation techniques
as well as of application protocols—considering the cascade of events through which skeletal muscle
tissue repair/regeneration progresses—is a priority in order to perform meaningful comparative
analyses, to enable reproducibility and reach reliable conclusions. Moreover, a full characterization of
plasma preparations is also necessary, evaluating the quantity and the type of the contained bioactive
factors, as well as a deep investigation of their effects on the main local cell types involved in the
skeletal muscle tissue regeneration. This may lead to novel and optimized plasma formulations for
muscle regenerative purposes, based on the selection of factors capable, for instance, of exerting a
pro-regenerative and anti-fibrotic action on skeletal muscle tissue.
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